{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "dcc48271",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\satis\\OneDrive\\Desktop\\MiniProjectsem_7\\venv\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "from ingest_data import fetch_data\n",
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "2e1dad21",
   "metadata": {},
   "outputs": [],
   "source": [
    "dataset_name = \"louisbrulenaudet/clinical-trials\"\n",
    "clinical_trials_dataset = fetch_data(dataset_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "ea8e54b0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "datasets.dataset_dict.DatasetDict"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(clinical_trials_dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "83b52b52",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "DatasetDict({\n",
       "    train: Dataset({\n",
       "        features: ['nct_id', 'updated_at', 'brief_title', 'official_title', 'acronym', 'study_type', 'overall_status', 'study_first_submit_date', 'start_date', 'primary_completion_date', 'completion_date', 'phases', 'enrollment_count', 'minimum_age', 'maximum_age', 'sex', 'healthy_volunteers', 'brief_summary', 'detailed_description', 'eligibility_criteria', 'lead_sponsor_name', 'lead_sponsor_class', 'org_study_id_info', 'why_stopped', 'expanded_access_info', 'last_update_submit_qc_date', 'last_update_post_date_struct', 'study_first_post_date_struct', 'std_ages', 'study_population', 'sampling_method', 'oversight_has_dmc', 'design_info', 'conditions', 'keywords', 'interventions', 'locations', 'collaborators', 'arm_groups', 'outcomes', 'overall_officials', 'study_references', 'misc_info_module', 'condition_browse_module', 'intervention_browse_module', 'mesh_terms'],\n",
       "        num_rows: 541897\n",
       "    })\n",
       "})"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clinical_trials_dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "76272469",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "nct_id",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "updated_at",
         "rawType": "datetime64[us]",
         "type": "unknown"
        },
        {
         "name": "brief_title",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "official_title",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "acronym",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "study_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "overall_status",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "study_first_submit_date",
         "rawType": "datetime64[ms]",
         "type": "unknown"
        },
        {
         "name": "start_date",
         "rawType": "datetime64[ms]",
         "type": "unknown"
        },
        {
         "name": "primary_completion_date",
         "rawType": "datetime64[ms]",
         "type": "unknown"
        },
        {
         "name": "completion_date",
         "rawType": "datetime64[ms]",
         "type": "unknown"
        },
        {
         "name": "phases",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "enrollment_count",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "minimum_age",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "maximum_age",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "sex",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "healthy_volunteers",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "brief_summary",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "detailed_description",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "eligibility_criteria",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "lead_sponsor_name",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "lead_sponsor_class",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "org_study_id_info",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "why_stopped",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "expanded_access_info",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "last_update_submit_qc_date",
         "rawType": "datetime64[ms]",
         "type": "unknown"
        },
        {
         "name": "last_update_post_date_struct",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "study_first_post_date_struct",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "std_ages",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "study_population",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "sampling_method",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "oversight_has_dmc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "design_info",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "conditions",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "keywords",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "interventions",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "locations",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "collaborators",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "arm_groups",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "outcomes",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "overall_officials",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "study_references",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "misc_info_module",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "condition_browse_module",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "intervention_browse_module",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "mesh_terms",
         "rawType": "object",
         "type": "unknown"
        }
       ],
       "ref": "09407d4f-3c9f-45d9-98e7-32279a5d71fd",
       "rows": [
        [
         "0",
         "NCT01273766",
         null,
         "Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies",
         "Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload",
         "None",
         "INTERVENTIONAL",
         "COMPLETED",
         "2011-01-07 00:00:00",
         null,
         null,
         null,
         "['PHASE2']",
         "16.0",
         "18.0",
         null,
         "ALL",
         "False",
         "RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions.\n\nPURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.",
         "PRIMARY OBJECTIVES: I. To determine the effects of the iron-chelating agent deferasirox on changes in: neutrophil function; macrophage function; lymphocyte function.\n\nSECONDARY OBJECTIVES: I. To determine the effect of chelation on the incidence of bacterial, viral and fungal infections documented by clinical, microbiologically-proven versus radiologically-proven criteria. II. To determine the effect of iron chelation on mortality and morbidity with incidence of the following parameters: Need for hospitalization; Duration of hospitalization; Need for ventilatory support; Need for exchange transfusion/apheresis; Need for treatment with antifungals or antibiotics for documented infections.\n\nOUTLINE: Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.",
         "Inclusion Criteria:\n\n* Patients must have a pathology confirmed diagnosis of one of the following: myelodysplastic syndrome (MDS); acute leukemia; multiple myeloma; myelofibrosis; lymphoma; chronic anemia; sickle cell anemia\n* Iron score \\>= 2\n* Absolute Neutrophil Count (ANC) \\>= 1,000\n* Platelets \\>= 50,000\n* Albumin \\>= 2 g/dL\n* Alkaline phosphatase =\\< 5X Upper Limit of Normal (ULN)\n* Total bilirubin =\\< 1.5\n* Creatinine =\\< 2X age-appropriate Upper Limit of Normal (ULN) OR creatinine clearance \\>= 40 ml/min\n* Serum Glutamic Oxaloacetic Transaminase (SGOT) \\[AST\\] and Serum Glutamic Pyruvic Transaminase (SGPT) \\[ALT\\] =\\< 5X Upper Limit of Normal (ULN)\n* Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients with active disease undergoing chemotherapy treatment\n* Patient who have been treated with rituximab or immunomodulating drugs =\\< 1 month prior to enrollment\n* HIV-positive patients\n* Hepatitis-C positive patients\n* Women who are pregnant or breastfeeding\n* Patients on hemodialysis/patients with renal failure\n* Patients with sepsis or acute illness\n* Known hypersensitivity to deferasirox\n* Patients with moderate or severe hearing loss as defined by audiogram",
         "Wake Forest University Health Sciences",
         "OTHER",
         "{'id': 'IRB00015287', 'link': None, 'type': None}",
         "Unknown",
         "{'hasExpandedAccess': False, 'nctId': None, 'statusForNctId': None}",
         "2011-01-07 00:00:00",
         "{'date': '2018-09-07', 'type': 'ACTUAL'}",
         "{'date': '2011-01-10', 'type': 'ESTIMATED'}",
         "['ADULT' 'OLDER_ADULT']",
         null,
         null,
         "True",
         "{'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': None, 'maskingInfo': {'masking': 'NONE', 'maskingDescription': None, 'whoMasked': None}, 'observationalModel': None, 'primaryPurpose': 'SUPPORTIVE_CARE', 'timePerspective': None}",
         "['Acute Undifferentiated Leukemia'\n 'Adult Acute Lymphoblastic Leukemia in Remission'\n 'Adult Acute Myeloid Leukemia in Remission'\n 'Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities'\n 'Adult Acute Myeloid Leukemia With Del(5q)'\n 'Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)'\n 'Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)'\n 'Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)'\n 'Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)'\n 'Adult Grade III Lymphomatoid Granulomatosis'\n 'Adult Langerhans Cell Histiocytosis'\n 'Adult Nasal Type Extranodal NK/T-cell Lymphoma'\n 'Anaplastic Large Cell Lymphoma' 'Angioimmunoblastic T-cell Lymphoma'\n 'Contiguous Stage II Adult Burkitt Lymphoma'\n 'Contiguous Stage II Adult Diffuse Large Cell Lymphoma'\n 'Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma'\n 'Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma'\n 'Contiguous Stage II Adult Lymphoblastic Lymphoma'\n 'Contiguous Stage II Grade 1 Follicular Lymphoma'\n 'Contiguous Stage II Grade 2 Follicular Lymphoma'\n 'Contiguous Stage II Grade 3 Follicular Lymphoma'\n 'Contiguous Stage II Mantle Cell Lymphoma'\n 'Contiguous Stage II Marginal Zone Lymphoma'\n 'Contiguous Stage II Small Lymphocytic Lymphoma'\n 'Cutaneous B-cell Non-Hodgkin Lymphoma'\n 'de Novo Myelodysplastic Syndromes'\n 'Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue'\n 'Hepatosplenic T-cell Lymphoma' 'Intraocular Lymphoma'\n 'Mast Cell Leukemia' 'Myelodysplastic Syndrome With Isolated Del(5q)'\n 'Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable'\n 'Myeloid/NK-cell Acute Leukemia' 'Nodal Marginal Zone B-cell Lymphoma'\n 'Noncontiguous Stage II Adult Burkitt Lymphoma'\n 'Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma'\n 'Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma'\n 'Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma'\n 'Noncontiguous Stage II Adult Lymphoblastic Lymphoma'\n 'Noncontiguous Stage II Grade 1 Follicular Lymphoma'\n 'Noncontiguous Stage II Grade 2 Follicular Lymphoma'\n 'Noncontiguous Stage II Grade 3 Follicular Lymphoma'\n 'Noncontiguous Stage II Mantle Cell Lymphoma'\n 'Noncontiguous Stage II Marginal Zone Lymphoma'\n 'Noncontiguous Stage II Small Lymphocytic Lymphoma'\n 'Noncutaneous Extranodal Lymphoma' 'Peripheral T-cell Lymphoma'\n 'Previously Treated Myelodysplastic Syndromes' 'Primary Myelofibrosis'\n 'Recurrent Adult Acute Lymphoblastic Leukemia'\n 'Recurrent Adult Acute Myeloid Leukemia'\n 'Recurrent Adult Burkitt Lymphoma'\n 'Recurrent Adult Diffuse Large Cell Lymphoma'\n 'Recurrent Adult Diffuse Mixed Cell Lymphoma'\n 'Recurrent Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Recurrent Adult Grade III Lymphomatoid Granulomatosis'\n 'Recurrent Adult Hodgkin Lymphoma'\n 'Recurrent Adult Immunoblastic Large Cell Lymphoma'\n 'Recurrent Adult Lymphoblastic Lymphoma'\n 'Recurrent Adult T-cell Leukemia/Lymphoma'\n 'Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Recurrent Grade 1 Follicular Lymphoma'\n 'Recurrent Grade 2 Follicular Lymphoma'\n 'Recurrent Grade 3 Follicular Lymphoma' 'Recurrent Mantle Cell Lymphoma'\n 'Recurrent Marginal Zone Lymphoma'\n 'Recurrent Mycosis Fungoides/Sezary Syndrome'\n 'Recurrent Small Lymphocytic Lymphoma' 'Refractory Anemia'\n 'Refractory Multiple Myeloma' 'Secondary Acute Myeloid Leukemia'\n 'Secondary Myelofibrosis' 'Small Intestine Lymphoma'\n 'Splenic Marginal Zone Lymphoma' 'Stage I Adult Burkitt Lymphoma'\n 'Stage I Adult Diffuse Large Cell Lymphoma'\n 'Stage I Adult Diffuse Mixed Cell Lymphoma'\n 'Stage I Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Stage I Adult Hodgkin Lymphoma'\n 'Stage I Adult Immunoblastic Large Cell Lymphoma'\n 'Stage I Adult Lymphoblastic Lymphoma'\n 'Stage I Adult T-cell Leukemia/Lymphoma'\n 'Stage I Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage I Grade 1 Follicular Lymphoma'\n 'Stage I Grade 2 Follicular Lymphoma'\n 'Stage I Grade 3 Follicular Lymphoma' 'Stage I Mantle Cell Lymphoma'\n 'Stage I Marginal Zone Lymphoma' 'Stage I Multiple Myeloma'\n 'Stage I Mycosis Fungoides/Sezary Syndrome'\n 'Stage I Small Lymphocytic Lymphoma' 'Stage II Adult Hodgkin Lymphoma'\n 'Stage II Adult T-cell Leukemia/Lymphoma'\n 'Stage II Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage II Multiple Myeloma' 'Stage II Mycosis Fungoides/Sezary Syndrome'\n 'Stage III Adult Burkitt Lymphoma'\n 'Stage III Adult Diffuse Large Cell Lymphoma'\n 'Stage III Adult Diffuse Mixed Cell Lymphoma'\n 'Stage III Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Stage III Adult Hodgkin Lymphoma'\n 'Stage III Adult Immunoblastic Large Cell Lymphoma'\n 'Stage III Adult Lymphoblastic Lymphoma'\n 'Stage III Adult T-cell Leukemia/Lymphoma'\n 'Stage III Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage III Grade 1 Follicular Lymphoma'\n 'Stage III Grade 2 Follicular Lymphoma'\n 'Stage III Grade 3 Follicular Lymphoma' 'Stage III Mantle Cell Lymphoma'\n 'Stage III Marginal Zone Lymphoma' 'Stage III Multiple Myeloma'\n 'Stage III Mycosis Fungoides/Sezary Syndrome'\n 'Stage III Small Lymphocytic Lymphoma' 'Stage IV Adult Burkitt Lymphoma'\n 'Stage IV Adult Diffuse Large Cell Lymphoma'\n 'Stage IV Adult Diffuse Mixed Cell Lymphoma'\n 'Stage IV Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Stage IV Adult Hodgkin Lymphoma'\n 'Stage IV Adult Immunoblastic Large Cell Lymphoma'\n 'Stage IV Adult Lymphoblastic Lymphoma'\n 'Stage IV Adult T-cell Leukemia/Lymphoma'\n 'Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage IV Grade 1 Follicular Lymphoma'\n 'Stage IV Grade 2 Follicular Lymphoma'\n 'Stage IV Grade 3 Follicular Lymphoma' 'Stage IV Mantle Cell Lymphoma'\n 'Stage IV Marginal Zone Lymphoma'\n 'Stage IV Mycosis Fungoides/Sezary Syndrome'\n 'Stage IV Small Lymphocytic Lymphoma' 'Testicular Lymphoma'\n 'Untreated Adult Acute Lymphoblastic Leukemia'\n 'Untreated Adult Acute Myeloid Leukemia' 'Waldenstrom Macroglobulinemia']",
         null,
         null,
         "[{'city': 'Winston-Salem', 'country': 'United States', 'facility': 'Comprehensive Cancer Center of Wake Forest University', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}, 'state': 'North Carolina'}]",
         "[{'class': 'NIH', 'name': 'National Cancer Institute (NCI)'}]",
         null,
         "{'other': None, 'primary': array([{'description': None, 'measure': 'Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only)', 'timeFrame': 'Baseline, up to 6 months'}],\n      dtype=object), 'secondary': array([{'description': None, 'measure': 'Need for Hospitalization, Ventilator Support, Exchange Transfusion/Apheresis or Treatment With Antifungals or Antibiotics', 'timeFrame': 'Baseline, up to 6 months'},\n       {'description': None, 'measure': 'Cumulative Incidence of Documented Bacterial, Fungal, and Viral Infections', 'timeFrame': 'Baseline, up to 6 months'}],\n      dtype=object)}",
         "[{'affiliation': 'Wake Forest University Health Sciences', 'name': 'Mary Ann Knovich, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}]",
         null,
         "{\"versionHolder\": \"2025-06-18\"}",
         "{'ancestors': array([{'id': 'D004194', 'term': 'Disease'},\n       {'id': 'D010335', 'term': 'Pathologic Processes'},\n       {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'},\n       {'id': 'D009369', 'term': 'Neoplasms'},\n       {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'},\n       {'id': 'D008206', 'term': 'Lymphatic Diseases'},\n       {'id': 'D007160', 'term': 'Immunoproliferative Disorders'},\n       {'id': 'D007154', 'term': 'Immune System Diseases'},\n       {'id': 'D006402', 'term': 'Hematologic Diseases'},\n       {'id': 'D020969', 'term': 'Disease Attributes'},\n       {'id': 'D020141', 'term': 'Hemostatic Disorders'},\n       {'id': 'D014652', 'term': 'Vascular Diseases'},\n       {'id': 'D002318', 'term': 'Cardiovascular Diseases'},\n       {'id': 'D010265', 'term': 'Paraproteinemias'},\n       {'id': 'D001796', 'term': 'Blood Protein Disorders'},\n       {'id': 'D006474', 'term': 'Hemorrhagic Disorders'},\n       {'id': 'D009385', 'term': 'Neoplastic Processes'},\n       {'id': 'D001855', 'term': 'Bone Marrow Diseases'},\n       {'id': 'D011230', 'term': 'Precancerous Conditions'},\n       {'id': 'D015448', 'term': 'Leukemia, B-Cell'},\n       {'id': 'D002908', 'term': 'Chronic Disease'},\n       {'id': 'D020031', 'term': 'Epstein-Barr Virus Infections'},\n       {'id': 'D006566', 'term': 'Herpesviridae Infections'},\n       {'id': 'D004266', 'term': 'DNA Virus Infections'},\n       {'id': 'D014777', 'term': 'Virus Diseases'},\n       {'id': 'D007239', 'term': 'Infections'},\n       {'id': 'D014412', 'term': 'Tumor Virus Infections'},\n       {'id': 'D001423', 'term': 'Bacterial Infections and Mycoses'},\n       {'id': 'D000740', 'term': 'Anemia'},\n       {'id': 'D019189', 'term': 'Iron Metabolism Disorders'},\n       {'id': 'D008659', 'term': 'Metabolic Diseases'},\n       {'id': 'D000072281', 'term': 'Lymphadenopathy'},\n       {'id': 'D017563', 'term': 'Lung Diseases, Interstitial'},\n       {'id': 'D008171', 'term': 'Lung Diseases'},\n       {'id': 'D012140', 'term': 'Respiratory Tract Diseases'},\n       {'id': 'D005134', 'term': 'Eye Neoplasms'},\n       {'id': 'D009371', 'term': 'Neoplasms by Site'},\n       {'id': 'D034721', 'term': 'Mastocytosis, Systemic'},\n       {'id': 'D008415', 'term': 'Mastocytosis'},\n       {'id': 'D000090362', 'term': 'Mast Cell Activation Disorders'}],\n      dtype=object), 'browseBranches': array([{'abbrev': 'BC04', 'name': 'Neoplasms'},\n       {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n       {'abbrev': 'All', 'name': 'All Conditions'},\n       {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n       {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n       {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n       {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'},\n       {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n       {'abbrev': 'BC01', 'name': 'Infections'},\n       {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n       {'abbrev': 'BC11', 'name': 'Eye Diseases'},\n       {'abbrev': 'Rare', 'name': 'Rare Diseases'}], dtype=object), 'browseLeaves': array([{'asFound': 'Secondary', 'id': 'M12307', 'name': 'Neoplasm Metastasis', 'relevance': 'HIGH'},\n       {'asFound': 'Syndrome', 'id': 'M16355', 'name': 'Syndrome', 'relevance': 'HIGH'},\n       {'asFound': 'Recurrent', 'id': 'M14850', 'name': 'Recurrence', 'relevance': 'HIGH'},\n       {'asFound': 'Multiple Myeloma', 'id': 'M12058', 'name': 'Multiple Myeloma', 'relevance': 'HIGH'},\n       {'asFound': 'Multiple Myeloma', 'id': 'M27588', 'name': 'Neoplasms, Plasma Cell', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M12', 'name': 'Congenital Abnormalities', 'relevance': 'LOW'},\n       {'asFound': 'Acute Myeloid Leukemia', 'id': 'M18127', 'name': 'Leukemia, Myeloid, Acute', 'relevance': 'HIGH'},\n       {'asFound': 'Myelodysplastic Syndrome', 'id': 'M12145', 'name': 'Myelodysplastic Syndromes', 'relevance': 'HIGH'},\n       {'asFound': 'Leukemia', 'id': 'M10945', 'name': 'Leukemia', 'relevance': 'HIGH'},\n       {'asFound': 'Myeloid Leukemia', 'id': 'M10955', 'name': 'Leukemia, Myeloid', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M4070', 'name': 'Anemia', 'relevance': 'LOW'},\n       {'asFound': 'Lymphoblastic Leukemia', 'id': 'M10951', 'name': 'Leukemia, Lymphoid', 'relevance': 'HIGH'},\n       {'asFound': 'Small lymphocytic lymphoma', 'id': 'M18116', 'name': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'Lymphoma', 'id': 'M11220', 'name': 'Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Diffuse small cleaved cell lymphoma', 'id': 'M11222', 'name': 'Lymphoma, Non-Hodgkin', 'relevance': 'HIGH'},\n       {'asFound': 'B-cell Lymphoma', 'id': 'M18828', 'name': 'Lymphoma, B-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'Mantle Cell Lymphoma', 'id': 'M22307', 'name': 'Lymphoma, Mantle-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'Marginal zone B-cell lymphoma', 'id': 'M20554', 'name': 'Lymphoma, B-Cell, Marginal Zone', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n       {'asFound': 'T-cell non-Hodgkin lymphoma', 'id': 'M18829', 'name': 'Lymphoma, T-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'T-cell Lymphoma', 'id': 'M18833', 'name': 'Lymphoma, T-Cell, Peripheral', 'relevance': 'HIGH'},\n       {'asFound': 'Langerhans Cell Histiocytosis', 'id': 'M9721', 'name': 'Histiocytosis, Langerhans-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'Histiocytosis', 'id': 'M18216', 'name': 'Histiocytosis', 'relevance': 'HIGH'},\n       {'asFound': 'Adult Hodgkin lymphoma', 'id': 'M9751', 'name': 'Hodgkin Disease', 'relevance': 'HIGH'},\n       {'asFound': 'Acute Lymphoblastic Leukemia', 'id': 'M27585', 'name': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Mycosis', 'id': 'M12136', 'name': 'Mycoses', 'relevance': 'HIGH'},\n       {'asFound': 'Mycosis Fungoides', 'id': 'M12137', 'name': 'Mycosis Fungoides', 'relevance': 'HIGH'},\n       {'asFound': 'Myeloproliferative Neoplasms', 'id': 'M12149', 'name': 'Myeloproliferative Disorders', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M21314', 'name': 'Hematologic Neoplasms', 'relevance': 'LOW'},\n       {'asFound': 'Anaplastic Large Cell Lymphoma', 'id': 'M19941', 'name': 'Lymphoma, Large-Cell, Anaplastic', 'relevance': 'HIGH'},\n       {'asFound': 'Diffuse large cell lymphoma', 'id': 'M18831', 'name': 'Lymphoma, Large B-Cell, Diffuse', 'relevance': 'HIGH'},\n       {'asFound': 'Myelodysplastic Syndrome', 'id': 'M14164', 'name': 'Preleukemia', 'relevance': 'HIGH'},\n       {'asFound': 'Sezary syndrome', 'id': 'M15560', 'name': 'Sezary Syndrome', 'relevance': 'HIGH'},\n       {'asFound': 'Waldenstrom Macroglobulinemia', 'id': 'M11251', 'name': 'Waldenstrom Macroglobulinemia', 'relevance': 'HIGH'},\n       {'asFound': 'Myelofibrosis', 'id': 'M28312', 'name': 'Primary Myelofibrosis', 'relevance': 'HIGH'},\n       {'asFound': 'Intraocular lymphoma', 'id': 'M30199', 'name': 'Intraocular Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Follicular lymphoma', 'id': 'M11221', 'name': 'Lymphoma, Follicular', 'relevance': 'HIGH'},\n       {'asFound': 'Cutaneous T-cell non-Hodgkin lymphoma', 'id': 'M18832', 'name': 'Lymphoma, T-Cell, Cutaneous', 'relevance': 'HIGH'},\n       {'asFound': 'Burkitt lymphoma', 'id': 'M5321', 'name': 'Burkitt Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Refractory anemia', 'id': 'M4083', 'name': 'Anemia, Refractory', 'relevance': 'HIGH'},\n       {'asFound': 'Immunoblastic large cell lymphoma', 'id': 'M381', 'name': 'Plasmablastic Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Immunoblastic large cell lymphoma', 'id': 'M18830', 'name': 'Lymphoma, Large-Cell, Immunoblastic', 'relevance': 'HIGH'},\n       {'asFound': 'T-cell leukemia', 'id': 'M18119', 'name': 'Leukemia, T-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'Adult T-cell leukemia/lymphoma', 'id': 'M18120', 'name': 'Leukemia-Lymphoma, Adult T-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'Angioimmunoblastic T-cell lymphoma', 'id': 'M10167', 'name': 'Immunoblastic Lymphadenopathy', 'relevance': 'HIGH'},\n       {'asFound': 'Iron Overload', 'id': 'M21178', 'name': 'Iron Overload', 'relevance': 'HIGH'},\n       {'asFound': 'Mast cell leukemia', 'id': 'M10952', 'name': 'Leukemia, Mast-Cell', 'relevance': 'HIGH'},\n       {'asFound': 'Lymphomatoid granulomatosis', 'id': 'M11223', 'name': 'Lymphomatoid Granulomatosis', 'relevance': 'HIGH'},\n       {'asFound': 'Grade III lymphomatoid granulomatosis', 'id': 'M27676', 'name': 'Lymphoma, Extranodal NK-T-Cell', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M994', 'name': 'Lymphadenopathy', 'relevance': 'LOW'},\n       {'asFound': 'Myelodysplastic/Myeloproliferative Neoplasms', 'id': 'M27707', 'name': 'Myelodysplastic-Myeloproliferative Diseases', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M11225', 'name': 'Lymphoproliferative Disorders', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M11203', 'name': 'Lymphatic Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M10206', 'name': 'Immunoproliferative Disorders', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M21977', 'name': 'Hemostatic Disorders', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M5059', 'name': 'Blood Coagulation Disorders', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M13178', 'name': 'Paraproteinemias', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M5077', 'name': 'Blood Protein Disorders', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M9560', 'name': 'Hemorrhagic Disorders', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M12330', 'name': 'Neoplastic Processes', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M5134', 'name': 'Bone Marrow Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M14111', 'name': 'Precancerous Conditions', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M18115', 'name': 'Leukemia, B-Cell', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M21881', 'name': 'Epstein-Barr Virus Infections', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M9643', 'name': 'Herpesviridae Infections', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M7442', 'name': 'DNA Virus Infections', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M17162', 'name': 'Tumor Virus Infections', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M4722', 'name': 'Bacterial Infections', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M4721', 'name': 'Bacterial Infections and Mycoses', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M21177', 'name': 'Iron Metabolism Disorders', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M19813', 'name': 'Lung Diseases, Interstitial', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M8277', 'name': 'Eye Neoplasms', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M11399', 'name': 'Mastocytosis', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M24449', 'name': 'Mastocytosis, Systemic', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M2776', 'name': 'Mast Cell Activation Disorders', 'relevance': 'LOW'},\n       {'asFound': 'Myeloid Leukemia', 'id': 'T3995', 'name': 'Myeloid Leukemia', 'relevance': 'HIGH'},\n       {'asFound': 'Multiple Myeloma', 'id': 'T3947', 'name': 'Multiple Myeloma', 'relevance': 'HIGH'},\n       {'asFound': 'Acute Myeloid Leukemia', 'id': 'T182', 'name': 'Acute Myeloid Leukemia', 'relevance': 'HIGH'},\n       {'asFound': 'Acute Myeloid Leukemia', 'id': 'T188', 'name': 'Acute Non Lymphoblastic Leukemia', 'relevance': 'HIGH'},\n       {'asFound': 'Myelodysplastic Syndrome', 'id': 'T3993', 'name': 'Myelodysplastic Syndromes', 'relevance': 'HIGH'},\n       {'asFound': 'Small lymphocytic lymphoma', 'id': 'T1308', 'name': 'Chronic Lymphocytic Leukemia', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'T170', 'name': 'Acute Graft Versus Host Disease', 'relevance': 'LOW'},\n       {'asFound': 'Lymphoma', 'id': 'T3543', 'name': 'Lymphosarcoma', 'relevance': 'HIGH'},\n       {'asFound': 'Follicular lymphoma', 'id': 'T2361', 'name': 'Follicular Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'B-cell Lymphoma', 'id': 'T640', 'name': 'B-cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Mantle Cell Lymphoma', 'id': 'T3601', 'name': 'Mantle Cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Marginal zone lymphoma', 'id': 'T3612', 'name': 'Marginal Zone Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'T-cell Lymphoma', 'id': 'T4496', 'name': 'Peripheral T-cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Langerhans Cell Histiocytosis', 'id': 'T3306', 'name': 'Langerhans Cell Histiocytosis', 'relevance': 'HIGH'},\n       {'asFound': 'Hodgkin Lymphoma', 'id': 'T2817', 'name': 'Hodgkin Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Acute Lymphoblastic Leukemia', 'id': 'T175', 'name': 'Acute Lymphoblastic Leukemia', 'relevance': 'HIGH'},\n       {'asFound': 'Lymphoblastic lymphoma', 'id': 'T3533', 'name': 'Lymphoblastic Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Mycosis Fungoides', 'id': 'T3986', 'name': 'Mycosis Fungoides', 'relevance': 'HIGH'},\n       {'asFound': 'Myeloproliferative Neoplasms', 'id': 'T1311', 'name': 'Chronic Myeloproliferative Disorders', 'relevance': 'HIGH'},\n       {'asFound': 'Anaplastic Large Cell Lymphoma', 'id': 'T367', 'name': 'Anaplastic Large Cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Diffuse large cell lymphoma', 'id': 'T1866', 'name': 'Diffuse Large B-Cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Sezary syndrome', 'id': 'T5200', 'name': 'Sezary Syndrome', 'relevance': 'HIGH'},\n       {'asFound': 'NK/T-cell Lymphoma', 'id': 'T2165', 'name': 'Extranodal Nasal NK/T Cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Waldenstrom Macroglobulinemia', 'id': 'T5887', 'name': 'Waldenstrom Macroglobulinemia', 'relevance': 'HIGH'},\n       {'asFound': 'Myelofibrosis', 'id': 'T4705', 'name': 'Primary Myelofibrosis', 'relevance': 'HIGH'},\n       {'asFound': 'Cutaneous T-cell non-Hodgkin lymphoma', 'id': 'T1689', 'name': 'Cutaneous T-cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Burkitt lymphoma', 'id': 'T892', 'name': 'Burkitt Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Immunoblastic large cell lymphoma', 'id': 'T4586', 'name': 'Plasmablastic Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Immunoblastic large cell lymphoma', 'id': 'T3539', 'name': 'Lymphoma, Large-cell, Immunoblastic', 'relevance': 'HIGH'},\n       {'asFound': 'T-cell leukemia', 'id': 'T3393', 'name': 'Leukemia, T-cell, Chronic', 'relevance': 'HIGH'},\n       {'asFound': 'Adult T-cell leukemia/lymphoma', 'id': 'T224', 'name': 'Adult T-cell Leukemia/lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Angioimmunoblastic T-cell lymphoma', 'id': 'T391', 'name': 'Angioimmunoblastic T-cell Lymphoma', 'relevance': 'HIGH'},\n       {'asFound': 'Angioimmunoblastic T-cell lymphoma', 'id': 'T390', 'name': 'Angioimmunoblastic Lymphadenopathy With Dysproteinemia', 'relevance': 'HIGH'},\n       {'asFound': 'Myelodysplastic/Myeloproliferative Neoplasms', 'id': 'T3994', 'name': 'Myelodysplastic/myeloproliferative Disease', 'relevance': 'HIGH'},\n       {'asFound': 'Lymphomatoid granulomatosis', 'id': 'T3540', 'name': 'Lymphomatoid Granulomatosis', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'T3626', 'name': 'Mastocytosis', 'relevance': 'LOW'}],\n      dtype=object), 'meshes': array([{'id': 'D002051', 'term': 'Burkitt Lymphoma'},\n       {'id': 'D009181', 'term': 'Mycoses'},\n       {'id': 'D008223', 'term': 'Lymphoma'},\n       {'id': 'D007938', 'term': 'Leukemia'},\n       {'id': 'D007951', 'term': 'Leukemia, Myeloid'},\n       {'id': 'D009101', 'term': 'Multiple Myeloma'},\n       {'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'},\n       {'id': 'D015470', 'term': 'Leukemia, Myeloid, Acute'},\n       {'id': 'D008224', 'term': 'Lymphoma, Follicular'},\n       {'id': 'D009362', 'term': 'Neoplasm Metastasis'},\n       {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'},\n       {'id': 'D011289', 'term': 'Preleukemia'},\n       {'id': 'D016393', 'term': 'Lymphoma, B-Cell'},\n       {'id': 'D054198', 'term': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma'},\n       {'id': 'D007945', 'term': 'Leukemia, Lymphoid'},\n       {'id': 'D006689', 'term': 'Hodgkin Disease'},\n       {'id': 'D020522', 'term': 'Lymphoma, Mantle-Cell'},\n       {'id': 'D016399', 'term': 'Lymphoma, T-Cell'},\n       {'id': 'D016411', 'term': 'Lymphoma, T-Cell, Peripheral'},\n       {'id': 'D018442', 'term': 'Lymphoma, B-Cell, Marginal Zone'},\n       {'id': 'D015451', 'term': 'Leukemia, Lymphocytic, Chronic, B-Cell'},\n       {'id': 'D016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'},\n       {'id': 'D016400', 'term': 'Lymphoma, Large-Cell, Immunoblastic'},\n       {'id': 'D000069293', 'term': 'Plasmablastic Lymphoma'},\n       {'id': 'D009182', 'term': 'Mycosis Fungoides'},\n       {'id': 'D012751', 'term': 'Sezary Syndrome'},\n       {'id': 'D015458', 'term': 'Leukemia, T-Cell'},\n       {'id': 'D008258', 'term': 'Waldenstrom Macroglobulinemia'},\n       {'id': 'D016410', 'term': 'Lymphoma, T-Cell, Cutaneous'},\n       {'id': 'D015459', 'term': 'Leukemia-Lymphoma, Adult T-Cell'},\n       {'id': 'D017728', 'term': 'Lymphoma, Large-Cell, Anaplastic'},\n       {'id': 'D008230', 'term': 'Lymphomatoid Granulomatosis'},\n       {'id': 'D054391', 'term': 'Lymphoma, Extranodal NK-T-Cell'},\n       {'id': 'D064090', 'term': 'Intraocular Lymphoma'},\n       {'id': 'D007946', 'term': 'Leukemia, Mast-Cell'},\n       {'id': 'D006646', 'term': 'Histiocytosis, Langerhans-Cell'},\n       {'id': 'D009190', 'term': 'Myelodysplastic Syndromes'},\n       {'id': 'D055728', 'term': 'Primary Myelofibrosis'},\n       {'id': 'D009196', 'term': 'Myeloproliferative Disorders'},\n       {'id': 'D000753', 'term': 'Anemia, Refractory'},\n       {'id': 'D007119', 'term': 'Immunoblastic Lymphadenopathy'},\n       {'id': 'D054437', 'term': 'Myelodysplastic-Myeloproliferative Diseases'},\n       {'id': 'D015614', 'term': 'Histiocytosis'},\n       {'id': 'D019190', 'term': 'Iron Overload'},\n       {'id': 'D013577', 'term': 'Syndrome'},\n       {'id': 'D012008', 'term': 'Recurrence'}], dtype=object)}",
         "{'ancestors': array([{'id': 'D007502', 'term': 'Iron Chelating Agents'},\n       {'id': 'D002614', 'term': 'Chelating Agents'},\n       {'id': 'D064449', 'term': 'Sequestering Agents'},\n       {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}],\n      dtype=object), 'browseBranches': array([{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n       {'abbrev': 'Micro', 'name': 'Micronutrients'}], dtype=object), 'browseLeaves': array([{'asFound': 'Leukocyte', 'id': 'M1848', 'name': 'Deferasirox', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M10533', 'name': 'Iron', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M5860', 'name': 'Chelating Agents', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M10534', 'name': 'Iron Chelating Agents', 'relevance': 'LOW'}],\n      dtype=object), 'meshes': array([{'id': 'D000077588', 'term': 'Deferasirox'}], dtype=object)}",
         "{'conditions': array([{'id': 'D002051', 'term': 'Burkitt Lymphoma'},\n       {'id': 'D009181', 'term': 'Mycoses'},\n       {'id': 'D008223', 'term': 'Lymphoma'},\n       {'id': 'D007938', 'term': 'Leukemia'},\n       {'id': 'D007951', 'term': 'Leukemia, Myeloid'},\n       {'id': 'D009101', 'term': 'Multiple Myeloma'},\n       {'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'},\n       {'id': 'D015470', 'term': 'Leukemia, Myeloid, Acute'},\n       {'id': 'D008224', 'term': 'Lymphoma, Follicular'},\n       {'id': 'D009362', 'term': 'Neoplasm Metastasis'},\n       {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'},\n       {'id': 'D011289', 'term': 'Preleukemia'},\n       {'id': 'D016393', 'term': 'Lymphoma, B-Cell'},\n       {'id': 'D054198', 'term': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma'},\n       {'id': 'D007945', 'term': 'Leukemia, Lymphoid'},\n       {'id': 'D006689', 'term': 'Hodgkin Disease'},\n       {'id': 'D020522', 'term': 'Lymphoma, Mantle-Cell'},\n       {'id': 'D016399', 'term': 'Lymphoma, T-Cell'},\n       {'id': 'D016411', 'term': 'Lymphoma, T-Cell, Peripheral'},\n       {'id': 'D018442', 'term': 'Lymphoma, B-Cell, Marginal Zone'},\n       {'id': 'D015451', 'term': 'Leukemia, Lymphocytic, Chronic, B-Cell'},\n       {'id': 'D016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'},\n       {'id': 'D016400', 'term': 'Lymphoma, Large-Cell, Immunoblastic'},\n       {'id': 'D000069293', 'term': 'Plasmablastic Lymphoma'},\n       {'id': 'D009182', 'term': 'Mycosis Fungoides'},\n       {'id': 'D012751', 'term': 'Sezary Syndrome'},\n       {'id': 'D015458', 'term': 'Leukemia, T-Cell'},\n       {'id': 'D008258', 'term': 'Waldenstrom Macroglobulinemia'},\n       {'id': 'D016410', 'term': 'Lymphoma, T-Cell, Cutaneous'},\n       {'id': 'D015459', 'term': 'Leukemia-Lymphoma, Adult T-Cell'},\n       {'id': 'D017728', 'term': 'Lymphoma, Large-Cell, Anaplastic'},\n       {'id': 'D008230', 'term': 'Lymphomatoid Granulomatosis'},\n       {'id': 'D054391', 'term': 'Lymphoma, Extranodal NK-T-Cell'},\n       {'id': 'D064090', 'term': 'Intraocular Lymphoma'},\n       {'id': 'D007946', 'term': 'Leukemia, Mast-Cell'},\n       {'id': 'D006646', 'term': 'Histiocytosis, Langerhans-Cell'},\n       {'id': 'D009190', 'term': 'Myelodysplastic Syndromes'},\n       {'id': 'D055728', 'term': 'Primary Myelofibrosis'},\n       {'id': 'D009196', 'term': 'Myeloproliferative Disorders'},\n       {'id': 'D000753', 'term': 'Anemia, Refractory'},\n       {'id': 'D007119', 'term': 'Immunoblastic Lymphadenopathy'},\n       {'id': 'D054437', 'term': 'Myelodysplastic-Myeloproliferative Diseases'},\n       {'id': 'D015614', 'term': 'Histiocytosis'},\n       {'id': 'D019190', 'term': 'Iron Overload'},\n       {'id': 'D013577', 'term': 'Syndrome'},\n       {'id': 'D012008', 'term': 'Recurrence'}], dtype=object), 'interventions': array([{'id': 'D000077588', 'term': 'Deferasirox'}], dtype=object)}"
        ],
        [
         "1",
         "NCT00787566",
         null,
         "Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting",
         "A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic Chemotherapy",
         "None",
         "INTERVENTIONAL",
         "COMPLETED",
         "2008-11-05 00:00:00",
         null,
         null,
         null,
         "['PHASE2']",
         "68.0",
         "18.0",
         null,
         "ALL",
         "False",
         "Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV) associated with the administration of highly emetogenic chemotherapy.\n\nPrimary Objective: To select a dose for Phase 3 by assessing the efficacy, safety, and tolerability of 3 doses of TRG in patients with CINV associated with the administration of highly emetogenic chemotherapy.",
         null,
         "Inclusion Criteria:\n\n* Patients with histologically and/or cytologically confirmed cancer\n* ECOG performance status of 0, 1, or 2\n* Patients with life expectancy of at least 3 months\n* Patients who are chemotherapy naÃ¯ve\n* Patients who will be receiving the first cycle of a highly emetogenic regimen according to the MASCC criteria or the Hesketh criteria\n* Patients with adequate metabolic or hematologic values for chemotherapy\n* Patients with intact nasal mucosa\n* Non child-bearing potential patients\n* Patients able to read and write at a competent level, and capable of giving legal consent\n* Patients who have provided written informed consent\n\nExclusion Criteria:\n\n* Patients who do not receive a chemotherapy regimen which is a highly emetogenic chemotherapy regimen according to the MASCC or the Hesketh criteria\n* Patients with nasal cancers, pharyngeal cancers, maxillary sinus cancers, or ethmoid sinus cancers\n* Patients with nasal ulcers, septal perforation, or other nasal conditions that may interfere with IN administration\n* Patients with any episode of retching, vomiting, or uncontrolled nausea within 48 hours before dosing with TRG and/or administration of chemotherapy\n* Patients who have received radiation therapy in the 14 days before dosing with TRG, or for whom radiation therapy is scheduled during the 7 days after a TRG dose\n* Patients who have received any investigational product within 30 days prior to study entry\n* Patients who have received any drug or who were scheduled to receive any drug with antiemetic efficacy within 24 hours of the start of treatment\n* Patients who have an allergy or hypersensitivity to granisetron or other selective 5hydroxytryptamine3(5-HT3) receptor antagonists\n* Patients with ECOG performance status of 3 or 4\n* Patients who have or have a history of brain tumors, head cancers, or neck cancers\n* Patients who have a psychological problem that, in the Investigator's opinion, is severe enough to interfere with study eligibility or with interpretation of study results\n* Patients who are pregnant (urine test) or breastfeeding\n* Patients who have received prior cytotoxic chemotherapy given for the treatment of cancer\n* Patients scheduled to receive multiple day chemotherapy\n* Patients with clinically relevant abnormal laboratory values at the discretion of the Investigator\n* Patients with clinically relevant hepatic, renal, infectious, neurological, or psychiatric disorders, or any other major systemic illness at the discretion of the Investigator\n* Patients with any prevalence or cause of nausea and vomiting other than chemotherapy\n* Patients using systemic steroids for any indication, or patients using steroids other than dexamethasone for prevention of chemotherapy-induced nausea and vomiting, or patients using dexamethasone for chemotherapy-induced nausea and vomiting at doses other than recommended in the MASCC antiemetic guidelines\n* Patients with a QT interval greater than 500 ms or with acute ischemic changes or cardiac abnormality predisposing to arrhythmia on screening electrocardiogram (ECG) or by history\n* Patients with a history of drug and/or alcohol abuse.",
         "Shin Nippon Biomedical Laboratories, Ltd.",
         "INDUSTRY",
         "{'id': 'TRG-002', 'link': None, 'type': None}",
         "Unknown",
         "{'hasExpandedAccess': False, 'nctId': None, 'statusForNctId': None}",
         "2008-11-06 00:00:00",
         "{'date': '2011-07-12', 'type': 'ESTIMATED'}",
         "{'date': '2008-11-07', 'type': 'ESTIMATED'}",
         "['ADULT' 'OLDER_ADULT']",
         null,
         null,
         null,
         "{'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': None, 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': None, 'whoMasked': array(['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR'], dtype=object)}, 'observationalModel': None, 'primaryPurpose': 'PREVENTION', 'timePerspective': None}",
         "['Chemotherapy-Induced Nausea and Vomiting']",
         "[\"Highly emetogenic chemotherapy induced nausea and vomiting\"]",
         null,
         "[{'city': 'The study is managed by Kendle International, in Wilmington', 'country': 'United States', 'facility': 'The study is conducted at 14 Centers, in 14 cities accross the United States', 'geoPoint': None, 'state': 'North Carolina'}]",
         null,
         null,
         "{'other': None, 'primary': array([{'description': None, 'measure': 'Percentage of Patients With Complete Control', 'timeFrame': '24 hours'}],\n      dtype=object), 'secondary': array([{'description': None, 'measure': 'Percentage of Patients With Complete Response', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Percentage of Patients With Total Response', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Percentage of Patients With Major Control of Emesis', 'timeFrame': '24 hrs'},\n       {'description': None, 'measure': 'Percentage of Patients With Minor Control of Emesis', 'timeFrame': '24 hrs'},\n       {'description': None, 'measure': 'Percentage of Patients With Failure', 'timeFrame': '24 hrs'},\n       {'description': None, 'measure': 'Percentage of Patients Using Rescue Medications', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Time to First Emetic Episode', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Time to First Rescue Medication', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Time to Treatment Failure', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Number of Emetic Episodes', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Severity of Nausea Measured by a 4 Categorical Scale', 'timeFrame': '24 hours'},\n       {'description': None, 'measure': 'Patient Global Satisfaction With Antiemetic Therapy Measured by a VAS', 'timeFrame': '24 hours'}],\n      dtype=object)}",
         null,
         null,
         "{\"versionHolder\": \"2025-06-18\"}",
         "{'ancestors': array([{'id': 'D012817', 'term': 'Signs and Symptoms, Digestive'}],\n      dtype=object), 'browseBranches': array([{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n       {'abbrev': 'All', 'name': 'All Conditions'}], dtype=object), 'browseLeaves': array([{'asFound': 'Nausea', 'id': 'M12273', 'name': 'Nausea', 'relevance': 'HIGH'},\n       {'asFound': 'Vomiting', 'id': 'M17582', 'name': 'Vomiting', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M15622', 'name': 'Signs and Symptoms, Digestive', 'relevance': 'LOW'}],\n      dtype=object), 'meshes': array([{'id': 'D009325', 'term': 'Nausea'},\n       {'id': 'D014839', 'term': 'Vomiting'}], dtype=object)}",
         "{'ancestors': array([{'id': 'D000932', 'term': 'Antiemetics'},\n       {'id': 'D001337', 'term': 'Autonomic Agents'},\n       {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'},\n       {'id': 'D045505', 'term': 'Physiological Effects of Drugs'},\n       {'id': 'D005765', 'term': 'Gastrointestinal Agents'},\n       {'id': 'D058831', 'term': 'Serotonin 5-HT3 Receptor Antagonists'},\n       {'id': 'D012702', 'term': 'Serotonin Antagonists'},\n       {'id': 'D018490', 'term': 'Serotonin Agents'},\n       {'id': 'D018377', 'term': 'Neurotransmitter Agents'},\n       {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}],\n      dtype=object), 'browseBranches': array([{'abbrev': 'AnEm', 'name': 'Antiemetics'},\n       {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'},\n       {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n       {'abbrev': 'Emet', 'name': 'Emetics'}], dtype=object), 'browseLeaves': array([{'asFound': 'Homework', 'id': 'M20020', 'name': 'Granisetron', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M7805', 'name': 'Emetics', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M4251', 'name': 'Antiemetics', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M15512', 'name': 'Serotonin', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M29246', 'name': 'Serotonin 5-HT3 Receptor Antagonists', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M15513', 'name': 'Serotonin Antagonists', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'}],\n      dtype=object), 'meshes': array([{'id': 'D017829', 'term': 'Granisetron'}], dtype=object)}",
         "{'conditions': array([{'id': 'D009325', 'term': 'Nausea'},\n       {'id': 'D014839', 'term': 'Vomiting'}], dtype=object), 'interventions': array([{'id': 'D017829', 'term': 'Granisetron'}], dtype=object)}"
        ],
        [
         "2",
         "NCT00497666",
         null,
         "Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study",
         "Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study",
         "None",
         "OBSERVATIONAL",
         "UNKNOWN",
         "2007-07-06 00:00:00",
         null,
         null,
         null,
         null,
         null,
         "18.0",
         "90.0",
         "ALL",
         null,
         "Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.\n\nWe decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.",
         "Background Type 2 diabetes mellitus is a public health concern, and projections of its future effect are alarming. According to the World Health Organization, diabetes affects more than 170 million people worldwide, and this number will rise to 370 million by 2030 \\[1\\]. About one third of those affected will eventually have progressive deterioration of renal function \\[2, 3\\]. The first clinical sign of renal dysfunction in patients with diabetes is generally microalbuminuria (a sign of endothelial dysfunction that is not necessarily confined to the kidney)\\[4\\], which develops in 2 to 5 percent of patients per year \\[5,6\\]. In type 2 diabetes, unlike type 1 diabetes \\[7\\], microalbuminuria is seldom reversible \\[8\\], but, instead, progresses to overt proteinuria in 20 to 40 percent of patients.\\[9,10\\]. In 10 to 50 percent of patients with proteinuria, chronic kidney disease develops that ultimately requires dialysis or transplantation \\[11,12,13\\]. Forty to 50 percent of patients with type 2 diabetes who have microalbuminuria eventually die of cardiovascular disease \\[14,15\\]; this is three times as high a rate of death from cardiac causes as among patients who have diabetes but have no evidence of renal disease \\[6\\].\n\nIn patients with diabetes and renal disease, lowering blood pressure and the levels of urinary albumin is effective in reducing the risk of end-stage renal disease as well as that of myocardial infarction, heart failure, and stroke \\[16\\]. Angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II antagonists appear to be the most effective renoprotective and antihypertensive agents \\[11, 12, 17-21\\] . Treatment with the ACE inhibitor enalapril over a period of six years decreased the incidence of microalbuminuria in patients with type 2 diabetes who were normotensive and not obese \\[22\\].\n\nPreventing (or delaying) the development of microalbuminuria is a key treatment goal for renoprotection \\[23\\] and, possibly, for cardioprotection \\[4\\]. Recent clinical trials suggested that inhibition of the renin-angiotensin system may actually prevent nephropathy. The post hoc analyses of the reduction in hypertension in the Heart Outcomes Prevention Evaluation study \\[18\\] and in the Losartan Intervention for Endpoint study \\[24\\] found a lower incidence of overt nephropathy in subjects with type 2 diabetes who received therapy that inhibited the renin-angiotensin system than in controls.\n\nRecent BENEDICT study indicates that treatment with trandolapril with or without verapamil significantly reduces the incidence of microalbuminuria in patients with type 2 diabetes and normal urinary albumin excretion, as compared with placebo \\[25\\]. Trandolapril alone also appeared to decrease the incidence of microalbuminuria, whereas verapamil had no effect. Thiseffect of trandolapril plus verapamil and trandolapril alone in preventing microalbuminuria exceeded expectations based on changes in blood pressure alone.\n\nUnfortunately, even with the appropriate use of available therapy, diabetic nephropathy still remains the leading cause of ESRD \\[2\\]. More effective strategies are needed in order to retard the progression of diabetic nephropathy and to reduce cardiovascular mortality in diabetic population.\n\nThiazolidinediones (TZDs) represent a class of compounds currently used for the treatment of type 2 DM that exert their hypoglycemic properties through reduction of IR \\[26\\]. These agents act by stimulating a certain type of nuclear receptor, called peroxisome proliferator-activated receptor gamma (PPAR ). Such receptors are abundant in adipose tissue cells, but they are also present in various other cell types, such as vascular smooth muscle cells, macrophages, vascular endothelial cells, colon epithelial cells, as well as renal glomerular and tubular cells. Through transcriptional regulation of various genes, PPAR receptors play an important role in adipocyte differentiation and lipid and carbohydrate metabolism \\[26\\]. Apart from improving glycemic control in patients with type 2 DM, several lines of evidence support the notion that TZDs have beneficial effects on other components of the metabolic syndrome, such as blood pressure (BP) lowering, triglyceride reduction, high-density lipoprotein-cholesterol elevation, redistribution of body fat away from the central compartment, decrease of C-reactive protein and plasminogen activator inhibitor -1 (PAI-1) levels, and others \\[26\\].\n\nAdditionally, several animal studies demonstrate that TZDs also reduce urine albumin or protein excretion and protect against injury to the kidney \\[27\\]. Moreover, experimental studies exposed numerous actions of TZDs in the kidney that could explain a possible renoprotective effect \\[27-30\\]. Our recent study on diabetic rats showed that rosiglitazone exerts its anti-inflammatory renoprotective effect by inhibition of mesangial cells proliferation, downregulation of apoptosis and blunting responsiveness to angiotensin-2 \\[31\\].\n\nHuman study also report significant reductions in UAE among patients with type 2 diabetes by rosiglitazone \\[32\\].\n\nAnother human study was part of a cardiac safety study where rosiglitazone 4 mg b.i.d. was compared to glyburide in 121 patients for 52 weeks \\[32\\]. After 28 weeks of treatment, both groups had significant reductions in ACR of about 30%, but after 52 weeks only rosiglitazone group continued to demonstrate a significant ACR reduction. This finding suggests that duration of follow-up is an important variable in assessing the effect of TZDs \\[32\\].\n\nOverall, the above data clearly show that TZD treatment can reduce UAE. However, it should be emphasized that currently there are no trials that examine the effects of TZDs on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy \\[33\\]. Such studies are needed in order to provide the best evidence for a renoprotective effect of TZDs.\n\nBased on this data, we decided to study the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.\n\nMethods. Study population. The study is planned as retrospective cohort study using automated clinical data of Central Region Clalit Health Survices from 1999 until 2007.\n\nInclusion criteria: 1. Diagnosis of Diabetes Mellitus Type II; 2. Treatment With Oral hypoglycemics; 3. Availability of Baseline and follow up clinical data Exclusion criteria: 1. Insulin Therapy at baseline; 2. Malignancy Patients will be divided into 2 groups: rosiglitazone-treated group and non-treated with rosiglitazone ( control) group.\n\nBaseline Data ( separately for two groups). Number of patients. Gender Race/etnicity Age Weight, BMI Duration of DM Diabetic microangiopathy: retinopathy, neuropathy, nephropathy Medications for DM Creatinine Microalbumin Proteinuria HbA1c% Hb Ca, P, PTH Albumin Hypertension: BP Cholesterol, LDL, TG Smoking: current, previous Alcohol consumption Comorbidites: HTN, CAD, CHF, PVD, Hypercholesterolemia, CVA/TIA Drugs: ACEi, ARBs, CCB, beta-blockers, statines, antiplatlate Use of nephrotoxic medications: NSAIDs\n\nFollow up data Duration of rosiglitasone therapy/follow up Use of contrast media during study\n\nEvery year data:\n\nCreatinine eGFR Microalbumin Proteinuria HbA1C% Start of insulin therapy\n\nEvents:\n\nHospitalisation (cause) Death (cause) ESRD/Dialysis Reported CHF MI CVA Angiography PVD Amputation References\n\n1. World Health Organization. The Diabetes Program 2004. (at http://www.who.int/diabetes/en/.)\n2. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-1151.\n3. Ruggenenti P, Remuzzi G. The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. Curr Opin Nephrol Hypertens 1997;6:141-145.\n4. Ritz E. Albuminuria and vascular damage -- the vicious twins. N Engl J Med 2003;348:2349-2352.\n5. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997;314:783-788.\n6. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232.\n7. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285-2293\n8. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878\n9. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360\n10. Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH. Assessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991;151:1761-1765.\n11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.\n12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.\n13. Nelson RG, Newman JM, Knowler WC, et al. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1988;31:730-736\n14. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004;27:1330-1334.\n15. Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner \\& Rector's The kidney. 7th ed. Vol. 2. Philadelphia: Saunders, 2004:1777-818.\n16. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997;157:1413-1418\n17. Parving HH, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996;49:1778-1782\n18. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes melllitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259. \\[Erratum, Lancet 2000;356:860.\\]\n19. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279.\n20. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996;156:286-289\n21. Lewis EJ, Hunsicker LG, Bain RF, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462. \\[Erratum, N Engl J Med 1993;330:152.\n22. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1998;128:982-988\n23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. \\[Erratum, Lancet 1999;354:602.\\]\n24. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:1004-1010.\n25. Ruggenenti P, Fassi A, Ilieva A, et al. Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351: 1941-51.\n26. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56: 265-294.\n27. Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 2001; 38: S178-S181\n28. Asano T, Wakisaka M, Yoshinari M et al. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta 2000; 1497: 148-154\n29. Xiong Z, Huang H, Li J et al. Anti-inflammatory effect of PPARgamma in cultured human mesangial cells. Renal Failure 2004; 26: 497-505.\n30. Gumieniczek A. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003; 74: 553-562\n31. Weissgarten J, Berman S, Efrati S, et al. Apoptosis and proliferation of cultured mesangial cell isolated from kidneys of rosiglitasone-treated pregnant diabetic rats. Nephrol Dial Transplant 2006; 21: 1198-204\n32. Bakris G, Viberti G, Weston WM et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003; 17: 7-12.\n33. Sarafidis P, Bakris G. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233.",
         "Inclusion Criteria:\n\n1. Diagnosis of Diabetes Mellitus Type II\n2. Treatment With Oral hypoglycemics\n3. Availability of Baseline and follow up clinical data\n\nExclusion Criteria:\n\n1. Insulin Therapy at baseline\n2. Malignancy",
         "Assaf-Harofeh Medical Center",
         "OTHER_GOV",
         "{'id': '346147Rosi', 'link': None, 'type': None}",
         "Unknown",
         "{'hasExpandedAccess': False, 'nctId': None, 'statusForNctId': None}",
         "2007-07-06 00:00:00",
         "{'date': '2007-07-09', 'type': 'ESTIMATED'}",
         "{'date': '2007-07-09', 'type': 'ESTIMATED'}",
         "['ADULT' 'OLDER_ADULT']",
         null,
         null,
         "False",
         "{'allocation': None, 'interventionModel': None, 'interventionModelDescription': None, 'maskingInfo': None, 'observationalModel': 'CASE_CONTROL', 'primaryPurpose': None, 'timePerspective': 'OTHER'}",
         "['Diabetes' 'Diabetic Nephropathy' 'Renal Protection']",
         "[\"Diabetes\", \"Diabetic nephropathy\", \"renal protection\"]",
         null,
         "[{'city': 'Zerifin,', 'country': 'Israel', 'facility': 'Clalit Health Cervices, Central District', 'geoPoint': {'lat': 31.95857, 'lon': 4.83723}, 'state': None}]",
         null,
         null,
         null,
         "[{'affiliation': 'Nephrology Division, Assaf Harofeh Medical Center, Zerifin,', 'name': 'Leonid S Feldman', 'role': 'PRINCIPAL_INVESTIGATOR'}\n {'affiliation': 'Assaf-Harofeh Medical Center', 'name': 'Leonid S Feldman', 'role': 'PRINCIPAL_INVESTIGATOR'}]",
         null,
         "{\"versionHolder\": \"2025-06-18\"}",
         "{'ancestors': array([{'id': 'D014570', 'term': 'Urologic Diseases'},\n       {'id': 'D052776', 'term': 'Female Urogenital Diseases'},\n       {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n       {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n       {'id': 'D052801', 'term': 'Male Urogenital Diseases'},\n       {'id': 'D048909', 'term': 'Diabetes Complications'},\n       {'id': 'D003920', 'term': 'Diabetes Mellitus'},\n       {'id': 'D004700', 'term': 'Endocrine System Diseases'},\n       {'id': 'D020969', 'term': 'Disease Attributes'},\n       {'id': 'D010335', 'term': 'Pathologic Processes'}], dtype=object), 'browseBranches': array([{'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n       {'abbrev': 'All', 'name': 'All Conditions'},\n       {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n       {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n       {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}],\n      dtype=object), 'browseLeaves': array([{'asFound': 'Nephropathy', 'id': 'M10698', 'name': 'Kidney Diseases', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'},\n       {'asFound': 'Diabetic Nephropathy', 'id': 'M7123', 'name': 'Diabetic Nephropathies', 'relevance': 'HIGH'},\n       {'asFound': 'Clinical Course', 'id': 'M20559', 'name': 'Disease Progression', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}],\n      dtype=object), 'meshes': array([{'id': 'D007674', 'term': 'Kidney Diseases'},\n       {'id': 'D003928', 'term': 'Diabetic Nephropathies'},\n       {'id': 'D018450', 'term': 'Disease Progression'}], dtype=object)}",
         "{'ancestors': None, 'browseBranches': array([{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'},\n       {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}], dtype=object), 'browseLeaves': array([{'asFound': None, 'id': 'M1677', 'name': 'Rosiglitazone', 'relevance': 'LOW'}],\n      dtype=object), 'meshes': None}",
         "{'conditions': array([{'id': 'D007674', 'term': 'Kidney Diseases'},\n       {'id': 'D003928', 'term': 'Diabetic Nephropathies'},\n       {'id': 'D018450', 'term': 'Disease Progression'}], dtype=object), 'interventions': array([], dtype=object)}"
        ],
        [
         "3",
         "NCT01978366",
         null,
         "Open Label Extension Study of HT-100 in Patients With DMD",
         "An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01",
         "None",
         "INTERVENTIONAL",
         "TERMINATED",
         "2013-10-31 00:00:00",
         null,
         "2016-04-30 00:00:00",
         "2016-04-30 00:00:00",
         "['PHASE2']",
         "17.0",
         "6.0",
         "20.0",
         "MALE",
         "False",
         "This study is designed to provide 6-months continuous dosing with the study medication, called HT-100, on participants who successfully completed the predecessor study (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability, pharmacodynamic activity (testing the drug's effect on DMD) and population pharmacokinetics (measuring how much drug is in the bloodstream) in participants with a broad spectrum of Duchenne muscular dystrophy (DMD).",
         null,
         "Inclusion Criteria:\n\n* Completed both the single ascending dose (SAD) and multiple ascending dose (MAD) phases of predecessor study HALO-DMD-01\n* Maintained the same corticosteroid therapy from the predecessor study HALO-DMD-01\n* Ability to provide written informed consent\n* Ambulatory or non-ambulatory\n\nExclusion Criteria:\n\n* Recent, substantial change in use of cardiac medications or medications affecting muscle function\n* Clinically significant major disease, not related to DMD\n* Significantly compromised cardio-respiratory function\n* History of severe allergic or anaphylactic reactions\n* Prior treatment with another investigational product in past 6 months\n* Inability to undergo magnetic resonance imaging (MRI)\n* Current drug or alcohol abuse or prior treatment for abuse",
         "Processa Pharmaceuticals",
         "INDUSTRY",
         "{'id': 'HALO-DMD-02', 'link': None, 'type': None}",
         "Dosing stopped",
         "{'hasExpandedAccess': False, 'nctId': None, 'statusForNctId': None}",
         "2013-10-31 00:00:00",
         "{'date': '2020-09-03', 'type': 'ACTUAL'}",
         "{'date': '2013-11-07', 'type': 'ESTIMATED'}",
         "['CHILD' 'ADULT']",
         null,
         null,
         "True",
         "{'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': None, 'maskingInfo': {'masking': 'NONE', 'maskingDescription': None, 'whoMasked': None}, 'observationalModel': None, 'primaryPurpose': 'TREATMENT', 'timePerspective': None}",
         "['Duchenne Muscular Dystrophy']",
         "[\"Duchenne muscular dystrophy\", \"halofuginone hydrobromide\", \"anti-fibrotic\", \"anti-inflammatory\", \"muscle regeneration\", \"protein synthesis inhibitor\"]",
         null,
         "[{'city': 'Sacramento', 'country': 'United States', 'facility': 'University of California, Davis Medical Center', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}, 'state': 'California'}\n {'city': 'Baltimore', 'country': 'United States', 'facility': 'Kennedy Krieger Institute, Johns Hopkins School of Medicine', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}, 'state': 'Maryland'}\n {'city': 'Saint Louis', 'country': 'United States', 'facility': 'Washington University School of Medicine', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}, 'state': 'Missouri'}\n {'city': 'Cincinnati', 'country': 'United States', 'facility': \"Cincinnati Children's Hospital Medical Center\", 'geoPoint': {'lat': 39.12713, 'lon': -84.51435}, 'state': 'Ohio'}\n {'city': 'Columbus', 'country': 'United States', 'facility': \"Nationwide Children's Hospital\", 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}, 'state': 'Ohio'}]",
         null,
         null,
         "{'other': None, 'primary': array([{'description': None, 'measure': 'Safety and tolerability of administration of 6 months of chronic, oral, multiple doses of HT-100 to boys with DMD.', 'timeFrame': 'Months 2, 4, 6, 7'}],\n      dtype=object), 'secondary': array([{'description': None, 'measure': 'Pharmacodynamic signals of HT-100 following chronic oral administration of multiple doses to boys with DMD.', 'timeFrame': 'Months 4, 6, 7'},\n       {'description': None, 'measure': 'Pharmacokinetic plasma profile of HT-100 following chronic oral administration of multiple doses to boys with DMD.', 'timeFrame': 'Months 4, 6'}],\n      dtype=object)}",
         "[{'affiliation': 'AkashiTherapeutics', 'name': 'Diana M Escolar, MD', 'role': 'STUDY_DIRECTOR'}]",
         null,
         "{\"versionHolder\": \"2025-06-18\"}",
         "{'ancestors': array([{'id': 'D020966', 'term': 'Muscular Disorders, Atrophic'},\n       {'id': 'D009135', 'term': 'Muscular Diseases'},\n       {'id': 'D009140', 'term': 'Musculoskeletal Diseases'},\n       {'id': 'D009468', 'term': 'Neuromuscular Diseases'},\n       {'id': 'D009422', 'term': 'Nervous System Diseases'},\n       {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'},\n       {'id': 'D040181', 'term': 'Genetic Diseases, X-Linked'}],\n      dtype=object), 'browseBranches': array([{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n       {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n       {'abbrev': 'BC16', 'name': 'Diseases and Abnormalities at or Before Birth'},\n       {'abbrev': 'All', 'name': 'All Conditions'},\n       {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n       {'abbrev': 'Rare', 'name': 'Rare Diseases'}], dtype=object), 'browseLeaves': array([{'asFound': 'Muscular Dystrophy', 'id': 'M12093', 'name': 'Muscular Dystrophies', 'relevance': 'HIGH'},\n       {'asFound': 'Duchenne Muscular Dystrophy', 'id': 'M22185', 'name': 'Muscular Dystrophy, Duchenne', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M22697', 'name': 'Muscular Disorders, Atrophic', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M24877', 'name': 'Genetic Diseases, X-Linked', 'relevance': 'LOW'},\n       {'asFound': 'Muscular Dystrophy', 'id': 'T3963', 'name': 'Muscular Dystrophy', 'relevance': 'HIGH'},\n       {'asFound': 'Duchenne Muscular Dystrophy', 'id': 'T698', 'name': 'Becker Muscular Dystrophy', 'relevance': 'HIGH'},\n       {'asFound': 'Duchenne Muscular Dystrophy', 'id': 'T1945', 'name': 'Duchenne Muscular Dystrophy', 'relevance': 'HIGH'}],\n      dtype=object), 'meshes': array([{'id': 'D009136', 'term': 'Muscular Dystrophies'},\n       {'id': 'D020388', 'term': 'Muscular Dystrophy, Duchenne'}],\n      dtype=object)}",
         "{'ancestors': array([{'id': 'D000970', 'term': 'Antineoplastic Agents'},\n       {'id': 'D003049', 'term': 'Coccidiostats'},\n       {'id': 'D000981', 'term': 'Antiprotozoal Agents'},\n       {'id': 'D000977', 'term': 'Antiparasitic Agents'},\n       {'id': 'D000890', 'term': 'Anti-Infective Agents'},\n       {'id': 'D011500', 'term': 'Protein Synthesis Inhibitors'},\n       {'id': 'D004791', 'term': 'Enzyme Inhibitors'},\n       {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'},\n       {'id': 'D020533', 'term': 'Angiogenesis Inhibitors'},\n       {'id': 'D043924', 'term': 'Angiogenesis Modulating Agents'},\n       {'id': 'D006133', 'term': 'Growth Substances'},\n       {'id': 'D045505', 'term': 'Physiological Effects of Drugs'},\n       {'id': 'D006131', 'term': 'Growth Inhibitors'}], dtype=object), 'browseBranches': array([{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'},\n       {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n       {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n       {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}], dtype=object), 'browseLeaves': array([{'asFound': None, 'id': 'M4217', 'name': 'Anti-Inflammatory Agents', 'relevance': 'LOW'},\n       {'asFound': 'Transplantation, Allogeneic', 'id': 'M341691', 'name': 'Halofuginone', 'relevance': 'HIGH'},\n       {'asFound': None, 'id': 'M4298', 'name': 'Antiprotozoal Agents', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M4294', 'name': 'Antiparasitic Agents', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M22318', 'name': 'Angiogenesis Inhibitors', 'relevance': 'LOW'},\n       {'asFound': None, 'id': 'M9231', 'name': 'Growth Inhibitors', 'relevance': 'LOW'}],\n      dtype=object), 'meshes': array([{'id': 'C010176', 'term': 'Halofuginone'}], dtype=object)}",
         "{'conditions': array([{'id': 'D009136', 'term': 'Muscular Dystrophies'},\n       {'id': 'D020388', 'term': 'Muscular Dystrophy, Duchenne'}],\n      dtype=object), 'interventions': array([{'id': 'C010176', 'term': 'Halofuginone'}], dtype=object)}"
        ],
        [
         "4",
         "NCT01971866",
         null,
         "Camera Based System to Monitor Patient Movement During Radiation Treatment",
         "Improving Safety and Accuracy of Proton Therapy by Use of Camera-Based Patient Localization System",
         "DS02",
         "OBSERVATIONAL",
         "TERMINATED",
         "2013-10-17 00:00:00",
         null,
         null,
         null,
         null,
         "1.0",
         "18.0",
         null,
         "ALL",
         "False",
         "This study aims to investigate the advantages of using AlignRT, a commercially available, FDA approved camera-based imaging system for proton therapy patients prior to and during their radiation treatment delivery.",
         null,
         "Inclusion Criteria:\n\nPatients with tumors of the brain, head and neck, thorax, upper abdomen, posterior spine/sacrum and extremities",
         "University of Florida",
         "OTHER",
         "{'id': 'UFPTI 1215-DS02', 'link': None, 'type': None}",
         "Slow enrollment, feasibility issues",
         "{'hasExpandedAccess': False, 'nctId': None, 'statusForNctId': None}",
         "2013-10-23 00:00:00",
         "{'date': '2016-01-27', 'type': 'ESTIMATED'}",
         "{'date': '2013-10-29', 'type': 'ESTIMATED'}",
         "['ADULT' 'OLDER_ADULT']",
         "Patients who are undergoing proton radiation therapy at UFPTI",
         "NON_PROBABILITY_SAMPLE",
         "True",
         "{'allocation': None, 'interventionModel': None, 'interventionModelDescription': None, 'maskingInfo': None, 'observationalModel': 'CASE_ONLY', 'primaryPurpose': None, 'timePerspective': 'PROSPECTIVE'}",
         "['Set up and Monitoring of Patients Receiving Proton Radiation']",
         "[\"Proton radiation\", \"AlignRT\"]",
         null,
         "[{'city': 'Jacksonville', 'country': 'United States', 'facility': 'University of Florida Proton Therapy Institute', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}, 'state': 'Florida'}]",
         null,
         null,
         "{'other': None, 'primary': array([{'description': None, 'measure': 'Paired difference between image accuracy plan data from the AlignRT system compared to the current x-ray based imaging system.', 'timeFrame': '3 months'}],\n      dtype=object), 'secondary': None}",
         "[{'affiliation': 'University of Florida Proton Therapy Institute', 'name': 'Maria Mamalui-Hunter, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}]",
         null,
         "{\"versionHolder\": \"2025-06-18\"}",
         null,
         null,
         null
        ]
       ],
       "shape": {
        "columns": 46,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>updated_at</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>acronym</th>\n",
       "      <th>study_type</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>start_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>...</th>\n",
       "      <th>locations</th>\n",
       "      <th>collaborators</th>\n",
       "      <th>arm_groups</th>\n",
       "      <th>outcomes</th>\n",
       "      <th>overall_officials</th>\n",
       "      <th>study_references</th>\n",
       "      <th>misc_info_module</th>\n",
       "      <th>condition_browse_module</th>\n",
       "      <th>intervention_browse_module</th>\n",
       "      <th>mesh_terms</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT01273766</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Deferasirox in Treating Iron Overload Caused B...</td>\n",
       "      <td>Impact of Intervention With Deferasirox on the...</td>\n",
       "      <td>None</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2011-01-07</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>...</td>\n",
       "      <td>[{'city': 'Winston-Salem', 'country': 'United ...</td>\n",
       "      <td>[{'class': 'NIH', 'name': 'National Cancer Ins...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'other': None, 'primary': [{'description': No...</td>\n",
       "      <td>[{'affiliation': 'Wake Forest University Healt...</td>\n",
       "      <td>None</td>\n",
       "      <td>{\"versionHolder\": \"2025-06-18\"}</td>\n",
       "      <td>{'ancestors': [{'id': 'D004194', 'term': 'Dise...</td>\n",
       "      <td>{'ancestors': [{'id': 'D007502', 'term': 'Iron...</td>\n",
       "      <td>{'conditions': [{'id': 'D002051', 'term': 'Bur...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00787566</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Phase 2 Study of Efficacy, Tolerability, and S...</td>\n",
       "      <td>A Randomized, Single Administration, Double-bl...</td>\n",
       "      <td>None</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2008-11-05</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>...</td>\n",
       "      <td>[{'city': 'The study is managed by Kendle Inte...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>{'other': None, 'primary': [{'description': No...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>{\"versionHolder\": \"2025-06-18\"}</td>\n",
       "      <td>{'ancestors': [{'id': 'D012817', 'term': 'Sign...</td>\n",
       "      <td>{'ancestors': [{'id': 'D000932', 'term': 'Anti...</td>\n",
       "      <td>{'conditions': [{'id': 'D009325', 'term': 'Nau...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00497666</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Association Between Rosiglitazone Use and Clin...</td>\n",
       "      <td>Retrospective Study Evaluating the Association...</td>\n",
       "      <td>None</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>2007-07-06</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>...</td>\n",
       "      <td>[{'city': 'Zerifin,', 'country': 'Israel', 'fa...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>[{'affiliation': 'Nephrology Division, Assaf H...</td>\n",
       "      <td>None</td>\n",
       "      <td>{\"versionHolder\": \"2025-06-18\"}</td>\n",
       "      <td>{'ancestors': [{'id': 'D014570', 'term': 'Urol...</td>\n",
       "      <td>{'ancestors': None, 'browseBranches': [{'abbre...</td>\n",
       "      <td>{'conditions': [{'id': 'D007674', 'term': 'Kid...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01978366</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Open Label Extension Study of HT-100 in Patien...</td>\n",
       "      <td>An Open Label Extension Study of HT-100 in Pat...</td>\n",
       "      <td>None</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>2013-10-31</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2016-04-30</td>\n",
       "      <td>...</td>\n",
       "      <td>[{'city': 'Sacramento', 'country': 'United Sta...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>{'other': None, 'primary': [{'description': No...</td>\n",
       "      <td>[{'affiliation': 'AkashiTherapeutics', 'name':...</td>\n",
       "      <td>None</td>\n",
       "      <td>{\"versionHolder\": \"2025-06-18\"}</td>\n",
       "      <td>{'ancestors': [{'id': 'D020966', 'term': 'Musc...</td>\n",
       "      <td>{'ancestors': [{'id': 'D000970', 'term': 'Anti...</td>\n",
       "      <td>{'conditions': [{'id': 'D009136', 'term': 'Mus...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01971866</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Camera Based System to Monitor Patient Movemen...</td>\n",
       "      <td>Improving Safety and Accuracy of Proton Therap...</td>\n",
       "      <td>DS02</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>2013-10-17</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>...</td>\n",
       "      <td>[{'city': 'Jacksonville', 'country': 'United S...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>{'other': None, 'primary': [{'description': No...</td>\n",
       "      <td>[{'affiliation': 'University of Florida Proton...</td>\n",
       "      <td>None</td>\n",
       "      <td>{\"versionHolder\": \"2025-06-18\"}</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows Ã 46 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id updated_at                                        brief_title  \\\n",
       "0  NCT01273766        NaT  Deferasirox in Treating Iron Overload Caused B...   \n",
       "1  NCT00787566        NaT  Phase 2 Study of Efficacy, Tolerability, and S...   \n",
       "2  NCT00497666        NaT  Association Between Rosiglitazone Use and Clin...   \n",
       "3  NCT01978366        NaT  Open Label Extension Study of HT-100 in Patien...   \n",
       "4  NCT01971866        NaT  Camera Based System to Monitor Patient Movemen...   \n",
       "\n",
       "                                      official_title acronym      study_type  \\\n",
       "0  Impact of Intervention With Deferasirox on the...    None  INTERVENTIONAL   \n",
       "1  A Randomized, Single Administration, Double-bl...    None  INTERVENTIONAL   \n",
       "2  Retrospective Study Evaluating the Association...    None   OBSERVATIONAL   \n",
       "3  An Open Label Extension Study of HT-100 in Pat...    None  INTERVENTIONAL   \n",
       "4  Improving Safety and Accuracy of Proton Therap...    DS02   OBSERVATIONAL   \n",
       "\n",
       "  overall_status study_first_submit_date start_date primary_completion_date  \\\n",
       "0      COMPLETED              2011-01-07        NaT                     NaT   \n",
       "1      COMPLETED              2008-11-05        NaT                     NaT   \n",
       "2        UNKNOWN              2007-07-06        NaT                     NaT   \n",
       "3     TERMINATED              2013-10-31        NaT              2016-04-30   \n",
       "4     TERMINATED              2013-10-17        NaT                     NaT   \n",
       "\n",
       "   ...                                          locations  \\\n",
       "0  ...  [{'city': 'Winston-Salem', 'country': 'United ...   \n",
       "1  ...  [{'city': 'The study is managed by Kendle Inte...   \n",
       "2  ...  [{'city': 'Zerifin,', 'country': 'Israel', 'fa...   \n",
       "3  ...  [{'city': 'Sacramento', 'country': 'United Sta...   \n",
       "4  ...  [{'city': 'Jacksonville', 'country': 'United S...   \n",
       "\n",
       "                                       collaborators  arm_groups  \\\n",
       "0  [{'class': 'NIH', 'name': 'National Cancer Ins...        None   \n",
       "1                                               None        None   \n",
       "2                                               None        None   \n",
       "3                                               None        None   \n",
       "4                                               None        None   \n",
       "\n",
       "                                            outcomes  \\\n",
       "0  {'other': None, 'primary': [{'description': No...   \n",
       "1  {'other': None, 'primary': [{'description': No...   \n",
       "2                                               None   \n",
       "3  {'other': None, 'primary': [{'description': No...   \n",
       "4  {'other': None, 'primary': [{'description': No...   \n",
       "\n",
       "                                   overall_officials study_references  \\\n",
       "0  [{'affiliation': 'Wake Forest University Healt...             None   \n",
       "1                                               None             None   \n",
       "2  [{'affiliation': 'Nephrology Division, Assaf H...             None   \n",
       "3  [{'affiliation': 'AkashiTherapeutics', 'name':...             None   \n",
       "4  [{'affiliation': 'University of Florida Proton...             None   \n",
       "\n",
       "                  misc_info_module  \\\n",
       "0  {\"versionHolder\": \"2025-06-18\"}   \n",
       "1  {\"versionHolder\": \"2025-06-18\"}   \n",
       "2  {\"versionHolder\": \"2025-06-18\"}   \n",
       "3  {\"versionHolder\": \"2025-06-18\"}   \n",
       "4  {\"versionHolder\": \"2025-06-18\"}   \n",
       "\n",
       "                             condition_browse_module  \\\n",
       "0  {'ancestors': [{'id': 'D004194', 'term': 'Dise...   \n",
       "1  {'ancestors': [{'id': 'D012817', 'term': 'Sign...   \n",
       "2  {'ancestors': [{'id': 'D014570', 'term': 'Urol...   \n",
       "3  {'ancestors': [{'id': 'D020966', 'term': 'Musc...   \n",
       "4                                               None   \n",
       "\n",
       "                          intervention_browse_module  \\\n",
       "0  {'ancestors': [{'id': 'D007502', 'term': 'Iron...   \n",
       "1  {'ancestors': [{'id': 'D000932', 'term': 'Anti...   \n",
       "2  {'ancestors': None, 'browseBranches': [{'abbre...   \n",
       "3  {'ancestors': [{'id': 'D000970', 'term': 'Anti...   \n",
       "4                                               None   \n",
       "\n",
       "                                          mesh_terms  \n",
       "0  {'conditions': [{'id': 'D002051', 'term': 'Bur...  \n",
       "1  {'conditions': [{'id': 'D009325', 'term': 'Nau...  \n",
       "2  {'conditions': [{'id': 'D007674', 'term': 'Kid...  \n",
       "3  {'conditions': [{'id': 'D009136', 'term': 'Mus...  \n",
       "4                                               None  \n",
       "\n",
       "[5 rows x 46 columns]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = clinical_trials_dataset[\"train\"].to_pandas()\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "d388e51b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(541897, 46)"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "ef7172ec",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['nct_id', 'updated_at', 'brief_title', 'official_title', 'acronym',\n",
       "       'study_type', 'overall_status', 'study_first_submit_date', 'start_date',\n",
       "       'primary_completion_date', 'completion_date', 'phases',\n",
       "       'enrollment_count', 'minimum_age', 'maximum_age', 'sex',\n",
       "       'healthy_volunteers', 'brief_summary', 'detailed_description',\n",
       "       'eligibility_criteria', 'lead_sponsor_name', 'lead_sponsor_class',\n",
       "       'org_study_id_info', 'why_stopped', 'expanded_access_info',\n",
       "       'last_update_submit_qc_date', 'last_update_post_date_struct',\n",
       "       'study_first_post_date_struct', 'std_ages', 'study_population',\n",
       "       'sampling_method', 'oversight_has_dmc', 'design_info', 'conditions',\n",
       "       'keywords', 'interventions', 'locations', 'collaborators', 'arm_groups',\n",
       "       'outcomes', 'overall_officials', 'study_references', 'misc_info_module',\n",
       "       'condition_browse_module', 'intervention_browse_module', 'mesh_terms'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "f1010dfb",
   "metadata": {},
   "outputs": [],
   "source": [
    "columns_to_keep = [\n",
    "    'nct_id',\n",
    "    'eligibility_criteria',\n",
    "    'overall_status',\n",
    "    'phases',\n",
    "    'study_type',\n",
    "    'minimum_age',\n",
    "    'maximum_age',\n",
    "    'sex',\n",
    "    'healthy_volunteers',\n",
    "    'conditions',\n",
    "    'keywords',\n",
    "    'interventions',\n",
    "    'mesh_terms',\n",
    "    'locations',\n",
    "    'brief_title',\n",
    "    'official_title',\n",
    "    'brief_summary'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "ee5e048d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(541897, 17)"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df=df[columns_to_keep]\n",
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "07650584",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "nct_id",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "eligibility_criteria",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "overall_status",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "phases",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "study_type",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "minimum_age",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "maximum_age",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "sex",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "healthy_volunteers",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "conditions",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "keywords",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "interventions",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "mesh_terms",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "locations",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "brief_title",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "official_title",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "brief_summary",
         "rawType": "object",
         "type": "unknown"
        }
       ],
       "ref": "b4682ad8-aaa8-41fe-a11d-b783ec496468",
       "rows": [
        [
         "0",
         "NCT01273766",
         "Inclusion Criteria:\n\n* Patients must have a pathology confirmed diagnosis of one of the following: myelodysplastic syndrome (MDS); acute leukemia; multiple myeloma; myelofibrosis; lymphoma; chronic anemia; sickle cell anemia\n* Iron score \\>= 2\n* Absolute Neutrophil Count (ANC) \\>= 1,000\n* Platelets \\>= 50,000\n* Albumin \\>= 2 g/dL\n* Alkaline phosphatase =\\< 5X Upper Limit of Normal (ULN)\n* Total bilirubin =\\< 1.5\n* Creatinine =\\< 2X age-appropriate Upper Limit of Normal (ULN) OR creatinine clearance \\>= 40 ml/min\n* Serum Glutamic Oxaloacetic Transaminase (SGOT) \\[AST\\] and Serum Glutamic Pyruvic Transaminase (SGPT) \\[ALT\\] =\\< 5X Upper Limit of Normal (ULN)\n* Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients with active disease undergoing chemotherapy treatment\n* Patient who have been treated with rituximab or immunomodulating drugs =\\< 1 month prior to enrollment\n* HIV-positive patients\n* Hepatitis-C positive patients\n* Women who are pregnant or breastfeeding\n* Patients on hemodialysis/patients with renal failure\n* Patients with sepsis or acute illness\n* Known hypersensitivity to deferasirox\n* Patients with moderate or severe hearing loss as defined by audiogram",
         "COMPLETED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Acute Undifferentiated Leukemia'\n 'Adult Acute Lymphoblastic Leukemia in Remission'\n 'Adult Acute Myeloid Leukemia in Remission'\n 'Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities'\n 'Adult Acute Myeloid Leukemia With Del(5q)'\n 'Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)'\n 'Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)'\n 'Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)'\n 'Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)'\n 'Adult Grade III Lymphomatoid Granulomatosis'\n 'Adult Langerhans Cell Histiocytosis'\n 'Adult Nasal Type Extranodal NK/T-cell Lymphoma'\n 'Anaplastic Large Cell Lymphoma' 'Angioimmunoblastic T-cell Lymphoma'\n 'Contiguous Stage II Adult Burkitt Lymphoma'\n 'Contiguous Stage II Adult Diffuse Large Cell Lymphoma'\n 'Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma'\n 'Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma'\n 'Contiguous Stage II Adult Lymphoblastic Lymphoma'\n 'Contiguous Stage II Grade 1 Follicular Lymphoma'\n 'Contiguous Stage II Grade 2 Follicular Lymphoma'\n 'Contiguous Stage II Grade 3 Follicular Lymphoma'\n 'Contiguous Stage II Mantle Cell Lymphoma'\n 'Contiguous Stage II Marginal Zone Lymphoma'\n 'Contiguous Stage II Small Lymphocytic Lymphoma'\n 'Cutaneous B-cell Non-Hodgkin Lymphoma'\n 'de Novo Myelodysplastic Syndromes'\n 'Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue'\n 'Hepatosplenic T-cell Lymphoma' 'Intraocular Lymphoma'\n 'Mast Cell Leukemia' 'Myelodysplastic Syndrome With Isolated Del(5q)'\n 'Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable'\n 'Myeloid/NK-cell Acute Leukemia' 'Nodal Marginal Zone B-cell Lymphoma'\n 'Noncontiguous Stage II Adult Burkitt Lymphoma'\n 'Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma'\n 'Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma'\n 'Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma'\n 'Noncontiguous Stage II Adult Lymphoblastic Lymphoma'\n 'Noncontiguous Stage II Grade 1 Follicular Lymphoma'\n 'Noncontiguous Stage II Grade 2 Follicular Lymphoma'\n 'Noncontiguous Stage II Grade 3 Follicular Lymphoma'\n 'Noncontiguous Stage II Mantle Cell Lymphoma'\n 'Noncontiguous Stage II Marginal Zone Lymphoma'\n 'Noncontiguous Stage II Small Lymphocytic Lymphoma'\n 'Noncutaneous Extranodal Lymphoma' 'Peripheral T-cell Lymphoma'\n 'Previously Treated Myelodysplastic Syndromes' 'Primary Myelofibrosis'\n 'Recurrent Adult Acute Lymphoblastic Leukemia'\n 'Recurrent Adult Acute Myeloid Leukemia'\n 'Recurrent Adult Burkitt Lymphoma'\n 'Recurrent Adult Diffuse Large Cell Lymphoma'\n 'Recurrent Adult Diffuse Mixed Cell Lymphoma'\n 'Recurrent Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Recurrent Adult Grade III Lymphomatoid Granulomatosis'\n 'Recurrent Adult Hodgkin Lymphoma'\n 'Recurrent Adult Immunoblastic Large Cell Lymphoma'\n 'Recurrent Adult Lymphoblastic Lymphoma'\n 'Recurrent Adult T-cell Leukemia/Lymphoma'\n 'Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Recurrent Grade 1 Follicular Lymphoma'\n 'Recurrent Grade 2 Follicular Lymphoma'\n 'Recurrent Grade 3 Follicular Lymphoma' 'Recurrent Mantle Cell Lymphoma'\n 'Recurrent Marginal Zone Lymphoma'\n 'Recurrent Mycosis Fungoides/Sezary Syndrome'\n 'Recurrent Small Lymphocytic Lymphoma' 'Refractory Anemia'\n 'Refractory Multiple Myeloma' 'Secondary Acute Myeloid Leukemia'\n 'Secondary Myelofibrosis' 'Small Intestine Lymphoma'\n 'Splenic Marginal Zone Lymphoma' 'Stage I Adult Burkitt Lymphoma'\n 'Stage I Adult Diffuse Large Cell Lymphoma'\n 'Stage I Adult Diffuse Mixed Cell Lymphoma'\n 'Stage I Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Stage I Adult Hodgkin Lymphoma'\n 'Stage I Adult Immunoblastic Large Cell Lymphoma'\n 'Stage I Adult Lymphoblastic Lymphoma'\n 'Stage I Adult T-cell Leukemia/Lymphoma'\n 'Stage I Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage I Grade 1 Follicular Lymphoma'\n 'Stage I Grade 2 Follicular Lymphoma'\n 'Stage I Grade 3 Follicular Lymphoma' 'Stage I Mantle Cell Lymphoma'\n 'Stage I Marginal Zone Lymphoma' 'Stage I Multiple Myeloma'\n 'Stage I Mycosis Fungoides/Sezary Syndrome'\n 'Stage I Small Lymphocytic Lymphoma' 'Stage II Adult Hodgkin Lymphoma'\n 'Stage II Adult T-cell Leukemia/Lymphoma'\n 'Stage II Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage II Multiple Myeloma' 'Stage II Mycosis Fungoides/Sezary Syndrome'\n 'Stage III Adult Burkitt Lymphoma'\n 'Stage III Adult Diffuse Large Cell Lymphoma'\n 'Stage III Adult Diffuse Mixed Cell Lymphoma'\n 'Stage III Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Stage III Adult Hodgkin Lymphoma'\n 'Stage III Adult Immunoblastic Large Cell Lymphoma'\n 'Stage III Adult Lymphoblastic Lymphoma'\n 'Stage III Adult T-cell Leukemia/Lymphoma'\n 'Stage III Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage III Grade 1 Follicular Lymphoma'\n 'Stage III Grade 2 Follicular Lymphoma'\n 'Stage III Grade 3 Follicular Lymphoma' 'Stage III Mantle Cell Lymphoma'\n 'Stage III Marginal Zone Lymphoma' 'Stage III Multiple Myeloma'\n 'Stage III Mycosis Fungoides/Sezary Syndrome'\n 'Stage III Small Lymphocytic Lymphoma' 'Stage IV Adult Burkitt Lymphoma'\n 'Stage IV Adult Diffuse Large Cell Lymphoma'\n 'Stage IV Adult Diffuse Mixed Cell Lymphoma'\n 'Stage IV Adult Diffuse Small Cleaved Cell Lymphoma'\n 'Stage IV Adult Hodgkin Lymphoma'\n 'Stage IV Adult Immunoblastic Large Cell Lymphoma'\n 'Stage IV Adult Lymphoblastic Lymphoma'\n 'Stage IV Adult T-cell Leukemia/Lymphoma'\n 'Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma'\n 'Stage IV Grade 1 Follicular Lymphoma'\n 'Stage IV Grade 2 Follicular Lymphoma'\n 'Stage IV Grade 3 Follicular Lymphoma' 'Stage IV Mantle Cell Lymphoma'\n 'Stage IV Marginal Zone Lymphoma'\n 'Stage IV Mycosis Fungoides/Sezary Syndrome'\n 'Stage IV Small Lymphocytic Lymphoma' 'Testicular Lymphoma'\n 'Untreated Adult Acute Lymphoblastic Leukemia'\n 'Untreated Adult Acute Myeloid Leukemia' 'Waldenstrom Macroglobulinemia']",
         null,
         null,
         "{'conditions': array([{'id': 'D002051', 'term': 'Burkitt Lymphoma'},\n       {'id': 'D009181', 'term': 'Mycoses'},\n       {'id': 'D008223', 'term': 'Lymphoma'},\n       {'id': 'D007938', 'term': 'Leukemia'},\n       {'id': 'D007951', 'term': 'Leukemia, Myeloid'},\n       {'id': 'D009101', 'term': 'Multiple Myeloma'},\n       {'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'},\n       {'id': 'D015470', 'term': 'Leukemia, Myeloid, Acute'},\n       {'id': 'D008224', 'term': 'Lymphoma, Follicular'},\n       {'id': 'D009362', 'term': 'Neoplasm Metastasis'},\n       {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'},\n       {'id': 'D011289', 'term': 'Preleukemia'},\n       {'id': 'D016393', 'term': 'Lymphoma, B-Cell'},\n       {'id': 'D054198', 'term': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma'},\n       {'id': 'D007945', 'term': 'Leukemia, Lymphoid'},\n       {'id': 'D006689', 'term': 'Hodgkin Disease'},\n       {'id': 'D020522', 'term': 'Lymphoma, Mantle-Cell'},\n       {'id': 'D016399', 'term': 'Lymphoma, T-Cell'},\n       {'id': 'D016411', 'term': 'Lymphoma, T-Cell, Peripheral'},\n       {'id': 'D018442', 'term': 'Lymphoma, B-Cell, Marginal Zone'},\n       {'id': 'D015451', 'term': 'Leukemia, Lymphocytic, Chronic, B-Cell'},\n       {'id': 'D016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'},\n       {'id': 'D016400', 'term': 'Lymphoma, Large-Cell, Immunoblastic'},\n       {'id': 'D000069293', 'term': 'Plasmablastic Lymphoma'},\n       {'id': 'D009182', 'term': 'Mycosis Fungoides'},\n       {'id': 'D012751', 'term': 'Sezary Syndrome'},\n       {'id': 'D015458', 'term': 'Leukemia, T-Cell'},\n       {'id': 'D008258', 'term': 'Waldenstrom Macroglobulinemia'},\n       {'id': 'D016410', 'term': 'Lymphoma, T-Cell, Cutaneous'},\n       {'id': 'D015459', 'term': 'Leukemia-Lymphoma, Adult T-Cell'},\n       {'id': 'D017728', 'term': 'Lymphoma, Large-Cell, Anaplastic'},\n       {'id': 'D008230', 'term': 'Lymphomatoid Granulomatosis'},\n       {'id': 'D054391', 'term': 'Lymphoma, Extranodal NK-T-Cell'},\n       {'id': 'D064090', 'term': 'Intraocular Lymphoma'},\n       {'id': 'D007946', 'term': 'Leukemia, Mast-Cell'},\n       {'id': 'D006646', 'term': 'Histiocytosis, Langerhans-Cell'},\n       {'id': 'D009190', 'term': 'Myelodysplastic Syndromes'},\n       {'id': 'D055728', 'term': 'Primary Myelofibrosis'},\n       {'id': 'D009196', 'term': 'Myeloproliferative Disorders'},\n       {'id': 'D000753', 'term': 'Anemia, Refractory'},\n       {'id': 'D007119', 'term': 'Immunoblastic Lymphadenopathy'},\n       {'id': 'D054437', 'term': 'Myelodysplastic-Myeloproliferative Diseases'},\n       {'id': 'D015614', 'term': 'Histiocytosis'},\n       {'id': 'D019190', 'term': 'Iron Overload'},\n       {'id': 'D013577', 'term': 'Syndrome'},\n       {'id': 'D012008', 'term': 'Recurrence'}], dtype=object), 'interventions': array([{'id': 'D000077588', 'term': 'Deferasirox'}], dtype=object)}",
         "[{'city': 'Winston-Salem', 'country': 'United States', 'facility': 'Comprehensive Cancer Center of Wake Forest University', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}, 'state': 'North Carolina'}]",
         "Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies",
         "Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload",
         "RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions.\n\nPURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies."
        ],
        [
         "1",
         "NCT00787566",
         "Inclusion Criteria:\n\n* Patients with histologically and/or cytologically confirmed cancer\n* ECOG performance status of 0, 1, or 2\n* Patients with life expectancy of at least 3 months\n* Patients who are chemotherapy naÃ¯ve\n* Patients who will be receiving the first cycle of a highly emetogenic regimen according to the MASCC criteria or the Hesketh criteria\n* Patients with adequate metabolic or hematologic values for chemotherapy\n* Patients with intact nasal mucosa\n* Non child-bearing potential patients\n* Patients able to read and write at a competent level, and capable of giving legal consent\n* Patients who have provided written informed consent\n\nExclusion Criteria:\n\n* Patients who do not receive a chemotherapy regimen which is a highly emetogenic chemotherapy regimen according to the MASCC or the Hesketh criteria\n* Patients with nasal cancers, pharyngeal cancers, maxillary sinus cancers, or ethmoid sinus cancers\n* Patients with nasal ulcers, septal perforation, or other nasal conditions that may interfere with IN administration\n* Patients with any episode of retching, vomiting, or uncontrolled nausea within 48 hours before dosing with TRG and/or administration of chemotherapy\n* Patients who have received radiation therapy in the 14 days before dosing with TRG, or for whom radiation therapy is scheduled during the 7 days after a TRG dose\n* Patients who have received any investigational product within 30 days prior to study entry\n* Patients who have received any drug or who were scheduled to receive any drug with antiemetic efficacy within 24 hours of the start of treatment\n* Patients who have an allergy or hypersensitivity to granisetron or other selective 5hydroxytryptamine3(5-HT3) receptor antagonists\n* Patients with ECOG performance status of 3 or 4\n* Patients who have or have a history of brain tumors, head cancers, or neck cancers\n* Patients who have a psychological problem that, in the Investigator's opinion, is severe enough to interfere with study eligibility or with interpretation of study results\n* Patients who are pregnant (urine test) or breastfeeding\n* Patients who have received prior cytotoxic chemotherapy given for the treatment of cancer\n* Patients scheduled to receive multiple day chemotherapy\n* Patients with clinically relevant abnormal laboratory values at the discretion of the Investigator\n* Patients with clinically relevant hepatic, renal, infectious, neurological, or psychiatric disorders, or any other major systemic illness at the discretion of the Investigator\n* Patients with any prevalence or cause of nausea and vomiting other than chemotherapy\n* Patients using systemic steroids for any indication, or patients using steroids other than dexamethasone for prevention of chemotherapy-induced nausea and vomiting, or patients using dexamethasone for chemotherapy-induced nausea and vomiting at doses other than recommended in the MASCC antiemetic guidelines\n* Patients with a QT interval greater than 500 ms or with acute ischemic changes or cardiac abnormality predisposing to arrhythmia on screening electrocardiogram (ECG) or by history\n* Patients with a history of drug and/or alcohol abuse.",
         "COMPLETED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Chemotherapy-Induced Nausea and Vomiting']",
         "[\"Highly emetogenic chemotherapy induced nausea and vomiting\"]",
         null,
         "{'conditions': array([{'id': 'D009325', 'term': 'Nausea'},\n       {'id': 'D014839', 'term': 'Vomiting'}], dtype=object), 'interventions': array([{'id': 'D017829', 'term': 'Granisetron'}], dtype=object)}",
         "[{'city': 'The study is managed by Kendle International, in Wilmington', 'country': 'United States', 'facility': 'The study is conducted at 14 Centers, in 14 cities accross the United States', 'geoPoint': None, 'state': 'North Carolina'}]",
         "Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting",
         "A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic Chemotherapy",
         "Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV) associated with the administration of highly emetogenic chemotherapy.\n\nPrimary Objective: To select a dose for Phase 3 by assessing the efficacy, safety, and tolerability of 3 doses of TRG in patients with CINV associated with the administration of highly emetogenic chemotherapy."
        ],
        [
         "2",
         "NCT00497666",
         "Inclusion Criteria:\n\n1. Diagnosis of Diabetes Mellitus Type II\n2. Treatment With Oral hypoglycemics\n3. Availability of Baseline and follow up clinical data\n\nExclusion Criteria:\n\n1. Insulin Therapy at baseline\n2. Malignancy",
         "UNKNOWN",
         null,
         "OBSERVATIONAL",
         "18.0",
         "90.0",
         "ALL",
         null,
         "['Diabetes' 'Diabetic Nephropathy' 'Renal Protection']",
         "[\"Diabetes\", \"Diabetic nephropathy\", \"renal protection\"]",
         null,
         "{'conditions': array([{'id': 'D007674', 'term': 'Kidney Diseases'},\n       {'id': 'D003928', 'term': 'Diabetic Nephropathies'},\n       {'id': 'D018450', 'term': 'Disease Progression'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Zerifin,', 'country': 'Israel', 'facility': 'Clalit Health Cervices, Central District', 'geoPoint': {'lat': 31.95857, 'lon': 4.83723}, 'state': None}]",
         "Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study",
         "Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study",
         "Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.\n\nWe decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy."
        ],
        [
         "3",
         "NCT01978366",
         "Inclusion Criteria:\n\n* Completed both the single ascending dose (SAD) and multiple ascending dose (MAD) phases of predecessor study HALO-DMD-01\n* Maintained the same corticosteroid therapy from the predecessor study HALO-DMD-01\n* Ability to provide written informed consent\n* Ambulatory or non-ambulatory\n\nExclusion Criteria:\n\n* Recent, substantial change in use of cardiac medications or medications affecting muscle function\n* Clinically significant major disease, not related to DMD\n* Significantly compromised cardio-respiratory function\n* History of severe allergic or anaphylactic reactions\n* Prior treatment with another investigational product in past 6 months\n* Inability to undergo magnetic resonance imaging (MRI)\n* Current drug or alcohol abuse or prior treatment for abuse",
         "TERMINATED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "6.0",
         "20.0",
         "MALE",
         "False",
         "['Duchenne Muscular Dystrophy']",
         "[\"Duchenne muscular dystrophy\", \"halofuginone hydrobromide\", \"anti-fibrotic\", \"anti-inflammatory\", \"muscle regeneration\", \"protein synthesis inhibitor\"]",
         null,
         "{'conditions': array([{'id': 'D009136', 'term': 'Muscular Dystrophies'},\n       {'id': 'D020388', 'term': 'Muscular Dystrophy, Duchenne'}],\n      dtype=object), 'interventions': array([{'id': 'C010176', 'term': 'Halofuginone'}], dtype=object)}",
         "[{'city': 'Sacramento', 'country': 'United States', 'facility': 'University of California, Davis Medical Center', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}, 'state': 'California'}\n {'city': 'Baltimore', 'country': 'United States', 'facility': 'Kennedy Krieger Institute, Johns Hopkins School of Medicine', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}, 'state': 'Maryland'}\n {'city': 'Saint Louis', 'country': 'United States', 'facility': 'Washington University School of Medicine', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}, 'state': 'Missouri'}\n {'city': 'Cincinnati', 'country': 'United States', 'facility': \"Cincinnati Children's Hospital Medical Center\", 'geoPoint': {'lat': 39.12713, 'lon': -84.51435}, 'state': 'Ohio'}\n {'city': 'Columbus', 'country': 'United States', 'facility': \"Nationwide Children's Hospital\", 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}, 'state': 'Ohio'}]",
         "Open Label Extension Study of HT-100 in Patients With DMD",
         "An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01",
         "This study is designed to provide 6-months continuous dosing with the study medication, called HT-100, on participants who successfully completed the predecessor study (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability, pharmacodynamic activity (testing the drug's effect on DMD) and population pharmacokinetics (measuring how much drug is in the bloodstream) in participants with a broad spectrum of Duchenne muscular dystrophy (DMD)."
        ],
        [
         "4",
         "NCT01971866",
         "Inclusion Criteria:\n\nPatients with tumors of the brain, head and neck, thorax, upper abdomen, posterior spine/sacrum and extremities",
         "TERMINATED",
         null,
         "OBSERVATIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Set up and Monitoring of Patients Receiving Proton Radiation']",
         "[\"Proton radiation\", \"AlignRT\"]",
         null,
         null,
         "[{'city': 'Jacksonville', 'country': 'United States', 'facility': 'University of Florida Proton Therapy Institute', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}, 'state': 'Florida'}]",
         "Camera Based System to Monitor Patient Movement During Radiation Treatment",
         "Improving Safety and Accuracy of Proton Therapy by Use of Camera-Based Patient Localization System",
         "This study aims to investigate the advantages of using AlignRT, a commercially available, FDA approved camera-based imaging system for proton therapy patients prior to and during their radiation treatment delivery."
        ],
        [
         "5",
         "NCT04912466",
         "Inclusion Criteria:\n\n1. Histologically/cytologically confirmed, locally advanced unresectable or metastatic tumors.\n2. Per RECIST1, at least one evaluable or measurable lesion.\n3. Male or female subject above 18 years old, no more than 75 years old.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status 0 or 1.\n5. Must have adequate organ function\n\nExclusion Criteria:\n\n1. Previous exposure to any anti-CD47 monoclonal antibody, SIRPÎ± antibody, or CD47/SIRPÎ± recombinant protein.\n2. Direct coombs test was positive or have history of hemolytic anemia.\n3. Subjects participating in another interventional clinical study, except for: observational (non-interventional) clinical studies or survival follow-up phase of interventional studies.\n4. Patients who are on anticoagulants and /or require concomitant aspirin or other nonsteroids anti-inflammatory medications. Patients with a history of a bleeding diathesis (von Willebrand disease, end stage liver disease, hemophilia, etc.)\n5. Subjects who have a history of blood transfusion within 2 weeks prior to the study.",
         "COMPLETED",
         "['PHASE1']",
         "INTERVENTIONAL",
         "18.0",
         "75.0",
         "ALL",
         "False",
         "['Advanced Solid Tumor']",
         null,
         null,
         "{'conditions': array([{'id': 'D009369', 'term': 'Neoplasms'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Jinan', 'country': 'China', 'facility': 'Shandong Province Cancer Hospital', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}, 'state': 'Shandong'}]",
         "IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.",
         "A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.",
         "The Phase Ia study was designed to evaluate the tolerability, safety, PK, PD, immunogenicity and primary resistance of single therapy tumor activity in subjects with advanced or metastatic solid tumors who have failed standard treatment. Phase Ib study was designed to evaluate the safety and initial efficacy of IBI322 in monotherapy or combination therapy in subjects with advanced or metastatic solid tumors. Investigators and sponsors determine the recommended dose of IBI322 for phase Ib based on PK, PD, safety and efficacy data obtained during phase Ia."
        ],
        [
         "6",
         "NCT03409666",
         "Inclusion Criteria:\n\n* Non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and rheumatoid arthritis.\n* Correction of functional deformity.\n* Male or female\n\n  -â¥ 18 and â¤ 70 years of age\n* Subjects willing to return for follow-up evaluations.\n* Subjects able to read and understand Dutch language.\n\nExclusion Criteria:\n\n* active Infection (or within 6 weeks after infection)\n* Sepsis\n* Osteomyelitis\n* Uncooperative patient or patient with neurologic disorders who are incapable of following directions\n* diagnosed Osteoporosis or Osteomalacia\n* Metabolic disorders which may impair bone formation\n* Distant foci of infections which may spread to the implant site\n* Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram\n* Vascular insufficiency, muscular atrophy or neuromuscular disease.",
         "COMPLETED",
         "['NA']",
         "INTERVENTIONAL",
         "18.0",
         "70.0",
         "ALL",
         "False",
         "['Hip Osteoarthritis' 'Noninflammatory Degenerative Joint Disease'\n 'Avascular Necrosis' 'Correction of Functional Deformity'\n 'Rheumatoid Arthritis']",
         "[\"Total Hip Arthroplasty\", \"Medical Device\", \"Performance\", \"Safety\", \"Hip prosthesis\", \"Roentgen Stereophotogrammetric Analysis\"]",
         null,
         "{'conditions': array([{'id': 'D010003', 'term': 'Osteoarthritis'},\n       {'id': 'D007592', 'term': 'Joint Diseases'},\n       {'id': 'D015207', 'term': 'Osteoarthritis, Hip'},\n       {'id': 'D009336', 'term': 'Necrosis'}], dtype=object), 'interventions': None}",
         "[{'city': 'Roosendaal', 'country': 'Netherlands', 'facility': 'Bravis', 'geoPoint': {'lat': 51.53083, 'lon': 4.46528}, 'state': None}]",
         "Randomized Controlled RSA Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty.",
         "Randomized Controlled Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty.",
         "This is a single center, prospective, randomized controlled study. The primary objective of this study is to measure migration over two years with RSA. Patients will be randomized in two arms, receiving a Taperloc Complete Reduced Distal or a Taperloc Complete Microplasty hip stem."
        ],
        [
         "7",
         "NCT00622466",
         "DISEASE CHARACTERISTICS:\n\nInclusion criteria:\n\n* Histologically\\* confirmed breast cancer\n\n  * Stage IV (metastatic) disease\n\n    * Radiographic evidence of metastases NOTE: \\*Histological confirmation of the actual metastasis is not required.\n* Measurable disease by RECIST criteria defined as â¥ 1 unidimensionally measurable lesion â¥ 20 mm by conventional techniques (i.e., physical examination, CT scan, MRI, or x-ray) or â¥ 10 mm by spiral CT scan\n\n  * No prior radiotherapy unless growth has been documented following radiotherapy\n* Primary tumor or metastatic tumor HER2-negative, defined as the following:\n\n  * Immunohistochemistry of 0 or 1+ OR the equivalent, if an automated quantitative assay is used\n  * HER2 fluorescent in situ hybridization (FISH) assay negative as defined by a HER2:chromosome 17 centromeric probe ratio \\< 1.8 (or \\< 2.2 if immunohistochemistry is less than 3+ or equivalent) OR equivalent values for negative FISH assays that do not normalize to chromosome 17\n* Hormone-receptor positive (estrogen receptor-\\[ER\\] or progesterone receptor \\[PgR\\]-positive) disease or hormone receptor-negative (ER- or PgR-negative) disease\n* Tumor block from initial breast cancer primary or a biopsy of a metastatic site must be available for correlative studies\n* Brain metastases allowed provided the patient is stable after completion of treatment (i.e., surgery and/or radiotherapy), asymptomatic, and off steroids with 2 consecutive stable brain scans at least 4 weeks after radiotherapy\n\nExclusion criteria:\n\n* Bone-only or other nonmeasurable-only disease\n* Newly diagnosed brain metastases\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* ECOG performance status 0-1\n* Life expectancy \\> 6 months\n* Menopausal status not specified\n* WBC â¥ 3,000/mcL\n* Absolute neutrophil count â¥ 1,500/mcL\n* Platelets â¥ 100,000/mcL\n* Total bilirubin \\< 1.5 times upper limit of normal (ULN)\n* AST and ALT transaminases â¤ 2.5 times ULN (\\< 5 times ULN if liver involvement)\n* Creatinine \\< 1.5 times ULN OR creatinine clearance \\> 60 mL/min\n* INR \\< 1.5 OR PT/PTT normal\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception prior to and during (women and men) and for at least 3 months after (men) study therapy\n* Able to swallow and absorb oral medications\n\nExclusion criteria:\n\n* Active or uncontrolled medical illness (e.g., active infection \\> CTCAE grade 2), including any of the following:\n\n  * HIV or chronic hepatitis B or C\n  * Uncontrolled diabetes\n  * NYHA class II-IV uncompensated congestive heart failure\n  * Unstable angina (anginal symptoms at rest)\n  * New onset angina (i.e., began within the past 3 months)\n  * Coronary artery disease\n* Myocardial infarction within the past 6 months\n* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\n* Evidence of bleeding diathesis or coagulopathy\n* Pulmonary hemorrhage/bleeding event \\> CTCAE grade 2 within 4 weeks of first dose of study drug\n* Any other hemorrhage/bleeding event \\> CTCAE grade 3 within 4 weeks of first study drug\n* Thrombotic or embolic events (i.e., cerebrovascular accident), including transient ischemic attacks within the past 6 months\n* Hypertension that cannot be controlled with medication to â¤ 150/90 mm Hg\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib tosylate\n* Prior invasive cancer other than breast cancer except nonmelanoma skin cancer\n* Chronic nonhealing wound or ulcer\n\nPRIOR CONCURRENT THERAPY:\n\n* No more than 1 prior chemotherapy regimen for metastatic breast cancer (MBC)\n* At least 3 weeks since prior hormonal therapy for MBC or adjuvant or neoadjuvant chemotherapy\n\n  * More than 1 year since adjuvant paclitaxel\n* At least 4 weeks since major thoracic, abdominal, or pelvic surgery and recovered\n* At least 3 weeks since prior and no concurrent investigational drugs\n* Concurrent bisphosphonates allowed\n* Concurrent anticoagulation agents (i.e., warfarin or heparin) allowed\n* No anticipated need for or concurrent radiotherapy\n* No concurrent Hypericum perforatum (St. John wort) or rifampin (rifampicin)\n* No other concurrent anti-neoplastic drugs",
         "TERMINATED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Breast Cancer']",
         "[\"stage IV breast cancer\", \"male breast cancer\", \"recurrent breast cancer\", \"HER2-negative breast cancer\"]",
         null,
         "{'conditions': array([{'id': 'D001943', 'term': 'Breast Neoplasms'}], dtype=object), 'interventions': array([{'id': 'D017239', 'term': 'Paclitaxel'},\n       {'id': 'D000077157', 'term': 'Sorafenib'}], dtype=object)}",
         "[{'city': 'Dallas', 'country': 'United States', 'facility': 'University of Texas Southwestern Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}, 'state': 'Texas'}]",
         "Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer",
         "Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer",
         "RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with paclitaxel may kill more tumor cells.\n\nPURPOSE: This phase II trial is studying the side effects of giving sorafenib together with paclitaxel and to how well it works in treating patients with metastatic breast cancer."
        ],
        [
         "8",
         "NCT03807466",
         "To Identify an LTC Resident\n\nInclusion Criteria:\n\nAn individual having a minimum of 2 records on separate days within the quarter meeting any combination of the following criteria:\n\n* a record for a non-emergency long-term care inpatient services OR\n* an Ontario Drug Benefits record administered in long-term care\n\nIndex date = The analysis will be anchored on the most recent of either of the records above within a given quarter or their date of death (whichever date is earliest)\n\nExclusion Criteria:\n\n* Non-Ontario resident at index date\n* Invalid age (age\\<19 or age\\>115) at index date\n* Missing or invalid sex or date of birth at index date\n* Death date is \\>7 days before index date\n* If the individual does not live in a nursing home or home for the aged\n* Cannot be linked to a Most Responsible Physician (MRP) (see methodology below)\n\nTo Identify the Most Responsible Physician (MRP) Using Virtual Rostering\n\nFor each patient in the above resident cohort, the study team will retrieve all records from health care providers in the 6 month period preceding the index date (180 days), keeping only records from physicians who have a specialty of 1) general practice, 2) community medicine or 3) geriatrics.\n\nSteps for MRP assignment:\n\nStep 1) The study team will first select physicians with the highest count of records for the monthly management of a nursing home or home for the aged. This is completed for as many residents as possible.\n\nStep 2) If there were no monthly management fee records as described above then the physician with highest count of non-emergency long-term care inpatient services records for each patient will be selected. This step is only applied to residents who could not be matched to a physician by Step 1. \\*\\*Physician must have seen the patient one or more times in 90 days prior to and including index date to be considered MRP. This criteria is applied to ensure the physician has seen the resident within the reporting quarter.\n\nStep 3) Some patients will virtually roster to physicians in Enrollment groups, some will virtually roster to physicians that are not in a group. For these, the study team will recode enrollment program type to 'NOR' (not otherwise rostered) - these are likely fee for service physicians.",
         "COMPLETED",
         "['NA']",
         "INTERVENTIONAL",
         null,
         null,
         "ALL",
         "False",
         "['Antibiotic Initiation' 'Antibiotic Duration']",
         null,
         null,
         "{'conditions': None, 'interventions': array([], dtype=object)}",
         "[{'city': 'Toronto', 'country': 'Canada', 'facility': 'ICES', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}, 'state': 'Ontario'}]",
         "Feedback to Improve Rational Strategies of Antibiotic Initiation and Duration in Long Term Care",
         "Feedback to Improve Rational Strategies of Antibiotic Initiation and Duration in Long Term",
         "There is a high rate of inappropriate antibiotic use in long-term care (LTC) facilities, with both unnecessary initiation and prolongation of treatments. Although there are challenges to rational antibiotic use in LTC, the variability in antibiotic initiation and use of prolonged treatment durations is driven by prescriber tendencies rather than resident characteristics. Audit-and-feedback is a well-established intervention to improve professional practices, and is ideally suited for use to improve antibiotic prescribing tendencies in LTC. The literature is saturated with trials indicating benefit of audit-and-feedback, but is in dire need of studies to identify methods to improve the impact of this technique. Health Quality Ontario (HQO), a key partner in the FIRST AID-LTC research program, is already providing audit-and-feedback for other inappropriate prescribing practices in LTC, and has identified antibiotic prescribing as a priority focus."
        ],
        [
         "9",
         "NCT04868266",
         "Inclusion Criteria:\n\n* pediatric patients undergoing minimal sedation for procedure.\n\nExclusion Criteria:\n\n* none",
         "ACTIVE_NOT_RECRUITING",
         "['NA']",
         "INTERVENTIONAL",
         null,
         "18.0",
         "ALL",
         "False",
         "['Complication of Anesthesia']",
         null,
         null,
         "{'conditions': array([], dtype=object), 'interventions': None}",
         "[{'city': 'Seoul', 'country': 'Korea, Republic of', 'facility': 'Jin-Tae Kim', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}, 'state': None}]",
         "End Tidal Carbon Dioxide in Minimal Sedation",
         "A Randomized Controlled Trial of the Effect of Capnography for Preventing Hypoxia in Minimally Sedated Pediatric Patients",
         "This randomized controlled study investigated the effect of end-tidal carbon dioxide monitoring in pediatric patients undergoing minimal sedation."
        ],
        [
         "10",
         "NCT06147466",
         "Inclusion Criteria:\n\n1. Women with type 2 diabetes diagnosed prior to pregnancy or prior to 20 weeks gestation with either a HbA1c of \\>6.5%, fasting glucose â¥7.0, or 2 hr glucose â¥11.1 on a 75g OGTT. To make the diagnosis in pregnancy one needs 2 values equal to or greater than the values above.\n2. â¤14 weeks gestation,\n3. age â¥18 years\n4. Willingness to use the study devices a minimum of 10 days per trimester\n5. Able to provide informed consent\n6. Have access to email\n\nExclusion Criteria:\n\n1. Non-type 2 diabetes\n2. Current treatment with drugs known to interfere with glucose metabolism as judged by the investigator such as high dose systemic corticosteroids\n3. Known or suspected allergy against insulin\n4. Women with nephropathy (eGFR\\<30), severe autonomic neuropathy, uncontrolled gastroparesis that, as judged by the investigator, is likely to interfere with the normal conduct of the study and interpretation of study results\n5. Severe visual or hearing impairment, as judged by the investigator to impact treatment compliance\n6. Unable to communicate effectively in English as judged by the investigator\n7. Any reason judged by the investigator that would likely interfere with the normal conduct of the study and interpretation of study results",
         "RECRUITING",
         null,
         "OBSERVATIONAL",
         "18.0",
         null,
         "FEMALE",
         "True",
         "['Diabete Type 2' 'Pregnancy in Diabetic']",
         "[\"glucose range\", \"neonatal outcomes\", \"glycemic control\", \"hypoglycemia\", \"insulin resistance\", \"preganant\", \"pregnancy\", \"CGM\", \"Continuous Glucose Monitoring\", \"Dexcom\", \"maternal outcomes\", \"Pregnancy in Diabetes\"]",
         null,
         "{'conditions': array([{'id': 'D011254', 'term': 'Pregnancy in Diabetics'},\n       {'id': 'D016640', 'term': 'Diabetes, Gestational'},\n       {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}],\n      dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Toronto', 'country': 'Canada', 'facility': 'Mount Sinai Hospital', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}, 'state': 'Ontario'}]",
         "Time Spent In Target Glucose Range in Women With T2D Diabetes in Pregnancy",
         "Time Spent In the Target Glucose Range and MatErnaL and Neonatal Effects in Women With tYpe 2 Diabetes in Pregnancy (TIMELY)",
         "Prospective cohort study to determine to what extent women with type 2 diabetes are achieving the time in the target range outlined for women with type 1 diabetes (70-140 mg/dl or 3.5-7.8 mmol/l), overall and by trimester, by standard CGM measures and functional data analysis"
        ],
        [
         "11",
         "NCT05279066",
         "Inclusion Criteria:\n\n1. â¥ 18 years of age.\n2. Subjects who are undergoing elective cardiac ultrasound as an outpatient for group 1 or are scheduled for/completed a pilmonary arterial catheterization for group 2.\n3. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. Subject is unable or unwilling to wear the wristband for the required duration.",
         "UNKNOWN",
         null,
         "OBSERVATIONAL",
         "18.0",
         null,
         "ALL",
         "True",
         "['Heart Failure']",
         "[\"ejection fraction\", \"cardiac output\"]",
         null,
         "{'conditions': array([{'id': 'D006333', 'term': 'Heart Failure'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Los Angeles', 'country': 'United States', 'facility': 'Ronald Reagan UCLA Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}, 'state': 'California'}]",
         "Validation of Ejection Fraction and Cardiac Output Using Biostrap Wristband",
         "A Clinical Validation Study for Measuring Cardiac Output and Ejection Fraction Using a Wrist-worn Device.",
         "In this study, the investigators will compare the accuracy of the Biostrap wristband, a wearable device with a clinical-grade Photoplethysmography (PPG) sensor, to measure ejection fraction and cardiac output in patients undergoing a cardiac ultrasound and pulmonary arterial catheterization, respectively."
        ],
        [
         "12",
         "NCT06874166",
         "Inclusion Criteria:\n\n* Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant).\n* Patients diagnosed with osteogenesis imperfecta.\n* Control group: participants without any neurological or psychiatric disorder\n\nExclusion Criteria:\n\n* presence of comorbid diagnoses,\n* sensory deficit\n* specific condition that could prevent the application of the tests and tasks under study, such as: a) the need for PEG; b) the need for tracheostomy; c) the need for assisted ventilation.\n* cognitive level lower than 60.",
         "NOT_YET_RECRUITING",
         null,
         "OBSERVATIONAL",
         "4.0",
         null,
         "MALE",
         "True",
         "['Duchenne / Becker Muscular Dystrophy' 'Osteogenesis Imperfecta (OI)'\n 'Social Cognition']",
         "[\"Social Cognition\", \"Duchenne / Becker muscular dystrophy\", \"Osteogenesis Imperfecta (OI)\", \"EEG\", \"Interpersonal distance\", \"Interoception\"]",
         null,
         "{'conditions': array([{'id': 'D009136', 'term': 'Muscular Dystrophies'},\n       {'id': 'D020388', 'term': 'Muscular Dystrophy, Duchenne'},\n       {'id': 'D010013', 'term': 'Osteogenesis Imperfecta'},\n       {'id': 'D065886', 'term': 'Neurodevelopmental Disorders'}],\n      dtype=object), 'interventions': None}",
         null,
         "Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders",
         "Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders. Behavioural and Psychophisiological Measures",
         "The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients affected by Becker (BMD) and Duchenne (DMD) muscular dystrophy, compared with a sample of patients affected by osteogenesis imperfecta (OI), and both compared with a control sample with typical development.\n\nThe secondary aim is to study cortical activity at rest, by means of electroencephalography (EEG), to explore frequencies and time course of EEG responses. Moreover, the relationship between EEG activity and neuropsychological, dispositional and subjective measures will be explored through correlational analyses."
        ],
        [
         "13",
         "NCT06580366",
         "Inclusion Criteria:\n\n* Adults aged 18-80 years scheduled for elective outpatient colonoscopy.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* History of intra-abdominal surgery.\n* Chronic kidney failure.\n* Congestive heart failure.\n* Chronic liver failure.\n* Inflammatory bowel disease.\n* Electrolyte imbalance.\n* Hospitalized patients.\n* Patients unable to use the bowel preparation treatment\n* Known allergy or hypersensitivity to Sennoside A+B or PM/Ca components\n* Known gastrointestinal motility disorders.",
         "NOT_YET_RECRUITING",
         "['PHASE4']",
         "INTERVENTIONAL",
         "18.0",
         "80.0",
         "ALL",
         "False",
         "['Bowel Preparation']",
         "[\"Bowel preparation\", \"Colonoscopy\", \"sennosid A+B\", \"Sodium Picosulfate\"]",
         null,
         "{'conditions': None, 'interventions': array([{'id': 'D008277', 'term': 'Magnesium Oxide'},\n       {'id': 'C005701', 'term': 'Picosulfate sodium'},\n       {'id': 'D019343', 'term': 'Citric Acid'},\n       {'id': 'D000077559', 'term': 'Sodium Citrate'}], dtype=object)}",
         "[{'city': 'Ãorum', 'country': 'Turkey', 'facility': 'Hitit University Erol Olcok Training and Research Hospital', 'geoPoint': {'lat': 40.54889, 'lon': 34.95333}, 'state': None}]",
         "Comparing Sennosid A+B and Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation",
         "Sennosid A+B Versus Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation; A Prospective Randomized Observer-Blinded Study",
         "Colonoscopy Preparation: Comparing Sennoside A+B and PM/Ca\n\nColonoscopy is a test used to examine the inside of the bowel. Proper bowel preparation is crucial because it helps doctors get a clear view during the procedure.\n\nWhat is Sennoside A+B? Sennoside A+B is a type of laxative made from the senna plant. It works by stimulating the bowel to move and reducing the absorption of water, making it easier to pass stools. Research has shown that high doses of sennoside A+B can be effective for bowel preparation.\n\nSennoside A+B vs. PEG:\n\nSome studies have found that sennoside A+B is more effective than PEG, another laxative, but can cause more abdominal pain. Other studies have found no significant difference in effectiveness between the two.\n\nWhat is Picosulfate/Magnesium Oxide/Citric Acid (PM/Ca)? PM/Ca is a combination of sodium picosulfate, magnesium oxide, and citric acid. Sodium picosulfate stimulates bowel movements, while magnesium oxide and citric acid help increase water in the bowel, making it easier to pass stools.\n\nPM/Ca vs. PEG:\n\nResearch has shown that PM/Ca is as effective as PEG for bowel preparation. Patients using PM/Ca generally tolerate the preparation process better than those using PEG.\n\nConclusion:\n\nWhile PEG is the preferred option according to guidelines, its high cost can make it less accessible in some places. In this study, we aim to compare the effectiveness and patient tolerance of Sennoside A+B and PM/Ca since no direct comparison between these two preparations has been made before."
        ],
        [
         "14",
         "NCT05371366",
         "Inclusion Criteria:\n\n1. aged 18-70 years;\n2. with congenital secundum atrial septal defect;\n3. the maximal ASD diameter was â¤38 mm;\n4. with atrial-level left-to-right shunt, with Qp/Qs shunt ratio â¥1.5:1, or TTE or clinical manifestations indicated the existence of defect that inducing overfilling of right atrium;\n5. the distance from the margin of defect to coronary sinus, atrioventricular (AV) valve, and right superior pulmonary vein (RSPV) was â¥5 mm, according to the echocardiography measurements;\n6. volunteered to participate in this study, and signed informed consents.\n\nExclusion Criteria:\n\n1. ostium primordium ASD and sinus venosus ASD.\n2. infective endocarditis and hemorrhagic disorders.\n3. active thrombosis.\n4. patients with severe pulmonary hypertension (mean pulmonary artery pressure measured by catheter \\> 30 mmHg) who are not taking targeted drugs\n5. patients with a porous atrial septal defect that cannot be completely occluded by a single occluder.\n6. with severe myocardial disorders or valvular disease not associated with ASD\n7. infectious disease within the last 1 month, or uncontrolled infectious disease\n8. bleeding disorders, untreated gastric or duodenal ulcers\n9. thrombosis in left atrium\n10. partial or total pulmonary vein ectopic drainage\n11. left atrial septum, left atrial or left ventricular dysplasia\n12. Patients whose size (too small for TEE probe, catheter size, etc.) or physical condition (active infection, etc.) makes them unsuitable for cardiac catheterization\n13. Patients who are allergic to nickel\n14. Patients with any contraindication to aspirin therapy (except for those able to take other antiplatelet agents for 6 consecutive months).\n15. Pregnant or lactating women and those who plan to become pregnant during the trial\n16. Patients with a life expectancy of \\<12 months or those who are unable to complete the study's prescribed follow-up schedule\n17. Participation in another clinical trial of a drug or medical device within 30 days prior to screening.\n18. Patients who have previously undergone surgical atrial septal defect repair or percutaneous interventional atrial septal defect closure.\n19. Patients who, in the opinion of the investigator, are not suitable for participation in this study.",
         "UNKNOWN",
         "['NA']",
         "INTERVENTIONAL",
         "18.0",
         "70.0",
         "ALL",
         "False",
         "['Atrial Septal Defect']",
         null,
         null,
         "{'conditions': array([{'id': 'D006343', 'term': 'Heart Septal Defects'},\n       {'id': 'D006344', 'term': 'Heart Septal Defects, Atrial'}],\n      dtype=object), 'interventions': None}",
         "[{'city': 'Shanghai', 'country': 'China', 'facility': '180 Fenglin Road', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}]",
         "The Puncturable Atrial Septal Defect Occluder Trial (the PASSER Trial)",
         "A Multicenter, Randomized, Parallel-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Atrial Septal Defect Occluder, ReAcesÂ®, and Delivery System for the Treatment of Atrial Septal Defect Occlusion",
         "A multicenter, randomized, parallel-controlled clinical trial to evaluate the efficacy and safety of a new atrial septal defect occluder, ReAcesÂ®, and delivery system for the treatment of atrial septal defect occlusion. Compared with the traditional atrial septal occluder, this new atrial septal occluder supports re-puncture after occluder implantation. Thus those patients who have undergone atrial septal defect closure with the novel device may be eligible for future radiofrequency ablation of atrial fibrillation or mitral valve intervention.\n\nThe trial is expected to enroll 128 patients who will be randomly assigned to the test group or control group in a 1:1 ratio. Patients in test group will received ReAces occluderï¼and the others the regular occluder.The experiment is scheduled to enroll 128 patients who will be randomly allocated to one of two groups: test or control. Patients in the test group will receive a ReAces occluder, while those in the control group will receive a standard occluder.The safety and efficacy of the two groups at 1 year after surgery will be compared."
        ],
        [
         "15",
         "NCT00992966",
         "Inclusion Criteria:\n\n1. Subject's parent or legal guardian, is able and willing to read the Informed Consent, understands the Informed Consent, and provides written Informed Consent for the subject; if the minor child is in fact able to give consent, the minor's consent must be obtained in addition to the consent of the minor's legal guardian.\n2. Boy or girl in the age range of 3-18 years.\n3. Patient presented with acute respiratory complaints, acute cough, onset of shortness of breath, or fever.\n4. Patient referred by ED physician and presented for CXR.\n\nExclusion Criteria:\n\n1. Body habitus or skin condition that might prevent the placement of the sound sensors on the back (e.g. severe scoliosis, kyphosis, chest wall deformation, skin lesion on the back or compression fracture);\n2. Potentially contagious skin lesion on the back;\n3. Subject has had lung surgery;\n4. Subject was prescribed the CXR for monitoring or follow up of a lung condition that pre-existed the current, acute symptoms.",
         "SUSPENDED",
         null,
         "OBSERVATIONAL",
         "3.0",
         "18.0",
         "ALL",
         "False",
         "['Pneumonia']",
         "[\"to acquire database of pneumonia cases in children\"]",
         null,
         "{'conditions': array([{'id': 'D011014', 'term': 'Pneumonia'},\n       {'id': 'D012818', 'term': 'Signs and Symptoms, Respiratory'}],\n      dtype=object), 'interventions': None}",
         null,
         "Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms",
         "Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms.",
         "The VRI device may provide a complementary diagnostic tool for lung examination and aid the physician in determining whether a chest x-ray should be performed."
        ],
        [
         "16",
         "NCT03829566",
         "Inclusion Criteria:\n\n1. Age 18 - 65 years old at the time of pre-transplant evaluation\n2. An established diagnosis of NMOSD (with or without aquaporin 4 (AQP4)-IgG antibody)\n\nExclusion Criteria:\n\n1. Under age of 18 or over age of 65\n2. Prisoners\n3. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible, or any adult who is unable to consent (for adults cognitively impaired due to disease, consent may be obtained from the closest living relative).\n4. Paraplegia or quadriplegia (must be able to use a walker if even for only a few feet)\n5. Extensive subcortical white matter lesions\n6. Uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment\n7. Myocardial infarction within the last 12 months. If longer than 12 months, must pass a dobutamine stress test and be cleared by cardiology.\n8. Active systemic lupus erythematous, Sjogren's, myasthenia gravis, or another autoimmune disease\n9. Sickle cell disease, sickle cell disease, or coagulopathy\n10. Prior history of malignancy that required any radiotherapy, chemotherapy, or biological therapy\n11. Positive pregnancy test, inability or unable to pursue effective means of birth control, or failure to willingly accept or comprehend irreversible sterility as a side effect of therapy\n12. Women who are breastfeeding\n13. Untreated life-threatening cardiac arrhythmia on electrocardiogram (EKG) or 24-hour holter\n14. Left ventricular ejection fraction (LVEF) \\<50%\n15. Tiffeneau-Pinelli index (FEV1/FVC) \\<70% of predicted after bronchodilator therapy (if necessary), or diffusing capacity of lung for carbon monoxide (DLCO) hemoglobin corrected \\<70 % predicted\n16. Serum creatinine \\>2.0 mg/dl\n17. Liver cirrhosis, transaminases \\>2x of normal limits, or bilirubin \\>2.0 mg/dl unless due to Gilbert's disease\n18. Major hematological abnormalities such as platelet count \\< 100,000/Î¼l or absolute neutrophil count (ANC) \\< 1000/Î¼l\n19. Active infection except asymptomatic bacteriuria\n20. Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have magnetic resonance imaging (MRI) exams\n21. Known hypersensitivity to mouse, rabbit, or E. coli derived proteins\n22. Human immunodeficiency virus (HIV) positive\n23. Hepatitis B or C positive\n24. Use of natalizumab (Tysabri) within the previous six months\n25. Use of fingolimod (Gilenya) within the previous three months\n26. Use of dimethyl fumarate (Tecfidera) within the previous three months\n27. Use of teriflunomide (Aubagio) unless cleared from the body (plasma concentration \\<0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a day for 11 days\n28. Use of alemtuzumab (Lemtrada/Campath) within previous 12 months\n29. Use of rituximab (Rituxan) or ocrelizumab (Ocrevus) within previous six months\n30. Prior treatment with mitoxantrone (Novantrone)",
         "WITHDRAWN",
         "['PHASE2' 'PHASE3']",
         "INTERVENTIONAL",
         "18.0",
         "65.0",
         "ALL",
         "False",
         "['Neuromyelitis Optica' \"Devic's Disease\" 'NMO Spectrum Disorder']",
         "[\"Autologous Stem Cell Transplantation\", \"Hematopoietic Stem Cell Transplant\"]",
         null,
         "{'conditions': array([{'id': 'D009471', 'term': 'Neuromyelitis Optica'}], dtype=object), 'interventions': array([{'id': 'D008775', 'term': 'Methylprednisolone'},\n       {'id': 'D000077555', 'term': 'Methylprednisolone Acetate'},\n       {'id': 'D008776', 'term': 'Methylprednisolone Hemisuccinate'},\n       {'id': 'D011239', 'term': 'Prednisolone'},\n       {'id': 'C009935', 'term': 'Prednisolone acetate'},\n       {'id': 'D003520', 'term': 'Cyclophosphamide'},\n       {'id': 'D000069283', 'term': 'Rituximab'},\n       {'id': 'C512542', 'term': 'Thymoglobulin'},\n       {'id': 'D000961', 'term': 'Antilymphocyte Serum'},\n       {'id': 'C021322', 'term': 'Prednisolone hemisuccinate'},\n       {'id': 'C009022', 'term': 'Prednisolone phosphate'}], dtype=object)}",
         "[{'city': 'Chicago', 'country': 'United States', 'facility': 'Northwestern University, Feinberg School of Medicine', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}, 'state': 'Illinois'}\n {'city': 'Chicago', 'country': 'United States', 'facility': 'Northwestern University', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}, 'state': 'Illinois'}]",
         "Autologous Transplant To End NMO Spectrum Disorder",
         "Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)",
         "This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission."
        ],
        [
         "17",
         "NCT05046366",
         "Inclusion Criteria:\n\n1. Participants with the clinical diagnosis of lung cancer, pulmonary tuberculosis, and COVID-19.\n2. Participants that have signed informed consent.\n3. Participants \\>= 18 years old and \\< 90 years old.\n4. Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.\n5. Healthy participants with no clinical diagnosis of lung cancer, pulmonary tuberculosis, and COVID-19.\n\nExclusion Criteria:\n\n1. Participants \\< 18 years old.\n2. Participants with primary clinical and pathological data missing.\n3. Participants lost to follow-up.\n4. Participants with too poor medical image quality to perform segment and mark ROI accurately.",
         "UNKNOWN",
         null,
         "OBSERVATIONAL",
         "18.0",
         "90.0",
         "ALL",
         "True",
         "['Artificial Intelligence' 'Deep Learning' 'Pathology, Molecular'\n 'Medical Informatics' 'Database' 'Lung Cancer' 'Pulmonary Tuberculosis'\n 'Covid19']",
         null,
         null,
         "{'conditions': array([{'id': 'D014376', 'term': 'Tuberculosis'},\n       {'id': 'D003141', 'term': 'Communicable Diseases'},\n       {'id': 'D007239', 'term': 'Infections'},\n       {'id': 'D014397', 'term': 'Tuberculosis, Pulmonary'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Wuhan', 'country': 'China', 'facility': 'Union Hospital, Tongji Medical College, Huazhong University of Science and Technology', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}, 'state': 'Hubei'}]",
         "Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.",
         "Research and Development of an Artificial Intelligence Technology System for Digital Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.",
         "To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical diagnosis and treatment information such as electronic medical records, image features, pathological features, and multi-omics information, and to develop a multi-modal data fusion-based technology system for individualized intelligent pathological diagnosis and therapeutic effect prediction using artificial intelligence technology."
        ],
        [
         "18",
         "NCT00003666",
         "DISEASE CHARACTERISTICS: Histologically or cytologically proven recurrent or refractory non-small cell lung cancer Squamous cell Adenocarcinoma (including bronchoalveolar cell) Large cell anaplastic (giant and clear cell carcinomas) Measurable disease (not bone disease only, pleural or pericardial effusions, or irradiated lesions, unless progression is documented after radiotherapy) No CNS metastases\n\nPATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater 1.5 mg/dL SGOT no greater than 2 times upper limit of normal (ULN) Renal: Creatinine no greater than ULN Cardiovascular: No active cardiac disease No unstable angina No myocardial infarction within 6 months No congestive heart failure No inability to tolerate hypotension Other: Not pregnant or nursing Fertile patients must use effective contraception HIV negative No uncontrolled diabetes mellitus No psychiatric disorders No concurrent secondary malignancies except nonmelanomatous skin cancer or patients with less than a 30% risk of relapse\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks since mitomycin) At least 1 prior chemotherapy agent or combination, including adjuvant or neoadjuvant therapy for non-small cell lung cancer No more than 1 prior chemotherapy agent or combination for metastatic or recurrent disease No prior HMAF No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy except for nondisease related conditions Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent palliative radiotherapy Surgery: Not specified",
         "COMPLETED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "18.0",
         "120.0",
         "ALL",
         "False",
         "['Lung Cancer']",
         "[\"recurrent non-small cell lung cancer\", \"squamous cell lung cancer\", \"large cell lung cancer\", \"adenocarcinoma of the lung\", \"bronchoalveolar cell lung cancer\"]",
         null,
         "{'conditions': array([{'id': 'D008175', 'term': 'Lung Neoplasms'},\n       {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}],\n      dtype=object), 'interventions': array([{'id': 'C102714', 'term': 'Irofulven'}], dtype=object)}",
         "[{'city': 'Birmingham', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Birmingham', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}, 'state': 'Alabama'}\n {'city': 'La Jolla', 'country': 'United States', 'facility': 'University of California San Diego Cancer Center', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}, 'state': 'California'}\n {'city': 'San Francisco', 'country': 'United States', 'facility': 'UCSF Cancer Center and Cancer Research Institute', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}, 'state': 'California'}\n {'city': 'San Francisco', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - San Francisco', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}, 'state': 'California'}\n {'city': 'Wilmington', 'country': 'United States', 'facility': 'CCOP - Christiana Care Health Services', 'geoPoint': {'lat': 39.74595, 'lon': -75.54659}, 'state': 'Delaware'}\n {'city': 'Washington', 'country': 'United States', 'facility': 'Vincent T. Lombardi Cancer Research Center, Georgetown University', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}, 'state': 'District of Columbia'}\n {'city': 'Washington', 'country': 'United States', 'facility': 'Walter Reed Army Medical Center', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}, 'state': 'District of Columbia'}\n {'city': 'Miami Beach', 'country': 'United States', 'facility': 'CCOP - Mount Sinai Medical Center', 'geoPoint': {'lat': 25.79065, 'lon': -80.13005}, 'state': 'Florida'}\n {'city': 'Chicago', 'country': 'United States', 'facility': 'University of Illinois at Chicago Health Sciences Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}, 'state': 'Illinois'}\n {'city': 'Chicago', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Chicago (Westside Hospital)', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}, 'state': 'Illinois'}\n {'city': 'Chicago', 'country': 'United States', 'facility': 'University of Chicago Cancer Research Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}, 'state': 'Illinois'}\n {'city': 'Iowa City', 'country': 'United States', 'facility': 'University of Iowa Hospitals and Clinics', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}, 'state': 'Iowa'}\n {'city': 'Togus', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Togus', 'geoPoint': {'lat': 44.27451, 'lon': -69.7031}, 'state': 'Maine'}\n {'city': 'Baltimore', 'country': 'United States', 'facility': 'Marlene & Stewart Greenebaum Cancer Center, University of Maryland', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}, 'state': 'Maryland'}\n {'city': 'Boston', 'country': 'United States', 'facility': 'Massachusetts General Hospital Cancer Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}, 'state': 'Massachusetts'}\n {'city': 'Boston', 'country': 'United States', 'facility': 'Dana-Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}, 'state': 'Massachusetts'}\n {'city': 'Worcester', 'country': 'United States', 'facility': 'University of Massachusetts Memorial Medical Center', 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}, 'state': 'Massachusetts'}\n {'city': 'Minneapolis', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Minneapolis', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}, 'state': 'Minnesota'}\n {'city': 'Columbia', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Columbia (Truman Memorial)', 'geoPoint': {'lat': 38.95171, 'lon': -92.33407}, 'state': 'Missouri'}\n {'city': 'Columbia', 'country': 'United States', 'facility': 'Ellis Fischel Cancer Center - Columbia', 'geoPoint': {'lat': 38.95171, 'lon': -92.33407}, 'state': 'Missouri'}\n {'city': 'Saint Louis', 'country': 'United States', 'facility': 'Barnes-Jewish Hospital', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}, 'state': 'Missouri'}\n {'city': 'Omaha', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Omaha', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}, 'state': 'Nebraska'}\n {'city': 'Omaha', 'country': 'United States', 'facility': 'University of Nebraska Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}, 'state': 'Nebraska'}\n {'city': 'Las Vegas', 'country': 'United States', 'facility': 'CCOP - Southern Nevada Cancer Research Foundation', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}, 'state': 'Nevada'}\n {'city': 'Lebanon', 'country': 'United States', 'facility': 'Norris Cotton Cancer Center', 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}, 'state': 'New Hampshire'}\n {'city': 'Buffalo', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Buffalo', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}, 'state': 'New York'}\n {'city': 'Buffalo', 'country': 'United States', 'facility': 'Roswell Park Cancer Institute', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}, 'state': 'New York'}\n {'city': 'Manhasset', 'country': 'United States', 'facility': 'CCOP - North Shore University Hospital', 'geoPoint': {'lat': 40.79788, 'lon': -73.69957}, 'state': 'New York'}\n {'city': 'Manhasset', 'country': 'United States', 'facility': 'North Shore University Hospital', 'geoPoint': {'lat': 40.79788, 'lon': -73.69957}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan-Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': 'New York Presbyterian Hospital - Cornell Campus', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': 'Mount Sinai Medical Center, NY', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'Syracuse', 'country': 'United States', 'facility': 'CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}, 'state': 'New York'}\n {'city': 'Syracuse', 'country': 'United States', 'facility': 'State University of New York - Upstate Medical University', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}, 'state': 'New York'}\n {'city': 'Syracuse', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Syracuse', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}, 'state': 'New York'}\n {'city': 'Chapel Hill', 'country': 'United States', 'facility': 'Lineberger Comprehensive Cancer Center, UNC', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}, 'state': 'North Carolina'}\n {'city': 'Durham', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Durham', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}, 'state': 'North Carolina'}\n {'city': 'Durham', 'country': 'United States', 'facility': 'Duke Comprehensive Cancer Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}, 'state': 'North Carolina'}\n {'city': 'Winston-Salem', 'country': 'United States', 'facility': 'CCOP - Southeast Cancer Control Consortium', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}, 'state': 'North Carolina'}\n {'city': 'Winston-Salem', 'country': 'United States', 'facility': 'Comprehensive Cancer Center of Wake Forest University Baptist Medical Center', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}, 'state': 'North Carolina'}\n {'city': 'Columbus', 'country': 'United States', 'facility': 'Arthur G. James Cancer Hospital - Ohio State University', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}, 'state': 'Ohio'}\n {'city': 'Providence', 'country': 'United States', 'facility': 'Rhode Island Hospital', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}, 'state': 'Rhode Island'}\n {'city': 'Charleston', 'country': 'United States', 'facility': 'Medical University of South Carolina', 'geoPoint': {'lat': 32.77657, 'lon': -79.93092}, 'state': 'South Carolina'}\n {'city': 'Memphis', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Memphis', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}, 'state': 'Tennessee'}\n {'city': 'Memphis', 'country': 'United States', 'facility': 'University of Tennessee, Memphis Cancer Center', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}, 'state': 'Tennessee'}\n {'city': 'White River Junction', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - White River Junction', 'geoPoint': {'lat': 43.64896, 'lon': -72.31926}, 'state': 'Vermont'}\n {'city': 'Richmond', 'country': 'United States', 'facility': 'Veterans Affairs Medical Center - Richmond', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}, 'state': 'Virginia'}\n {'city': 'Richmond', 'country': 'United States', 'facility': 'MBCCOP - Massey Cancer Center', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}, 'state': 'Virginia'}]",
         "Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer",
         "Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer",
         "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.\n\nPURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with relapsed or refractory non-small cell lung cancer."
        ],
        [
         "19",
         "NCT05698966",
         "Inclusion Criteria:- - Singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation at risk for / high probability of delivery in the late preterm period (34+0-36+5 weeks of gestation).\n\nCriteria for determination of late preterm delivery risk:\n\n1. Preterm uterine contractions with intact membranes, and at least 3 cm dilation or 75% cervical effacement\n2. Spontaneous rupture of the membranes\n3. Expected preterm delivery for any other indication via induction or cesarean between 24 hours to 7 days after the planned randomization, as determined by the obstetric provider.\n\n   -\n\n   Exclusion Criteria: They had already received a full course of betamethasone.\n   * Expected delivery in less than 12 hours, irrespective of cause including: 1)ruptured membranes in the presence of more than 6 contractions per hour or cervical dilation of 3 centimeters or more unless oxytocin was withheld for at least 12 hours (although other induction agents were allowed), 2) chorioamnionitis, 3) cervical dilation of 8 cm or more, and 4) evidence of non-reassuring fetal status requiring immediate delivery.\n   * Prior ACS treatment\n   * Current known or suspected infection ( viral, bacterial or other)\n   * Pre-gestational diabetes mellitus.\n   * Any infection that required antibiotics or hospitalization in the month prior to study allocation - Poor understanding of the inform consent language",
         "RECRUITING",
         "['NA']",
         "INTERVENTIONAL",
         "18.0",
         "45.0",
         "ALL",
         "False",
         "['Respiratory Morbidity' 'Preterm Labor']",
         "[\"corticosteroids\", \"low dose\", \"late prerterm\"]",
         null,
         "{'conditions': array([{'id': 'D047928', 'term': 'Premature Birth'},\n       {'id': 'D007752', 'term': 'Obstetric Labor, Premature'}],\n      dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Afula', 'country': 'Israel', 'facility': 'Emek Medical Center', 'geoPoint': {'lat': 32.60907, 'lon': 35.2892}, 'state': None}\n {'city': 'Ashkelon', 'country': 'Israel', 'facility': 'Kaplan Medical Center', 'geoPoint': {'lat': 31.66926, 'lon': 34.57149}, 'state': None}\n {'city': \"Be'er Sheva\", 'country': 'Israel', 'facility': 'Soroka Medical Center', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}, 'state': None}\n {'city': 'Hadera', 'country': 'Israel', 'facility': 'Hilel Yafee Medical Center', 'geoPoint': {'lat': 32.44192, 'lon': 34.9039}, 'state': None}\n {'city': 'Haifa', 'country': 'Israel', 'facility': 'Bnai Zion Medical Center', 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}, 'state': None}\n {'city': 'Haifa', 'country': 'Israel', 'facility': 'Carmel Medical Center', 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}, 'state': None}\n {'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam Health Care Cmpus', 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}, 'state': None}\n {'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah Ein Karem', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}, 'state': None}\n {'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah Har Hzofim', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}, 'state': None}\n {'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Shaare Zedek Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}, 'state': None}\n {'city': 'Kfar Saba', 'country': 'Israel', 'facility': 'Meir medical center', 'geoPoint': {'lat': 32.175, 'lon': 34.90694}, 'state': None}\n {'city': 'Nahariya', 'country': 'Israel', 'facility': 'Galilee Medical Center', 'geoPoint': {'lat': 33.00892, 'lon': 35.09814}, 'state': None}\n {'city': 'Petach Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}, 'state': None}\n {'city': 'Ramat Gan', 'country': 'Israel', 'facility': 'Sheba Medical Center', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}, 'state': None}\n {'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Sourasky Medical Center', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}, 'state': None}\n {'city': 'Zefat', 'country': 'Israel', 'facility': 'Ziv Medical Center', 'geoPoint': {'lat': 32.96465, 'lon': 35.496}, 'state': None}]",
         "Low Dose Antenatal Corticosteroids for Late Preterm Delivery",
         "Low Dose Antenatal Corticosteroids for Late Preterm Delivery (LoDAC Study)",
         "This is a study proposal for a clinical trial to evaluate the effectiveness of a reduced dose of antenatal betamethasone (a steroid medication) in preventing respiratory problems in late preterm infants (born between 34 and 36 weeks of gestation). The study will be conducted in medical centers in Israel and will involve women who are at high risk for delivering a late preterm infant. The participants will be randomly assigned to receive either a full dose (12 mg) or a quarter dose (3 mg) of betamethasone, administered 24 hours apart. The main outcome measure of the study will be the incidence of respiratory problems or neonatal death within 72 hours of delivery in the two groups. The study is designed to determine if the reduced dose of betamethasone is non-inferior (i.e., not significantly worse) than the full dose in preventing respiratory problems in late preterm infants."
        ],
        [
         "20",
         "NCT02861066",
         "Inclusion Criteria:\n\n* Consenting mood and anxiety outpatients referred to Dr. Selchen in the Sunnybrook Mindfulness-Based Therapy Clinic\n* Due to the nature of the assessment procedures, which include English-language self-report questionnaires and scales, ability to communicate in written and spoken English is an inclusion criterion\n\nExclusion Criteria:\n\n* Patients who have active or recent (within 3 months) substance abuse/dependence, a history of dementia, untreated posttraumatic stress symptoms, active psychotic or manic symptoms, recent suicide attempt/active suicidality, or current self-injurious behaviour\n* Previously completed a course (â¥ 8 weeks) of a Mindfulness-Based Therapy within the last 3 years",
         "COMPLETED",
         "['NA']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Anxiety' 'Depression' 'Mood']",
         "[\"Mindfulness-based Intervention\", \"Wellbeing\", \"Treatment\"]",
         null,
         "{'conditions': array([{'id': 'D003863', 'term': 'Depression'}], dtype=object), 'interventions': None}",
         null,
         "Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms",
         "Reducing Barriers to Mental Health Care: Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms in a Heterogeneous Clinical Outpatient Group",
         "Symptoms of depression and anxiety are extremely prevalent in the population. Unfortunately, patients often face barriers to accessing mental health care, particularly psychotherapeutic interventions, including long wait-times and demanding therapeutic protocols. For instance, Mindfulness-Based Therapy (MBT) has demonstrated effectiveness at decreasing symptoms of depression and anxiety, and improving wellbeing; however, 'traditional' MBT can demand over 30 hours of clinical time, and 50-60 hours of homework, all of which can be barriers to care. The goal of this project is to test the effectiveness of an Abbreviated MBT (\\<10 hours of clinical time and \\<10 hours of homework) in reducing symptoms of depression/anxiety and improving wellbeing. If effective, this Abbreviated MBT could reduce barriers to accessing mental health care."
        ],
        [
         "21",
         "NCT04059666",
         "Inclusion Criteria:\n\n* 7-18 days of age at Visit 1\n* Singleton birth\n* Gestational age of 37-42 weeks\n* Birth weight of 2500 g (5 lbs 8 oz) or more\n* Parent or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study\n* Signed informed consent and use of PHI for infant and birth mother\n* Receipt of three protocol-compliant Baseline stool samples\n\nInfants receiving formula:\n\n* Exclusively receiving infant formula for at least 24 hours prior to randomization\n* Parent(s) or legal guardian has full intention to exclusively feed study formula during the study period\n\nInfants receiving human milk:\n\n* Mother has intention to exclusively provide mother's-own breast milk for the duration of the study\n\nExclusion Criteria:\n\n* Caesarean delivery\n* Infant consumption of donor milk prior to randomization/registration\n* Maternal antibiotic use within 48 hours prior to or at time of delivery\n* Maternal antibiotic use while providing mother's-own breast milk to infant\n* Infant use of systemic antibiotics prior to randomization/registration\n* Any signs of an acute infection (i.e. fever, diarrhea) at randomization/registration\n* Weight at Visit 1 is \\<95% of birth weight\n* Infant use of probiotics\n* Evidence of significant feeding difficulties\n* Infant was born large for gestational age\n* History of underlying metabolic or chronic disease or congenital malformation\n* Infant is immunocompromised\n\nInfants receiving human milk:\n\n* Consumption of infant formula from 1 day of age",
         "TERMINATED",
         "['NA']",
         "INTERVENTIONAL",
         "7.0",
         "18.0",
         "ALL",
         "True",
         "['Gastrointestinal Microbiome']",
         null,
         null,
         "{'conditions': None, 'interventions': array([], dtype=object)}",
         "[{'city': 'Birmingham', 'country': 'United States', 'facility': 'Birmingham Pediatric Associates', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}, 'state': 'Alabama'}\n {'city': 'Altamonte Springs', 'country': 'United States', 'facility': \"Children's Research, LLC\", 'geoPoint': {'lat': 28.66111, 'lon': -81.36562}, 'state': 'Florida'}\n {'city': 'Owensboro', 'country': 'United States', 'facility': 'Owensboro Pediatrics', 'geoPoint': {'lat': 37.77422, 'lon': -87.11333}, 'state': 'Kentucky'}\n {'city': 'Kingsport', 'country': 'United States', 'facility': 'Holston Medical Group', 'geoPoint': {'lat': 36.54843, 'lon': -82.56182}, 'state': 'Tennessee'}\n {'city': 'Memphis', 'country': 'United States', 'facility': 'Memphis & Shelby County Pediatric', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}, 'state': 'Tennessee'}]",
         "Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas",
         "Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas",
         "This clinical trial will compare stool and oral microbiome composition between infants fed breast milk or one of two infant formulas for a 60 day feeding period."
        ],
        [
         "22",
         "NCT03539666",
         "Inclusion Criteria:\n\n* generally good health status based on one routine physical in the past 15 months, current health status\n* normal HbA1C, weigh 110 lb or more\n* Age 50 years or more, generally healthy, all races and both sexes\n* generally practicing a meat-based dietary pattern, do not have any special dietary requirement, and\n* willingness to comply with the study protocol, including on-site meal consumption and sample/data collection.\n\nExclusion Criteria:\n\n* medication usage, probiotic, long-term antibiotic, and tobacco/drug/alcohol use\n* Not on any special diet within 3 months of recruitment, and do not have any intention to lose weight.\n* impaired kidney functions\n* Active history of cancer, diabetes, heart, liver, and kidney diseases\n* major gastrointestinal disorders in the past 3 months\n* history of heart attacks or stroke\n* Unable to meet in-person visit requirements for dining, picking up meals, and tests\n* Any mental health condition that would affect the ability to provide written informed consent.\n* If they had not had a routine health checkup during the 12 months prior to recruitment.\n* If they were unwilling to abstain from taking nutritional supplements, alcohol, non-study foods, and beverage during the study period.",
         "COMPLETED",
         "['NA']",
         "INTERVENTIONAL",
         "50.0",
         null,
         "ALL",
         "True",
         "['Healthy']",
         null,
         null,
         null,
         "[{'city': 'Brookings', 'country': 'United States', 'facility': 'South Dakota State University, Wagner Hall 416', 'geoPoint': {'lat': 44.31136, 'lon': -96.79839}, 'state': 'South Dakota'}]",
         "Effect of Diets on the Gut Microbiota Composition and Cardiometabolic Wellbeing",
         "The Effect of Pork and Chicken Diets on Gut Microbiota Composition and Metabolites Related to Cardiometabolic Wellbeing",
         "The project will characterize human gut microbiome response to two different diets and the possible physiological and biochemical implications of such response on cardiometabolic risk factors. The study will use controlled-feeding, systems-biology, metagenomic, and metabolomic approaches to examine American dietary patterns."
        ],
        [
         "23",
         "NCT04328766",
         "Inclusion Criteria:\n\n* Healthy adults aged 19 to 50 years with BMI between 18.5 kg/m2 and 30.0 kg/m2\n* Capable of understanding provided information and complying with protocol requirements\n* Provide written informed consent to participate in the study",
         "COMPLETED",
         "['PHASE1']",
         "INTERVENTIONAL",
         "19.0",
         "50.0",
         "ALL",
         "True",
         "['Drug-drug Interaction']",
         null,
         null,
         "{'conditions': None, 'interventions': array([{'id': 'C000634065', 'term': 'Fexuprazan'}], dtype=object)}",
         "[{'city': 'Queensland', 'country': 'Australia', 'facility': 'Nucleus Network (QPharm)', 'geoPoint': None, 'state': None}]",
         "Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers",
         "An Open-Label, Multiple-Dose Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers",
         "An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers"
        ],
        [
         "24",
         "NCT04791566",
         "Inclusion Criteria:\n\n1. Adults (18 years or over) undergoing emergency laparotomy (laparotomy or laparoscopy) for following abdominal pathology:\n\n   1. Primary perforated viscus (perforated ulcer, small intestine or colon)\n   2. Primary intestinal obstruction ( small intestine or colon)\n2. Provided verbal and written informed consent\n3. Must speak and understand the Danish language\n\nExclusion Criteria:\n\n1. Appendectomies, cholecystectomies, negative diagnostic laparoscopies/laparotomies, herniotomies without bowel resections, sub-acute internal hernias after gastric bypass surgery, sub-acute surgery for inflammatory bowel diseases.\n2. Emergency re-operations after elective surgery owing to paralytic/obstructive ileus, perforated viscus, anastomotic leakage\n3. Reoperation owing to fascial separation with no other abdominal pathology identified and sub-acute colorectal cancer-surgery will be excluded from the cohort. Sub-acute surgery is defined as surgery planned within 48 hours.\n4. Intestinal Ischemia\n5. intraabdominal bleeding\n6. Traumas, gynecological, urogenital and other vascular pathology, pregnant participants.\n7. Dementia and/or cognitive dysfunction (diagnosed).\n8. Participants not oriented in time, place and person\n9. Insuline treatment for diabetes mellitus type I and II\n10. Current treatment with systemic glucocorticoids or immune suppressive treatment ( apart from inhalation steroids)\n11. Allergies to trial medicine\n\n    -",
         "COMPLETED",
         "['PHASE4']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Intestinal Obstruction and Ileus' 'Perforated Viscus' 'Sepsis'\n 'Pathophysiology' 'Inflammatory Response']",
         null,
         null,
         "{'conditions': array([{'id': 'D007415', 'term': 'Intestinal Obstruction'}], dtype=object), 'interventions': array([{'id': 'D003907', 'term': 'Dexamethasone'}], dtype=object)}",
         "[{'city': 'Hvidovre', 'country': 'Denmark', 'facility': 'Mirjana Cihoric', 'geoPoint': {'lat': 55.65719, 'lon': 12.47364}, 'state': None}]",
         "Preoperative High-dose Dexamethasone and Emergency Laparotomy",
         "The Effects of Preoperative High-dose Dexamethasone on Inflammatory Response and Recovery After Emergency Laparotomy, a Randomized, Double-blind, Placebo-controlled Clinical Trial - AHA STEROID TRIAL",
         "The aim of this trial is to evaluate the effect of high-dose glucocorticoid on inflammatory response and recovery after emergency laparotomy in participants with intestinal obstruction and perforated viscus.\n\nPrimary outcome is the reduction of C-reactive protein on postoperative day 1. Secondary outcomes are organ specific complications in the post anaesthesia phase, endothel and inflammatory markers, fluid status, preload dependency, pain, lung function, nausea and mobilization during the first 5 days after surgery, .\n\nThe investigators hypothesize, that a preoperative single high dose of glucocorticoid reduces systemic inflammatory response after emergency laparotomy."
        ],
        [
         "25",
         "NCT00251966",
         "Inclusion Criteria:\n\n* A clinical diagnosis of a condition (cardiovascular and/or cerebrovascular protection or other reasons) that requires daily intake of low-dose ASA, 75-325 mg, and is expected to continue for the duration of the study (daily is defined as at least 5 days per week).\n* Age \\>= 60 years.\n* No gastric and/or duodenal ulcer at the baseline endoscopy.\n* H. pylori negative by serology test at screening.\n\nExclusion Criteria:\n\n* Upper GI symptoms\n* Erosive oesophagitis\n* Malignancy",
         "COMPLETED",
         "['PHASE3']",
         "INTERVENTIONAL",
         "60.0",
         null,
         "ALL",
         "False",
         "['Gastroesophageal Reflux']",
         "[\"Prevention of gastroduodenal lesions\", \"erosive oesophagitis\", \"upper GI symptoms\"]",
         null,
         "{'conditions': array([{'id': 'D005764', 'term': 'Gastroesophageal Reflux'}], dtype=object), 'interventions': array([{'id': 'D064098', 'term': 'Esomeprazole'}], dtype=object)}",
         "[{'city': 'Bondi Junction', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -33.89275, 'lon': 151.24723}, 'state': 'New South Wales'}\n {'city': 'Bracken Ridge', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -27.3171, 'lon': 153.03097}, 'state': 'Queensland'}\n {'city': 'Carina Heights', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -27.50721, 'lon': 153.09126}, 'state': 'Queensland'}\n {'city': 'Adelaide', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}, 'state': 'South Australia'}\n {'city': 'Ashford', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -29.32191, 'lon': 151.09308}, 'state': 'South Australia'}\n {'city': 'Wayville', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -34.95, 'lon': 138.58333}, 'state': 'South Australia'}\n {'city': 'Woodville', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -34.88333, 'lon': 138.55}, 'state': 'South Australia'}\n {'city': 'Ballarat', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -37.56622, 'lon': 143.84957}, 'state': 'Victoria'}\n {'city': 'Malvern', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -32.02849, 'lon': 151.32225}, 'state': 'Victoria'}\n {'city': 'Burgas', 'country': 'Bulgaria', 'facility': 'Research Site', 'geoPoint': {'lat': 42.50606, 'lon': 27.46781}, 'state': None}\n {'city': 'Pleven', 'country': 'Bulgaria', 'facility': 'Research Site', 'geoPoint': {'lat': 43.41667, 'lon': 24.61667}, 'state': None}\n {'city': 'Russe', 'country': 'Bulgaria', 'facility': 'Research Site', 'geoPoint': {'lat': 43.85639, 'lon': 25.97083}, 'state': None}\n {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Research Site', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}, 'state': None}\n {'city': 'Varna', 'country': 'Bulgaria', 'facility': 'Research Site', 'geoPoint': {'lat': 43.21667, 'lon': 27.91667}, 'state': None}\n {'city': 'Edmonton', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}, 'state': 'Alberta'}\n {'city': 'Winnipeg', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}, 'state': 'Manitoba'}\n {'city': 'Bay Roberts', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 47.59989, 'lon': -53.26478}, 'state': 'Newfoundland and Labrador'}\n {'city': 'Carbonear', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 47.73305, 'lon': -53.21523}, 'state': 'Newfoundland and Labrador'}\n {'city': \"St. John's\", 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 47.56494, 'lon': -52.70931}, 'state': 'Newfoundland and Labrador'}\n {'city': 'Halifax', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 44.64533, 'lon': -63.57239}, 'state': 'Nova Scotia'}\n {'city': 'Hamilton', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}, 'state': 'Ontario'}\n {'city': 'London', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}, 'state': 'Ontario'}\n {'city': 'North York', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.76681, 'lon': -79.4163}, 'state': 'Ontario'}\n {'city': 'Oakville', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.45011, 'lon': -79.68292}, 'state': 'Ontario'}\n {'city': 'Sudbury', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 46.49, 'lon': -80.99001}, 'state': 'Ontario'}\n {'city': 'Thornhill', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': None, 'state': 'Ontario'}\n {'city': 'Toronto', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}, 'state': 'Ontario'}\n {'city': 'Parkdale', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': None, 'state': 'Prince Edward Island'}\n {'city': 'Courcelette', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': None, 'state': 'Quebec'}\n {'city': 'Quebec', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}, 'state': None}\n {'city': 'Stuttgart', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 48.78232, 'lon': 9.17702}, 'state': 'Baden-WÃ¼rttemberg'}\n {'city': 'MÃ¼nchen', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}, 'state': 'Bayern'}\n {'city': 'Cottbus', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.75769, 'lon': 14.32888}, 'state': 'Brandenburg'}\n {'city': 'Frankfurt', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}, 'state': 'Hessen'}\n {'city': 'Rostock', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 54.0887, 'lon': 12.14049}, 'state': 'Mecklenburg-Vorpommern'}\n {'city': 'Hannover', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}, 'state': 'Niedersachsen'}\n {'city': 'DÃ¼sseldorf', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}, 'state': 'Nordrhein-Westfalen'}\n {'city': 'MÃ¼nster', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}, 'state': 'Nordrhein-Westfalen'}\n {'city': 'Mainz', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 49.98419, 'lon': 8.2791}, 'state': 'Rheinland-Pfalz'}\n {'city': 'Halle', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.48159, 'lon': 11.97948}, 'state': 'Sachsen-Anhalt'}\n {'city': 'Hamburg', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 53.57532, 'lon': 10.01534}, 'state': None}\n {'city': 'Herne', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.5388, 'lon': 7.22572}, 'state': None}\n {'city': 'KÃ¶ln', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}, 'state': None}\n {'city': 'KÃ¼nzing', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 48.66667, 'lon': 13.08333}, 'state': None}\n {'city': 'Lienen', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.15, 'lon': 7.98333}, 'state': None}\n {'city': 'Ludwigshafen', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 49.48121, 'lon': 8.44641}, 'state': None}\n {'city': 'LÃ¼denscheid', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.21977, 'lon': 7.6273}, 'state': None}\n {'city': 'MÃ¼nster', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}, 'state': None}\n {'city': 'Oelde', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.8289, 'lon': 8.14724}, 'state': None}\n {'city': 'Paderborn', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.71905, 'lon': 8.75439}, 'state': None}\n {'city': 'Potsdam', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.39886, 'lon': 13.06566}, 'state': None}\n {'city': 'Ribnitz-Damgarten', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 54.2422, 'lon': 12.45666}, 'state': None}\n {'city': 'Rostock', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 54.0887, 'lon': 12.14049}, 'state': None}\n {'city': 'Siegen', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 50.87481, 'lon': 8.02431}, 'state': None}\n {'city': 'Wangen', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 48.72933, 'lon': 9.61175}, 'state': None}\n {'city': 'Wiesbaden', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 50.08258, 'lon': 8.24932}, 'state': None}\n {'city': 'WolfenbÃ¼ttel', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.16442, 'lon': 10.54095}, 'state': None}\n {'city': 'Wolmirstedt', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.24856, 'lon': 11.62945}, 'state': None}\n {'city': 'Zeven', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 53.29657, 'lon': 9.27685}, 'state': None}\n {'city': 'Athens', 'country': 'Greece', 'facility': 'Research Site', 'geoPoint': {'lat': 37.97945, 'lon': 23.71622}, 'state': None}\n {'city': 'Ioannina', 'country': 'Greece', 'facility': 'Research Site', 'geoPoint': {'lat': 39.66486, 'lon': 20.85189}, 'state': None}\n {'city': 'Piraeus', 'country': 'Greece', 'facility': 'Research Site', 'geoPoint': {'lat': 37.94745, 'lon': 23.63708}, 'state': None}\n {'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Research Site', 'geoPoint': {'lat': 40.64361, 'lon': 22.93086}, 'state': None}\n {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Research Site', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}, 'state': None}\n {'city': 'Budapest', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}, 'state': None}\n {'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.53333, 'lon': 21.63333}, 'state': None}\n {'city': 'Eger', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.90265, 'lon': 20.37329}, 'state': None}\n {'city': 'Gyula', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}, 'state': None}\n {'city': 'GyÂ¿r', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': None, 'state': None}\n {'city': 'KecskemÃ©t', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.90618, 'lon': 19.69128}, 'state': None}\n {'city': 'Miskolc', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 48.1, 'lon': 20.78333}, 'state': None}\n {'city': 'VÃ¡c', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.77591, 'lon': 19.13612}, 'state': None}\n {'city': 'Bologna', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}, 'state': 'BO'}\n {'city': 'Genova', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 44.40478, 'lon': 8.94438}, 'state': 'GE'}\n {'city': 'Parma', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 44.79935, 'lon': 10.32618}, 'state': 'PR'}\n {'city': 'Napoli', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 40.85216, 'lon': 14.26811}, 'state': None}\n {'city': 'Roma', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}, 'state': None}\n {'city': 'Cape Town', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}, 'state': None}\n {'city': 'Johannesurg', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': None, 'state': None}\n {'city': 'Lyttelton Manor', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': None, 'state': None}\n {'city': 'Parktown', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -26.18205, 'lon': 28.02671}, 'state': None}\n {'city': 'Tygerberg', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': None, 'state': None}\n {'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}, 'state': 'A CoruÃ±a'}\n {'city': 'Santiago', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': None, 'state': 'A CoruÃ±a'}\n {'city': 'San SebastiÃ¡n', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 43.31283, 'lon': -1.97499}, 'state': 'Guipuzcoa'}\n {'city': 'Granada', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 37.18817, 'lon': -3.60667}, 'state': None}\n {'city': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}, 'state': None}\n {'city': 'Murcia', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 37.98704, 'lon': -1.13004}, 'state': None}\n {'city': 'Sevilla', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}, 'state': None}\n {'city': 'Irvine', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 55.6194, 'lon': -4.65508}, 'state': 'Ayrshire'}\n {'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}, 'state': 'Scotland'}\n {'city': 'Cardiff', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.48, 'lon': -3.18}, 'state': 'South Wales'}\n {'city': 'Edinburgh', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}, 'state': None}]",
         "ASTERIX: Low Dose ASA and Nexium",
         "A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.",
         "The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA."
        ],
        [
         "26",
         "NCT02736266",
         "Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Ability to comply with the protocol.\n3. Age â¥ 18 years.\n4. Histopathologically confirmed transitional cell carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) transitional cell pattern.\n5. Fit and planned for cystectomy (according to local guidelines).\n6. Clinical stage T2-T4a N0 M0 disease by CT (or MRI) + PET/CT (within 4 weeks of randomization by RECIST v1.1).\n7. Residual disease after TURB (surgical opinion, cystoscopy or radiological presence).\n8. Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for testing at the study sponsor site and determined to be evaluable for tumor PD-L1 expression prior to study enrolment; patients with fewer than 15 unstained slides available at baseline (but no fewer than 10) may be eligible following discussion with Merck representatives.\n9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n10. Adequate hematologic and end-organ function tests.\n\nExclusion Criteria:\n\n* Patients taking regular oral steroids, above the allowed limit of 10mg/day methylprednisolone or analogues, for any reason. Patients must not have had steroids for 28 days prior to study entry.\n* Previously intravenous chemotherapy bladder cancer. Patients who have previously had radiotherapy or concurrent chemo-radiation would be eligible.\n* Malignancies other than UBC within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer (Gleason score â¤ 3 + 4 and PSA \\< 10 ng/mL undergoing active surveillance and treatment naive).\n* Evidence of measurable nodal or metastatic disease.\n* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).\n* Pregnant female patients. All female patients of childbearing potential with a positive pregnancy test within 2 weeks prior to the first dose of study treatment will be excluded from the study.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to enrolment, unstable arrhythmias, or unstable angina.\n* Severe infections within 4 weeks prior to enrolment in the study including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.\n* Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the pembrolizumab formulation\n* History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, SjÃ¶gren's syndrome, Guillain-BarrÃ© syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n* Patients with a history of autoimmune-related hypothyroidism, unless on a stable dose of thyroid-replacement hormone.\n* Patients with uncontrolled Type 1 diabetes mellitus\n* Uncontrolled hypercalcemia\n* Patients with prior allogeneic stem cell or solid organ transplantation.\n* History of idiopathic pulmonary fibrosis\n* Positive test for HIV.\n* Patients with active hepatitis infection\n* Patients with active tuberculosis.\n* Prior treatment with anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents.\n* Administration of a live, attenuated vaccine within 4 weeks prior to enrolment or anticipation that such a live, attenuated vaccine will be required during the study\n* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrolment\n* History of severe immune-related adverse effects from anti-CTLA-4 (CTCAE Grade 3 and 4).\n* Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrolment.",
         "COMPLETED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Urothelial Bladder Carcinoma']",
         "[\"Muscle-invasive\", \"Urothelial bladder carcinoma\", \"Neoadjuvant therapy\", \"Radical cystectomy\"]",
         null,
         "{'conditions': array([{'id': 'D002277', 'term': 'Carcinoma'},\n       {'id': 'D001749', 'term': 'Urinary Bladder Neoplasms'}],\n      dtype=object), 'interventions': array([{'id': 'C582435', 'term': 'Pembrolizumab'}], dtype=object)}",
         "[{'city': 'Milano', 'country': 'Italy', 'facility': 'Fondazione IRCCS Istituto Nazionale dei Tumori', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}, 'state': 'Mi'}]",
         "Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma",
         "An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.",
         "Patients with T2-T4a N0 urothelial bladder carcinoma (UBC) with residual disease after transurethral resection of the bladder (TURB, surgical opinion, cystoscopy or radiological presence) will receive 3 cycles of pembrolizumab (MK-3475) at the dose of 200mg 3 weekly prior to surgery (radical cystectomy). Cystectomy will be planned to be done within 3 weeks of the last dose (accounting for a total of 9 weeks).\n\nComputed tomography (CT) scan and fluorodeoxyglucose positron emission tomography (FDG-PET)/CT scan will be done during screening and before surgery. After cystectomy, patients with the evidence of pathologic stage T3-4 (pT3-4) and/or pathologically node-positive disease will be managed according to local guidelines. Further anti programmed-death (PD)-1 or anti PD-ligand 1 (PD-L1) therapy will not be given post-operatively.\n\nPD-L1 status will be centralized and assessed on TURB specimen using an anti-PD-L1 antibody (Ab) and a prototype immunohistochemical (IHC) assay. PD-L1 positivity will be defined as any staining in the stroma or in â¥1% of tumor cells.\n\nPathologic complete response (pCR) is the primary endpoint. All patients enrolled who receive at least 1 cycle of study drug will be includes in the intention-to-treat (ITT) analysis.\n\nThe alternative hypothesis (H1) is pCR â¥20% and null hypothesis (H0) pCRâ¤10%. A 2-stage design will be used to estimate the number of pts required. Out of 90 pts overall, with the first stage of 49 pts, â¥6 pCR will be required in the first stage, and â¥13 pCR in the whole study population (80% power and a 2-sided test of significance at the 10% level).\n\nCorrelative research on tissue/blood samples will include immune-cell profiling in tumor and blood during Pembrolizumab, cytokine assessment, and molecular profiling of tumor samples."
        ],
        [
         "27",
         "NCT01857466",
         "Inclusion Criteria:\n\n* age between 18 and 45 years\n* maximum diameter of the cyst between 3 and 10 cm\n* regular menstrual bleeding (defined as cycle length less than 21 or more than 45 days)\n* appropriate medical status for laparoscopic surgery (American Society of Anesthesiologists Physical Status classification 1 or 2).\n\nExclusion Criteria:\n\n* any suspicious finding of malignant ovarian diseases\n* postmenopausal status\n* baseline serum AMH \\< 0.50 ng/mL\n* pregnancy\n* lactation\n* any other endocrine diseases (such as thyroid dysfunction, hyperprolactinemia, or Cushing's syndrome)\n* use of hormonal treatments in the 3 months before enrollment",
         "COMPLETED",
         "['PHASE3']",
         "INTERVENTIONAL",
         "18.0",
         "45.0",
         "FEMALE",
         "False",
         "['Ovarian Cysts']",
         null,
         null,
         "{'conditions': array([{'id': 'D010048', 'term': 'Ovarian Cysts'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Goyang', 'country': 'Korea, Republic of', 'facility': 'National Health Insurance Service Ilsan Hospital', 'geoPoint': {'lat': 37.65639, 'lon': 126.835}, 'state': None}\n {'city': 'Seoul', 'country': 'Korea, Republic of', 'facility': 'CHA Gangnam Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}, 'state': None}\n {'city': 'Seoul', 'country': 'Korea, Republic of', 'facility': 'Kangbuk Samsung Hospital, Sungkyunkwan University', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}, 'state': None}]",
         "Ovarian Reserve After Ovarian Hemostasis by Floseal Matrix",
         "Additional Benefit of Hemostatic Sealant in Preserving Ovarian Reserve During Laparoscopic Ovarian Cystectomy: a Randomized Controlled Trial",
         "Laparoscopy has become the gold standard for the surgical treatment of benign ovarian cysts and is usually performed by stripping the ovarian cyst wall, followed by bleeding control of the ovarian wound ground using bipolar coagulation. However, the hemostasis with bipolar coagulation could result in the damage of ovarian reserve and decrease the response of the ovaries to hormonal stimulation for assisted reproductive technologies. The possible mechanism may contribute to thermal destruction of ovarian follicles by excessive use of bipolar coagulation for hemostasis purposes.\n\nTo avoid additional ovarian tissue damage by conventional bipolar coagulation being potentially important ovarian reproductive function, hemostasis using various topical hemostatic agents has introduced to control post-cystectomy ovarian wound bleeding. Among them, FloSeal (Baxter Healthcare Corporation, Deerfield, IL, USA) is a hemostatic matrix sealant composed of a gelatin-based matrix and thrombin solution. On coming into contact with blood after application at a bleeding site, the gelatin particles swell and tamponade bleeding. The bulk of the gelatin matrix-thrombin composite has the effect of slowing blood flow and providing exposure to a high thrombin concentration, thus hastening clot formation. Therefore, it may more suitable for use in post-cystectomy ovarian wound bleeding, where there is superficially pervasive focus of bleeding.\n\nOvarian reserve is defined as the functional potential of the ovary, which reflects the number and quality of antral follicles left in the ovary, and is correlated with the response to ovarian stimulation using exogenous gonadotropin. Serum anti-MÃ¼llerian hormone (AMH) has been accepted as the most reliable and easily measurable marker for postoperative assessment of ovarian reserve.\n\nThe investigators conducted a multicenter, large-scale, randomized controlled trial to investigate whether hemostasis by Floseal was superior to that by bipolar coagulation in preserving ovarian reserve by assessing serial AMH levels in patients undergoing laparoscopic ovarian cystectomy for benign ovarian cysts."
        ],
        [
         "28",
         "NCT03221166",
         "Inclusion Criteria:\n\n* Age at diagnosis \\<18 years and \\>=6 years\n* New diagnosis of CD based on Porto criteria\n* CD with inflammatory phenotype (non-penetrating, non-fistulizing) and with no need for surgery except for perinal fistulas\n* Presence of at least one of the following risk factors for poor prognosis:\n\n  * fistulizing perianal disease\n  * pan-enteric disease\n  * disease extension \\> 60 cm\n  * severe growth delay (height z-score \\< -2 DS)\n  * severe osteoporosis (z score \\< -2 DS)\n  * hypoalbuminemia (\\< 3g/dL) or high C-reactive protein (2 times higher the normal range)\n* Acceptance of the Risk Evaluation and Mitigation Strategy (REMS) program for reducing the teratogenic risk.\n\nExclusion Criteria:\n\n* ongoing pregnancy\n* presence of peripheral neuropathy\n* HIV\n* patients with transplanted organs\n* ongoing major infections or other severe diseases\n* participation to other experimental studies.",
         "TERMINATED",
         "['PHASE3']",
         "INTERVENTIONAL",
         "6.0",
         "17.0",
         "ALL",
         "False",
         "['Crohn Disease']",
         "[\"Children\", \"Crohn disease\", \"Thalidomide\", \"Mucosal healing\"]",
         null,
         "{'conditions': array([{'id': 'D003424', 'term': 'Crohn Disease'}], dtype=object), 'interventions': array([{'id': 'D013792', 'term': 'Thalidomide'},\n       {'id': 'D000069285', 'term': 'Infliximab'}], dtype=object)}",
         "[{'city': 'Napoli', 'country': 'Italy', 'facility': 'Dipartimento di Pediatria dell\\'UniversitÃ  di Napoli \"Federico II\"', 'geoPoint': {'lat': 40.85216, 'lon': 14.26811}, 'state': 'Campania'}\n {'city': 'Trieste', 'country': 'Italy', 'facility': 'IRCCS Burlo Garofolo', 'geoPoint': {'lat': 45.64953, 'lon': 13.77679}, 'state': 'Friuli Venezia Giulia'}\n {'city': 'Genoa', 'country': 'Italy', 'facility': 'Pediatria III Gastroenterologia ed Endoscopia Digestiva, Istituto Giannina Gaslini', 'geoPoint': {'lat': 44.40478, 'lon': 8.94438}, 'state': 'Liguria'}\n {'city': 'Monza', 'country': 'Italy', 'facility': 'Fondazione MBBM , Azienda Ospedaliera San Gerardo - UniversitÃ  Milano Bicocca', 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}, 'state': 'Lombardia'}\n {'city': 'Messina', 'country': 'Italy', 'facility': 'UnitÃ  di Gastroenterologia Pediatrica e Fibrosi Cistica, Dipartimento di Scienze Pediatriche Mediche e Chirurgiche, Policlinico Universitario', 'geoPoint': {'lat': 38.19394, 'lon': 15.55256}, 'state': 'Sicilia'}\n {'city': 'Firenze', 'country': 'Italy', 'facility': 'Gastroenterologia e Nutrizione Pediatrica, Azienda Ospedaliero Universitaria Meyer', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}, 'state': 'Toscana'}]",
         "Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors",
         "Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network",
         "Crohn's disease (CD) is a life-long inflammatory bowel disease disease with an unknown pathogenesis. The ultimate goal of therapy is to modify the natural history of CD thus reducing complications. Thalidomide is a small molecule with immunomodulatory and anti-angiogenetic properties. It is currently approved for the treatment of erythema nodosum leprosum, an immunological complication of leprosy and multiple myeloma. It has also been used in several other inflammatory diseases of the skin and of the mucosal membranes, such as Behcet disease, oropharyngeal ulcers in AIDS, cutaneous lupus, and graft versus host disease. Many case series and one pediatric randomized controlled trial proved the efficacy of thalidomide in the treatment of children with CD refractory to standard treatments. In these patients, clinical remission was achieved in about 50% of the cases and was maintained for a mean time superior of 3 years. Mucosal healing after 52 weeks of treatment was observed in 40% of the patients in clinical remission. Moreover, thalidomide was found to have a steroid-sparing effect and to decrease the need for surgical interventions. The clinical and endoscopic efficacy of thalidomide was also observed in children with failure to respond or intolerance to anti-TNF biological drugs.\n\nThe aim of this multicentric prospective randomized controlled is to evaluate the efficacy and safety of thalidomide vs infliximab in changing the natural history of CD in patients with poor prognostic outcome. Moreover, the study will evaluate the immunological and genetical mechanisms of CD, the mechanisms of action thalidomide in CD and will the pharmacokinetics, metabolomics and pharmacogenomics of thalidomide, and their impact on thalidomide safety and effectiveness."
        ],
        [
         "29",
         "NCT00895466",
         "Inclusion Criteria:\n\n* pathological confirmed prostatic adenocarcinoma, clinical stage (c) cT1-3, cN0-1/x, cM0\n* baseline testosterone levels of \\> 4 nmol/l\n* baseline PSA level of \\> 10 microg/l\n* eligible for hormone therapy\n* willingness to comply with the protocol conditions and procedures\n* willing and able to give informed consent\n\nExclusion Criteria:\n\n* clinical evidence of distant metastases\n* previous hormonal therapy administered specifically for prostatic carcinoma\n* development of another invasive neoplastic disease during the previous 5 years, or concomitant presence of another invasive neoplastic disease, except basal cell carcinoma or squamous cell carcinoma of the skin\n* primary or secondary immunodeficiency, including immunosuppressive disease or use of corticosteroids or other immunosuppressive medications\n* concomitant administration - or administration during the 12 weeks preceding study inclusion - of immune enhancing medication or testosterone supplements\n* concomitant radiotherapy for prostate cancer\n* presence of bacterial prostatitis causing a PSA increase during the 8 weeks preceding study inclusion\n* simultaneous participation in another clinical trial or participation in a clinical trial involving investigational drugs within 3 months before enrollment into the present study\n* BMI \\> 30 kg/square meter\n* previous serious reaction to a vaccine such as angioedema or anaphylaxis",
         "UNKNOWN",
         "['PHASE1' 'PHASE2']",
         "INTERVENTIONAL",
         null,
         null,
         "MALE",
         "False",
         "['Prostate Cancer']",
         "[\"prostatic diseases\", \"neoplasms\", \"prostatic neoplasms\", \"hormones\", \"androgen antagonists\", \"vaccines\", \"peptide vaccines\", \"adjuvants, immunological\"]",
         null,
         "{'conditions': array([{'id': 'D011471', 'term': 'Prostatic Neoplasms'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Groningen', 'country': 'Netherlands', 'facility': 'UMC Groningen', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}, 'state': None}\n {'city': 'Nijmegen', 'country': 'Netherlands', 'facility': 'UMC Nijmegen', 'geoPoint': {'lat': 51.8425, 'lon': 5.85278}, 'state': None}]",
         "Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients",
         "A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naÃ¯ve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.",
         "The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones."
        ],
        [
         "30",
         "NCT03958266",
         "Inclusion Criteria:\n\n* â¢ Any patient 16-80 years of age at inclusion\n\n  * Established diagnosis of IBD (including UC, CD, inflammatory bowel disease of uncertain aetiology (IBD-U) and inflammation of an ileo-anal pouch (pouchitis))\n  * for more than 6 months prior to enrolment\n  * Has a smart phone device with access to the Apple AppStore or Google Play Store\n  * On stable medication by which we mean\n\n    * No change in oral 5-ASA dose in the last 1 month. Note, addition of 'as required' topical 5-ASA therapy is permitted\n    * Any revent oral corticosteroids must have been finished within 4 weeks. Note\n    * No change in immunomodulator dose for 3 months\n    * No change in biologic (Adalimumab, Infliximab, Ustekinumab and Vedolizumab) regime for 8 weeks\n  * Must be able to comply with all study requirements for the duration of the study as outlined in the protocol.\n  * Must be able to understand and be willing to provide written informed consent\n\nExclusion Criteria:\n\n* â¢ Currently taking part in a clinical trial of an Investigation Medical Procedure\n\n  * Significant psychiatric morbidity\n  * Patients likely to change IBD team within the next 12 months\n  * Patients taking Cyclosporine or Tacrolimus",
         "WITHDRAWN",
         null,
         "OBSERVATIONAL",
         "16.0",
         "80.0",
         "ALL",
         "False",
         "['Inflammatory Bowel Diseases']",
         null,
         null,
         "{'conditions': array([{'id': 'D007410', 'term': 'Intestinal Diseases'},\n       {'id': 'D015212', 'term': 'Inflammatory Bowel Diseases'}],\n      dtype=object), 'interventions': None}",
         null,
         "MyIBD Care - Feasibility Study",
         "A Feasibility Study of a Novel Mobile Phone Application in the Long Term Management of Patients With Inflammatory Bowel Diseases",
         "The aim of this study is appraise the safety and feasibility of utilising a novel mobile phone application and linked clinical platform to replace and enhance traditional outpatient appointments for patients with Inflammatory Bowel Diseases. The goal of this study is to demonstrate whether the platform can reduce the costs of managing patients on complex immunomodulators and biologic therapies whilst maintaining safety monitoring such as clinical patient reported outcome measures (PROMs), haematological and biochemical tests."
        ],
        [
         "31",
         "NCT06385366",
         "Inclusion Criteria:\n\n1. At recruitment, women with singleton pregnancies must fulfill the conditions:\n\n   Cases: diagnosis of Preeclampsia/eclampsia, Preterm premature rupture of membranes (PPROM)/preterm labor leading to SPB, and/or gestational diabetes mellitus.\n\n   Controls: healthy pregnancy at â¥ 37 weeks of gestation\n2. History of undergoing non-invasive prenatal testing (NIPT) at 9-13 weeks 6 days of gestation at Gene Solutions Lab. NIPT report was at low-risk. No abnormal fetal and maternal conditions were confirmed at NIPT time.\n3. NIPT blood sample is available according to post-test sample storage procedures at Gene Solutions Lab.\n4. Consent to voluntarily participate in the study\n\nExclusion Criteria:\n\n1. Multiple pregnancies\n2. Pregnancy with any genetic abnormality\n3. Pregnancy with any fetal structural abnormality\n4. Pregnancy with indications for termination, miscarriage, or stillbirth due to other complications\n5. Maternal medical history of diabetes mellitus type 1/ type 2, chronic hypertension, and chronic kidney disease. Maternal abnormal uterus anatomy and history of cervical cone biopsy sample or loop electrocautery excision procedures (LEEP).",
         "NOT_YET_RECRUITING",
         null,
         "OBSERVATIONAL",
         "18.0",
         "80.0",
         "FEMALE",
         null,
         "['Pregnant With Complication' 'Preeclampsia' 'Preterm Birth'\n 'Gestational Diabetes']",
         "[\"cffDNA\", \"cfRNA\", \"Vietnam\"]",
         null,
         "{'conditions': array([{'id': 'D047928', 'term': 'Premature Birth'},\n       {'id': 'D016640', 'term': 'Diabetes, Gestational'},\n       {'id': 'D011225', 'term': 'Pre-Eclampsia'},\n       {'id': 'D011248', 'term': 'Pregnancy Complications'}], dtype=object), 'interventions': None}",
         null,
         "Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test",
         "Developing and Evaluating Models for Early Prediction of Obstetrical Diseases: Preeclampsia, Spontaneous Preterm Birth, and Gestational Diabetes in The Pregnant Women Performed Non-invasive Prenatal Screening (NIPT)",
         "This is Observational study, aiming to investigate the potentiality of cffDNA and cfRNA by a non-invasive test, in combination with clinical characteristics, to establish models for early screening and predicting high-risk pregnancy of PE, SPB, and GDM in Vietnam."
        ],
        [
         "32",
         "NCT02350166",
         "Inclusion Criteria:\n\n1. Pathologically confirmed resectable upper rectal cancer, sigmoid cancer, and left colon cancer\n2. MRI/CT confirmed resectable liver metastasis after muti-disciplinary team assessment\n3. No evidence of other metastasis\n4. Organs function well to tolerance simultaneous surgery, especially liver function\n5. No special treatment before surgery\n6. Informed consent was written\n\nExclusion Criteria:\n\n1. Right colon cancer and transverse colon cancer\n2. Pregnant or lactating women\n3. A history of malignant tumor within 5 years\n4. There was contraindication for operation\n5. Discovery of metastasis in other organs in the operation\n6. With mental disorder",
         "UNKNOWN",
         "['PHASE3']",
         "INTERVENTIONAL",
         "18.0",
         "80.0",
         "ALL",
         "False",
         "['Colorectal Cancer']",
         "[\"colorectal cancer\", \"hepatectomy\", \"laparoscopic surgery\", \"laparotomy\", \"complications\"]",
         null,
         "{'conditions': array([{'id': 'D015179', 'term': 'Colorectal Neoplasms'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Chengdu', 'country': 'China', 'facility': 'West China hospital, Sichuan University', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}, 'state': 'Sichuan'}\n {'city': 'Chengdu', 'country': 'China', 'facility': 'West China Hospital', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}, 'state': 'Sichuan'}]",
         "Short-term Effects of LASI Surgery Versus Conventional Laparotomy for Colorectal Liver Metastasis",
         "Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis",
         "Surgical resection is still recommended as the optional treatment for colorectal liver metastasis (CLM) patients. There are two main concerns for resectable colorectal liver metastasis which remain controversial: surgical time and surgical type. As for the former, synchronous resection of primary colorectal tumor and liver metastasis, with the reason of fare overall survival rate and absence of a second surgery, has gained wide population from gastrointestinal surgeons who believe it will bring benefits to CLM patients. With regard to surgical type, Open liver resection is the optimum choice for CLM patients no matter what the metastasis profile is. And for management of primary tumor, laparoscopic procedure is mature in surgical skill and has been evidenced equivalent overall survival rate compared with open resection. So, primary colorectal tumor resection could be either open or laparoscopic procedure. Therefore, the investigators team conducted the controlled trial to compare two surgical procedures in treatment of resectable colorectal liver metastasis. Patients will be randomly assigned into conventional laparotomy group for simultaneously resection of both primary colorectal tumor and liver metastasis, or laparoscopic-assisted small-incision group for resection of laparoscopic colorectal tumor combined with synchronously small-incision open resection of liver metastasis. The aim of this trial is to observing short-term operative effects after surgeries."
        ],
        [
         "33",
         "NCT05789966",
         "Inclusion Criteria:\n\n* East Asian ancestry\n* Do not meet the WHO-recommended levels of PA (i.e., â¥150 minutes/week of moderate-intensity PA, â¥75 minutes/week of vigorous-intensity PA, or an equivalent combination of the two; determined through the IPAQ-Short Form).\n\nExclusion Criteria:\n\n* Previously diagnosed with CHD, and/or participation in another exercise-intervention study.",
         "NOT_YET_RECRUITING",
         "['NA']",
         "INTERVENTIONAL",
         "60.0",
         null,
         "ALL",
         "True",
         "['Fitness Trackers' 'Sedentary Time' 'Genetic Predisposition to Disease'\n 'Coronary Heart Disease']",
         "[\"Coronary Heart Disease\", \"Genetic risk\", \"Sedentary Time\", \"Wearable Technology\", \"Randomized Controlled Trial\"]",
         null,
         "{'conditions': array([{'id': 'D006331', 'term': 'Heart Diseases'},\n       {'id': 'D003327', 'term': 'Coronary Disease'},\n       {'id': 'D003324', 'term': 'Coronary Artery Disease'},\n       {'id': 'D017202', 'term': 'Myocardial Ischemia'},\n       {'id': 'D020022', 'term': 'Genetic Predisposition to Disease'}],\n      dtype=object), 'interventions': None}",
         null,
         "Fullscale_Intervention Study: Genetic Risk Communication in Coronary Heart Disease and Wearables",
         "The Effect of Communicating Genetic Risk of Coronary Heart Disease and Wearable Technologies On Wearable-Device-Measured Behavioral Outcomes in East Asians: Protocol of a Randomized Controlled Trial",
         "Background: This study aims to determine the effects of communicating genetic risk for Coronary Heart Disease (CHD) alone or in combination with goal setting and prompts from a wearable device on objectively measured sedentary time (ST) in East Asians. It is hypothesized that this combination will lead to significant favorable changes in objectively ST, and that such changes will be more likely to be sustained over 6-month follow-up.\n\nMethods: In a parallel group, randomized controlled trial, a total 414 individuals of East Asians aged over 60years will be allocated into one of three groups: 1 control and 2 intervention groups. Blood samples will be used for estimation of CHD genetic and analysis of metabolic risk markers. Genetic risk for CHD will be estimated based on recently identified 79 SNPs (associated with CHD for East Asians) using an established methodology. Questionnaires and physical measurement will be administered at Before and after the 12-month intervention and at 6-month follow-up. Each group will receive a Fitbit device. Both intervention groups will be given CHD genetic risk estimates along with lifestyle advice but one of them will additionally use Fitbit's step-goal setting and prompt functions. The primary outcome is objectively measured sedentary time. Secondary outcomes include objectively measured MVPA, calories burned, and five intermediate metabolic risk markers (total cholesterol/HDL-C/LDL-C/triglycerides)."
        ],
        [
         "34",
         "NCT01629966",
         "Inclusion Criteria:\n\n* Male and female, 18 - 70 years of age\n* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder (GAD)\n* Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAM-A)\n\nExclusion Criteria:\n\n* Women who are pregnant, women who will be breastfeeding during the study and women of childbearing potential who are not practicing a reliable method of birth control\n* History of meeting DSM-IV-TR criteria for any of the following:\n\n  * Any manic or hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic or mixed episode\n  * Any depressive episode with psychotic or catatonic features\n  * Panic disorder with or without agoraphobia\n  * Obsessive-compulsive disorder\n  * Schizophrenia, schizoaffective, or other psychotic disorder\n  * Bulimia or anorexia nervosa\n  * Presence of borderline personality disorder or antisocial personality disorder\n  * Mental retardation, dementia, amnesia, or other significant cognitive disorders\n* Patients who are considered a suicide risk",
         "COMPLETED",
         "['PHASE3']",
         "INTERVENTIONAL",
         "18.0",
         "70.0",
         "ALL",
         "False",
         "['Generalized Anxiety Disorder']",
         "[\"Generalized Anxiety Disorder\", \"GAD\"]",
         null,
         "{'conditions': array([{'id': 'D001008', 'term': 'Anxiety Disorders'}], dtype=object), 'interventions': array([{'id': 'D000069503', 'term': 'Vilazodone Hydrochloride'}],\n      dtype=object)}",
         "[{'city': 'Birmingham', 'country': 'United States', 'facility': 'Forest Investigative Site 001', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}, 'state': 'Alabama'}\n {'city': 'Beverly Hills', 'country': 'United States', 'facility': 'Forest Investigative Site 021', 'geoPoint': {'lat': 34.07362, 'lon': -118.40036}, 'state': 'California'}\n {'city': 'Glendale', 'country': 'United States', 'facility': 'Forest Investigative Site 023', 'geoPoint': {'lat': 34.14251, 'lon': -118.25508}, 'state': 'California'}\n {'city': 'Paramount', 'country': 'United States', 'facility': 'Forest Investigative Site 011', 'geoPoint': {'lat': 33.88946, 'lon': -118.15979}, 'state': 'California'}\n {'city': 'Norwich', 'country': 'United States', 'facility': 'Forest Investigative Site 026', 'geoPoint': {'lat': 41.52426, 'lon': -72.07591}, 'state': 'Connecticut'}\n {'city': 'Waterbury', 'country': 'United States', 'facility': 'Forest Investigative Site 027', 'geoPoint': {'lat': 41.55815, 'lon': -73.0515}, 'state': 'Connecticut'}\n {'city': 'Delray Beach', 'country': 'United States', 'facility': 'Forest Investigative Site 005', 'geoPoint': {'lat': 26.46146, 'lon': -80.07282}, 'state': 'Florida'}\n {'city': 'Oakland Park', 'country': 'United States', 'facility': 'Forest Investigative Site 014', 'geoPoint': {'lat': 26.17231, 'lon': -80.13199}, 'state': 'Florida'}\n {'city': 'South Miami', 'country': 'United States', 'facility': 'Forest Investigative Site 019', 'geoPoint': {'lat': 25.7076, 'lon': -80.29338}, 'state': 'Florida'}\n {'city': 'Atlanta', 'country': 'United States', 'facility': 'Forest Investigative Site 038', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}, 'state': 'Georgia'}\n {'city': 'Decatur', 'country': 'United States', 'facility': 'Forest Investigative Site 035', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}, 'state': 'Georgia'}\n {'city': 'Chicago', 'country': 'United States', 'facility': 'Forest Investigative Site 028', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}, 'state': 'Illinois'}\n {'city': 'Schaumburg', 'country': 'United States', 'facility': 'Forest Investigative Site 030', 'geoPoint': {'lat': 42.03336, 'lon': -88.08341}, 'state': 'Illinois'}\n {'city': 'Topeka', 'country': 'United States', 'facility': 'Forest Investigative Site 029', 'geoPoint': {'lat': 39.04833, 'lon': -95.67804}, 'state': 'Kansas'}\n {'city': 'Wichita', 'country': 'United States', 'facility': 'Forest Investigative Site 033', 'geoPoint': {'lat': 37.69224, 'lon': -97.33754}, 'state': 'Kansas'}\n {'city': 'Lake Charles', 'country': 'United States', 'facility': 'Forest Investigative Site 010', 'geoPoint': {'lat': 30.21309, 'lon': -93.2044}, 'state': 'Louisiana'}\n {'city': 'Baltimore', 'country': 'United States', 'facility': 'Forest Investigative Site 031', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}, 'state': 'Maryland'}\n {'city': 'Boston', 'country': 'United States', 'facility': 'Forest Investigative Site 025', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}, 'state': 'Massachusetts'}\n {'city': 'Saint Louis', 'country': 'United States', 'facility': 'Forest Investigative Site 037', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}, 'state': 'Missouri'}\n {'city': 'Las Vegas', 'country': 'United States', 'facility': 'Forest Investigative Site 015', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}, 'state': 'Nevada'}\n {'city': 'Berlin', 'country': 'United States', 'facility': 'Forest Investigative Site 016', 'geoPoint': {'lat': 39.79123, 'lon': -74.92905}, 'state': 'New Jersey'}\n {'city': 'Brooklyn', 'country': 'United States', 'facility': 'Forest Investigative Site 007', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': 'Forest Investigative Site 024', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': 'Forest Investigative Site 032', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': 'Forest Investigative Site 012', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'Bismarck', 'country': 'United States', 'facility': 'Forest Investigative Site 020', 'geoPoint': {'lat': 46.80833, 'lon': -100.78374}, 'state': 'North Dakota'}\n {'city': 'Cincinnati', 'country': 'United States', 'facility': 'Forest Investigative Site 008', 'geoPoint': {'lat': 39.12713, 'lon': -84.51435}, 'state': 'Ohio'}\n {'city': 'Dayton', 'country': 'United States', 'facility': 'Forest Investigative Site 041', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}, 'state': 'Ohio'}\n {'city': 'Oklahoma City', 'country': 'United States', 'facility': 'Forest Investigative Site 004', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}, 'state': 'Oklahoma'}\n {'city': 'Oklahoma City', 'country': 'United States', 'facility': 'Forest Investigative Site 034', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}, 'state': 'Oklahoma'}\n {'city': 'Portland', 'country': 'United States', 'facility': 'Forest Investigative Site 013', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}, 'state': 'Oregon'}\n {'city': 'Memphis', 'country': 'United States', 'facility': 'Forest Investigative Site 006', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}, 'state': 'Tennessee'}\n {'city': 'Wichita Falls', 'country': 'United States', 'facility': 'Forest Investigative Site 017', 'geoPoint': {'lat': 33.91371, 'lon': -98.49339}, 'state': 'Texas'}\n {'city': 'Salt Lake City', 'country': 'United States', 'facility': 'Forest Investigative Site 003', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}, 'state': 'Utah'}\n {'city': 'Charlottesville', 'country': 'United States', 'facility': 'Forest Investigative Site 018', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}, 'state': 'Virginia'}\n {'city': 'Bellevue', 'country': 'United States', 'facility': 'Forest Investigative Site 040', 'geoPoint': {'lat': 47.61038, 'lon': -122.20068}, 'state': 'Washington'}\n {'city': 'Seattle', 'country': 'United States', 'facility': 'Forest Investigative Site 039', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}, 'state': 'Washington'}]",
         "Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder",
         "A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.",
         "The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)"
        ],
        [
         "35",
         "NCT03303066",
         "Key Inclusion Criteria:\n\n* Diagnosis of primary MDS classified as very low, low or intermediate risk with \\<5% blasts (documented within 12 weeks prior to Day 1)\n* Screening Hb \\<10 g/dL and â¥6g/dL\n* Transfusion independent defined as no red blood cell transfusions within 12 weeks of Day 1\n* Erythropoiesis-stimulating agent (ESA)-naÃ¯ve (not within 30 days of Day 1)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n\nKey Exclusion Criteria:\n\n* Diagnosis of secondary MDS\n* Significant myelofibrosis (\\>2+fibrosis)\n* Prior therapy with azacitidine, decitabine, antithymocyte globulin, cyclosporine, thalidomide, or lenalidomide within 12 weeks prior to Day 1\n* Baseline erythropoietin level of \\>400 units (U)/liter (L)\n* Clinically significant anemia due to non-MDS etiologies\n\nNote: Other inclusion and exclusion criteria may apply.",
         "COMPLETED",
         "['PHASE2' 'PHASE3']",
         "INTERVENTIONAL",
         "18.0",
         "80.0",
         "ALL",
         "False",
         "['Anemia' 'Myelodysplastic Syndrome']",
         "[\"Myelodysplastic Syndromes\", \"Anemia\", \"Hemoglobin (Hb)\", \"Low Risk Myelodysplastic Syndrome\"]",
         null,
         "{'conditions': array([{'id': 'D011289', 'term': 'Preleukemia'},\n       {'id': 'D000740', 'term': 'Anemia'},\n       {'id': 'D009190', 'term': 'Myelodysplastic Syndromes'},\n       {'id': 'D013577', 'term': 'Syndrome'}], dtype=object), 'interventions': array([], dtype=object)}",
         "[{'city': 'Bengbu', 'country': 'China', 'facility': 'The First Affiliated Hospital of Bengbu Medical College', 'geoPoint': {'lat': 32.94083, 'lon': 117.36083}, 'state': 'Anhui'}\n {'city': 'Hefei', 'country': 'China', 'facility': 'Anhui Provincial Hospital', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}, 'state': 'Anhui'}\n {'city': 'Hefei', 'country': 'China', 'facility': 'The First Affiliated Hospital of Anhui Medical University', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}, 'state': 'Anhui'}\n {'city': 'Beijing', 'country': 'China', 'facility': 'China-Japan Friendship Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}, 'state': 'Beijing'}\n {'city': 'Beijing', 'country': 'China', 'facility': 'Peking Union Medical College Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}, 'state': 'Beijing'}\n {'city': 'Beijing', 'country': 'China', 'facility': 'Peking University First Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}, 'state': 'Beijing'}\n {'city': 'Beijing', 'country': 'China', 'facility': 'Peking University Third Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}, 'state': 'Beijing'}\n {'city': 'Beijing', 'country': 'China', 'facility': 'Xiyuan Hospital, CACMS', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}, 'state': 'Beijing'}\n {'city': 'Fuzhou', 'country': 'China', 'facility': 'Fujian Medical University Union Hospital', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}, 'state': 'Fujian'}\n {'city': 'Lanzhou', 'country': 'China', 'facility': 'Lanzhou University Second Hospital', 'geoPoint': {'lat': 36.05701, 'lon': 103.83987}, 'state': 'Gansu'}\n {'city': 'Guangzhou', 'country': 'China', 'facility': 'Guangdong General Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}, 'state': 'Guangdong'}\n {'city': 'Guangzhou', 'country': 'China', 'facility': 'Nan Fang Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}, 'state': 'Guangdong'}\n {'city': 'Zhuzhou', 'country': 'China', 'facility': 'Zhuzhou Central Hospital', 'geoPoint': {'lat': 27.83333, 'lon': 113.15}, 'state': 'Guangdong'}\n {'city': 'Haikou', 'country': 'China', 'facility': 'Hainan Central Hospital', 'geoPoint': {'lat': 20.04583, 'lon': 110.34167}, 'state': 'Hainan'}\n {'city': 'Shijiazhuang', 'country': 'China', 'facility': 'Second hospital of Hebei Medical University', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}, 'state': 'Hebei'}\n {'city': 'Zhengzhou', 'country': 'China', 'facility': 'Tumor Hospital of Henan province', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}, 'state': 'Henan'}\n {'city': 'Wuhan', 'country': 'China', 'facility': 'Tongji Hospital, Tongji Medical College of HUST', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}, 'state': 'Hubei'}\n {'city': 'Wuhan', 'country': 'China', 'facility': 'Union Hospital Affiliated Tongji Medical College Huazhong University of Science and Technolog', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}, 'state': 'Hubei'}\n {'city': 'Changsha', 'country': 'China', 'facility': 'The Third Xiangya Hospital of Central South University', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}, 'state': 'Hunan'}\n {'city': 'Nanjing', 'country': 'China', 'facility': 'Jiangsu Province Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}, 'state': 'Jiangsu'}\n {'city': 'Nanjing', 'country': 'China', 'facility': 'Zhongda Hospital Southeast University', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}, 'state': 'Jiangsu'}\n {'city': 'Suzhou', 'country': 'China', 'facility': 'The First Affiliated Hospital Of Soochow University', 'geoPoint': {'lat': 31.30408, 'lon': 120.59538}, 'state': 'Jiangsu'}\n {'city': 'Yangzhou', 'country': 'China', 'facility': \"Northern Jiangsu People's Hospital\", 'geoPoint': {'lat': 32.39722, 'lon': 119.43583}, 'state': 'Jiangsu'}\n {'city': 'Jinan', 'country': 'China', 'facility': 'Affiliated Hospital of Shandong University of Traditional Chinese Medicine', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}, 'state': 'Shandong'}\n {'city': 'Jinan', 'country': 'China', 'facility': 'Qilu Hospital of Shandong University', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}, 'state': 'Shandong'}\n {'city': 'Jinan', 'country': 'China', 'facility': 'The Affiliated Hospital of Xuzhou Medical University', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}, 'state': 'Shandong'}\n {'city': 'Shanghai', 'country': 'China', 'facility': 'Huashan Hospital Affiliated to Fudan University', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}\n {'city': 'Shanghai', 'country': 'China', 'facility': \"Shanghai Sixth People's Hospital\", 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}\n {'city': 'Shanghai', 'country': 'China', 'facility': 'Shanghai Tongji Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}\n {'city': 'Xian', 'country': 'China', 'facility': \"Shaanxi Provincial People's Hospital\", 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}, 'state': 'Shanxi'}\n {'city': 'Xian', 'country': 'China', 'facility': \"The First Affiliated Hospital of Xi'an Jiao Tong University Medical College\", 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}, 'state': 'Shanxi'}\n {'city': 'Chengdu', 'country': 'China', 'facility': \"Sichuan Provincial People's Hospital\", 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}, 'state': 'Sichuan'}\n {'city': 'Chengdu', 'country': 'China', 'facility': 'West China Hospital, Sichuan University', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}, 'state': 'Sichuan'}\n {'city': 'Tianjin', 'country': 'China', 'facility': 'Blood disease hospital of Chinese Academy of Medical Sciences', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}, 'state': 'Tianjin'}\n {'city': 'Tianjin', 'country': 'China', 'facility': 'The Second Hospital of Tianjin Medical University', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}, 'state': 'Tianjin'}\n {'city': 'Tianjin', 'country': 'China', 'facility': 'Tianjin Medical University General Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}, 'state': 'Tianjin'}\n {'city': 'Kunming', 'country': 'China', 'facility': 'First Affiliated Hospital of Kunming Medical University', 'geoPoint': {'lat': 25.03889, 'lon': 102.71833}, 'state': 'Yunnan'}\n {'city': 'Hangzhou', 'country': 'China', 'facility': 'The First Affiliated Hospital, Zhejiang University Medical College', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}, 'state': 'Zhejiang'}]",
         "Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)",
         "A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome",
         "The objective of this study to evaluate the efficacy FG-4592 for the treatment of anemia in Chinese participants with lower risk MDS."
        ],
        [
         "36",
         "NCT02289066",
         "Inclusion Criteria:\n\nAll patients 18 years or older with diabetes for more than 2 years who present for their regular clinic visit will be eligible for inclusion in the survey part of the study. Further criteria for enrollment into the subgroup (n = 24) will include; Inclusion criteria\n\n* Answers on the questionnaire suggesting POD or gingivitis.\n* At least 16 teeth in place\n* On a stable treatment for their diabetes\n* Hemoglobin A1c between 6 and 10\n\nExclusion Criteria:\n\n* Treatment with anti-inflammatory medications\n* Cigarette smoking\n* Treatment with thiazolidinediones\n* Previous diagnosis of osteoporosis or treatment for osteoporosis with FDA approved agents.",
         "COMPLETED",
         null,
         "OBSERVATIONAL",
         "18.0",
         null,
         "ALL",
         "True",
         "['Periodontal Disease' 'Diabetes Mellitus']",
         null,
         null,
         "{'conditions': array([{'id': 'D010510', 'term': 'Periodontal Diseases'},\n       {'id': 'D003920', 'term': 'Diabetes Mellitus'}], dtype=object), 'interventions': None}",
         "[{'city': 'Las Vegas', 'country': 'United States', 'facility': 'University of Nevada School of Medicine', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}, 'state': 'Nevada'}]",
         "Impact of Periodontal Disease on Outcomes in Diabetes",
         "Impact of Periodontal Disease on Outcomes in Diabetes",
         "This study examines how periodontal disease affects the complications of diabetes and how treatment for periodontal disease affects biomarkers associated with the complications of diabetes."
        ],
        [
         "37",
         "NCT05523466",
         "Inclusion Criteria:\n\n* Individuals diagnosed with Multiple Sclerosis\n* Aged over 18 years\n* Motor and intellectual capacity to understand the evaluations\n* Light and moderate functional classification levels (EDSS scale)\n* Who accept to participate in the study through agreement with informed consent form\n\nExclusion Criteria:\n\n* Do not understand the evaluations\n* Cardiac diseases that impede the assessment of HRV\n* Have a cardiac pacemaker.",
         "UNKNOWN",
         "['NA']",
         "INTERVENTIONAL",
         "18.0",
         "50.0",
         "ALL",
         "False",
         "['Multiple Sclerosis']",
         null,
         null,
         "{'conditions': array([{'id': 'D009103', 'term': 'Multiple Sclerosis'},\n       {'id': 'D012598', 'term': 'Sclerosis'}], dtype=object), 'interventions': None}",
         null,
         "Effect of Acupuncture on Heart Rate Variability in Multiple Sclerosis",
         "Effect of Acupuncture on Heart Rate Variability in Individuals With Multiple Sclerosis",
         "The Objective of this study is to evaluate the heart rate variability in individuals with multiple sclerosis during the applicability of Acupuncture, to analyze the behavior of the autonomic nervous system before, during, and after therapy and the changes of the condition."
        ],
        [
         "38",
         "NCT00882466",
         "Inclusion Criteria:\n\n* Acute myocardial infarction \\<12hr\n* Age \\>18yrs\n* First myocardial infarction\n* culprit lesion : proximal to mid left anterior descending artery\n* Baseline coronary flow : TIMI Grade 0\\~1\n\nExclusion Criteria:\n\n* Patients with previous myocardial infarction\n* History of thrombotic complication\n* History of cerebral infarction\n* Uncontrolled hypertension\n* Increased hemoglobin level \\>17g/dL\n* Patients with mechanical valve\n* Cardiogenic shock",
         "COMPLETED",
         "['PHASE4']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Acute Myocardial Infarction']",
         "[\"erythropoietin\"]",
         null,
         "{'conditions': array([{'id': 'D009203', 'term': 'Myocardial Infarction'},\n       {'id': 'D007238', 'term': 'Infarction'}], dtype=object), 'interventions': array([{'id': 'D000068817', 'term': 'Epoetin Alfa'}], dtype=object)}",
         "[{'city': 'Seongnam', 'country': 'Korea, Republic of', 'facility': 'Seoul National University Bundang Hospital', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}, 'state': None}]",
         "The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction",
         "Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction",
         "The purpose of this study is to investigate the effect of intravenous human recombinant erythropoietin on the reperfusion injury at primary percutaneous coronary intervention in patients with acute myocardial infarction."
        ],
        [
         "39",
         "NCT02523066",
         "Inclusion Criteria:\n\n* The patients who implanted with Magna Ease Heart Valve (Type:7300TFX and 3300TFX) in Fuwai Hospital in China.\n* The patients agree to sign the inform consent form (ICF).\n\nExclusion Criteria:\n\n* No specific exclusion criteria.",
         "TERMINATED",
         null,
         "OBSERVATIONAL",
         null,
         null,
         "ALL",
         "False",
         "['Mitral Valve or Aortic Valve Replacement']",
         null,
         null,
         null,
         "[{'city': 'Beijing', 'country': 'China', 'facility': 'The Chinese academy of medical sciences fuwai hospital cardiovascular disease', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}, 'state': 'Beijing'}]",
         "Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients",
         "Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients",
         "Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese patients."
        ],
        [
         "40",
         "NCT00588666",
         "Inclusion Criteria:\n\n* Histologic documentation: diagnosis of transitional cell carcinoma of the bladder,urethra, ureter, or renal pelvis.\n* Unresectable or metastatic disease\n* Ineligible for cisplatin (or incurable with cisplatin)\n* â¥ 4 weeks since prior RT\n* Karnofsky Performance Status â¥ 60%\n* Age â¥ 18 years of age\n* Required Initial Laboratory Values: Absolute neutrophil count â¥ 1.2 x 109/L; Platelets â¥ 100 x 109/L; Bilirubin â¤ 1.5 times the upper limit of normal (x ULN) for the institution; Aspartate transaminase (AST) and alanine transaminase(ALT) â¤ 3.0 x ULN;Serum creatinine \\< 2.0 or calculated creatinine clearance (CrCl) â¥ 30 mL/min\n\nExclusion Criteria:\n\n* Prior treatment with systemic chemotherapy (prior intravesical therapy is permitted)\n* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study\n* Blood pressure of \\>150/100 mmHg\n* Unstable angina\n* New York Heart Association (NYHA) Grade II or greater congestive heart failure\n* History of myocardial infarction within 6 months\n* History of stroke within 6 months\n* Clinically significant peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Presence of central nervous system or brain metastases\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0\n* Anticipation of need for major surgical procedure during the course of the study\n* Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0\n* Pregnant (positive pregnancy test) or lactating\n* Albuminuria as demonstrated by a urinary albumin of greater or = to 1.0 g/24 hr at screening\n* History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 6 months prior to Day 0\n* Serious, non-healing wound, ulcer, or bone fracture\n* Inability to comply with study and/or follow-up procedures\n* History of persistent gross hematuria",
         "COMPLETED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Myeloproliferative Disorder' 'Urothelial Carcinoma' 'Cancer']",
         "[\"Myeloproliferative Disorder\", \"urinary bladder\", \"Cancer\", \"ureter\", \"renal pelvis\", \"chemotherapy\"]",
         null,
         "{'conditions': array([{'id': 'D002277', 'term': 'Carcinoma'},\n       {'id': 'D002295', 'term': 'Carcinoma, Transitional Cell'},\n       {'id': 'D009196', 'term': 'Myeloproliferative Disorders'}],\n      dtype=object), 'interventions': array([{'id': 'D000068258', 'term': 'Bevacizumab'},\n       {'id': 'D016190', 'term': 'Carboplatin'},\n       {'id': 'D000093542', 'term': 'Gemcitabine'}], dtype=object)}",
         "[{'city': 'Basking Ridge', 'country': 'United States', 'facility': 'Memorial Sloan-Kettering at Basking Ridge', 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}, 'state': 'New Jersey'}\n {'city': 'Basking Ridge', 'country': 'United States', 'facility': 'Memoral Sloan Kettering Cancer Center', 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}, 'state': 'New Jersey'}\n {'city': 'Commack', 'country': 'United States', 'facility': 'Memorial Sloan-Kettering Cancer Center @ Suffolk', 'geoPoint': {'lat': 40.84288, 'lon': -73.29289}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan-Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'Rockville Centre', 'country': 'United States', 'facility': 'Memorial Sloan-Kettering Cancer Center at Mercy Medical Center', 'geoPoint': {'lat': 40.65871, 'lon': -73.64124}, 'state': 'New York'}\n {'city': 'Sleepy Hollow', 'country': 'United States', 'facility': 'Memoral Sloan Kettering Cancer Center@Phelps', 'geoPoint': {'lat': 41.08565, 'lon': -73.85847}, 'state': 'New York'}]",
         "Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma",
         "Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma",
         "Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time. This has led scientists to look for different ways to treat cancer.\n\nNew drugs have been developed to treat cancer that work differently than standard chemotherapy drugs. One new class of drugs are called 'angiogenesis-inhibitors'. These drugs attempt to decrease the blood supply to tumors. By doing so, this may limit the tumor's source of oxygen and nutrients and prevent the tumor from growing. Bevacizumab is an anti-angiogenic drug.\n\nIn some other cancers such as colon cancer and lung cancer, combining bevacizumab with standard chemotherapy shrinks tumors in a greater proportion of patients and makes patients live longer than using standard chemotherapy alone. This has never been tested in urothelial cancer and we do not know if bevacizumab will have the same effects in this disease. The purpose of this study is to find out what effects, good and/or bad, the combination of gemcitabine, carboplatin, and bevacizumab has on you and your cancer."
        ],
        [
         "41",
         "NCT00927966",
         "Inclusion Criteria:\n\n* Histologically confirmed advanced sarcoma or other advanced malignant solid tumor for which no known curative therapy exists. Patients must have had prior progression on, intolerance or refused approved standard therapies proven to prolong life.\n* Measurable disease per RECIST. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrollment\n* 18 years of age or older\n* ECOG Performance Status 0-1\n* Participants must have normal organ and marrow function as outlined in the protocol\n* Fully recovered from the acute effects of prior cancer therapy before initiation of study drug\n* Negative urine or serum pregnancy test within 7 days prior to initiation of study drug for women of child-bearing potential\n* Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for up to 6 months after the last dose of study drug\n\nExclusion Criteria:\n\n* Participants with gastrointestinal tumors (GIST) on approved tyrosine kinase inhibitors within 2 weeks prior to study entry\n* All other participants who have had systemic anti-cancer therapy within 3 weeks (8 weeks for nitrosoureas or mitomycin C) prior to study entry\n* Participants who have had radiotherapy and/or major surgery within 2 weeks prior to study entry\n* Concurrent use of any other anti-cancer therapies, study agents, growth hormones, growth hormone inhibitors or aminoglycoside antibiotics\n* Participants who have had chronic high dose immunosuppressive steroid therapy within 2 weeks prior to enrollment. Previous high dose steroid treatment \\> 2 weeks prior to study entry, topical and inhaled corticosteroids are allowed\n* Presence of symptomatic or uncontrolled brain or central nervous system metastases\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to RAD001 and/or CP-751,871\n* Participants receiving any medications or substances that are inhibitors or inducers of CYP3A\n* Uncontrolled diabetes\n* Bleeding diathesis or requirement for therapeutic anticoagulation\n* Uncontrolled intercurrent illness\n* Pregnant or nursing women\n* HIV positive individuals on combination anti-retroviral therapy",
         "COMPLETED",
         "['PHASE1']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Sarcoma' 'Solid Tumor']",
         "[\"RAD001\", \"CP-751,871\", \"advanced sarcoma\", \"advanced malignant solid tumor\"]",
         null,
         "{'conditions': array([{'id': 'D009369', 'term': 'Neoplasms'},\n       {'id': 'D012509', 'term': 'Sarcoma'}], dtype=object), 'interventions': array([{'id': 'D000068338', 'term': 'Everolimus'}], dtype=object)}",
         "[{'city': 'Boston', 'country': 'United States', 'facility': 'Dana-Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}, 'state': 'Massachusetts'}]",
         "RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms",
         "Phase I Clinical Trial of RAD001 in Combination With CP-751,871 in Patients With Advanced Sarcomas and Other Malignant Neoplasms",
         "The purpose of this research study is to determine the safety of the combination of RAD001 and CP-751,871, as well as the highest dose of this combination that can be given to people safely. RAD001 is a newly discovered drug that may stop cancer cells from growing abnormally. This drug has been extensively studied in many cancers. In particular, it has shown to be effective in slowing down the growth of kidney cancer. CP-751,871 is another newly discovered drug that may stop tumor growth. It is currently being studied in a wide variety of cancers, and information from those other research studies suggests that these two drugs in combination may help to stop cancer growth."
        ],
        [
         "42",
         "NCT05064566",
         "Inclusion Criteria:\n\n* According to the American Society of Anesthesiologists (ASA) only status 1/ healthy patients\n* Completely erupted permanent dentition,\n* No fixed orthodontic apparatus, prosthetic restoration and filling material,\n* A minimum age of 18 years,\n* At least one third erupted molar teeth (third mandibular or third maxillary molar from each patient was included),\n* Non cavitated occlusal caries,\n* Teeth with no hypoplasia or hypomineralization,\n* Third molar teeth that require extraction for surgery, orthodontics and prosthetic reasons,\n* If clinical indicators suggest a current caries risk or activity that required additional diagnosis, the patients will be asked to participate in this additional examination.\n\nExclusion Criteria:\n\n* Patients younger than 18\n* Patients that can not be recruited according to the inclusion criteria.",
         "UNKNOWN",
         null,
         "OBSERVATIONAL",
         "18.0",
         null,
         "ALL",
         "True",
         "['Caries' 'Diagnoses Disease']",
         "[\"Caries detection;\", \"laser fluorescence\", \"micro-CT\", \"visual analog scale\"]",
         null,
         "{'conditions': None, 'interventions': array([], dtype=object)}",
         "[{'city': 'Yenisehir', 'country': 'Turkey', 'facility': 'Mersin University', 'geoPoint': {'lat': 40.26444, 'lon': 29.65306}, 'state': 'Mersin'}]",
         "Evaluation of Caries Detection Methods",
         "Clinical Performance of Diagnostic Methods in Early Occlusal Caries",
         "The investigators aim will be to compare the diagnostic performance of clinical visual examination (ICDAS II), intraoral/bite wing radiography (BW), near infrared light transillumination (NIR-LT), and laser fluorescence (LF), in comparison to microcomputed tomography (micro-CT) for the detection of non-cavitated occlusal enamel and dentin caries in third molar teeth. Potential participants will be consecutively recruited."
        ],
        [
         "43",
         "NCT02165566",
         "Inclusion Criteria:\n\n* critical care patients with blood glucose concentration \\>180mg/dl\n\nExclusion Criteria:\n\n* insulin dependent diabetes",
         "COMPLETED",
         "['PHASE4']",
         "INTERVENTIONAL",
         "18.0",
         "80.0",
         "ALL",
         "False",
         "['Hyperglycemia']",
         "[\"intensive insulin therapy\", \"critical care patients\", \"blood glucose concentration>180 mg/dl\"]",
         null,
         "{'conditions': array([{'id': 'D006943', 'term': 'Hyperglycemia'}], dtype=object), 'interventions': array([{'id': 'D007328', 'term': 'Insulin'},\n       {'id': 'C557859', 'term': 'Insulin, Globin Zinc'},\n       {'id': 'D061268', 'term': 'Insulin Lispro'}], dtype=object)}",
         "[{'city': 'Rome', 'country': 'Italy', 'facility': 'University of ROme \"La Sapienza\" Rome Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}, 'state': None}]",
         "Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit",
         null,
         "Insulin preparation -random assignment to regular insulin lin or lispro insulin as first treatment- was administered at constant infusion rate (0.04 units/Kg/h) in patients presenting blood glucose concentration â¥180 mg/dl and was discontinued when blood glucose concentration â¤140 mg/dl (therapeutic blood glucose concentration drop). Further reduction in blood glucose concentration after discontinuation of insulin infusion was recorded (post-infusional blood glucose concentration drop). During the study period blood glucose concentration, in whole blood, was measured every 30 minutes. At least 6 hours interval was allowed between the 2 treatments."
        ],
        [
         "44",
         "NCT01437566",
         "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* As per national or local treatment guidelines, endocrine therapy (i.e., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not necessary for participants, at time of entry into the study.\n* Part I: Postmenopausal women with locally ABC or MBC whose disease relapsed during treatment with (or within 6 months after discontinuation of) an AI in the adjuvant setting or progressed during treatment with an AI in the metastatic setting.\n* Part II: Postmenopausal women with locally ABC or MBC whose disease has progressed during or after treatment with an AI. Participants who discontinued the AI for toxicity rather than completion of regimen or for disease progression are not eligible\n* Estrogen receptor (ER)-positive disease and human epidermal receptor 2 (HER2)-negative disease\n* Participants must have measurable disease by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 or bone-only disease with radiologic scans\n* Adequate hematologic and end-organ function\n\nExclusion Criteria:\n\n* Prior treatment with fulvestrant, phosphoinositide 3-kinase (PI3K) inhibitor, or mechanistic target of rapamycin (mTOR) inhibitor for ABC or MBC\n* Prior anti-cancer therapy or radiotherapy within 2 weeks prior to Day 1 of Cycle 1\n* Prior treatment with greater than (\\>) one cytotoxic chemotherapy regimens or experienced recurrent or progressive disease on \\> two endocrine therapies for MBC\n* Participants requiring anti-hyperglycemic therapy\n* Clinically significant cardiac or pulmonary dysfunction\n* History of malabsorption syndrome or other condition that would interfere with enteral absorption\n* Clinically significant history of liver disease\n* Active uncontrolled autoimmune disease or active inflammatory disease\n* Immunocompromised status\n* Need for current chronic corticosteroid therapy\n* Pregnancy, lactation, or breastfeeding\n* Current severe, uncontrolled systemic disease\n* Symptomatic hypercalcemia\n* Known untreated or active central nervous system (CNS) metastases\n* History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or patients who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence",
         "COMPLETED",
         "['PHASE2']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "FEMALE",
         "False",
         "['Breast Cancer']",
         null,
         null,
         "{'conditions': array([{'id': 'D001943', 'term': 'Breast Neoplasms'}], dtype=object), 'interventions': array([{'id': 'D000077267', 'term': 'Fulvestrant'}], dtype=object)}",
         "[{'city': 'Birmingham', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}, 'state': 'Alabama'}\n {'city': 'Hayward', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.66882, 'lon': -122.0808}, 'state': 'California'}\n {'city': 'Oakland', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}, 'state': 'California'}\n {'city': 'Roseville', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 38.75212, 'lon': -121.28801}, 'state': 'California'}\n {'city': 'Sacramento', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}, 'state': 'California'}\n {'city': 'San Francisco', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}, 'state': 'California'}\n {'city': 'San Jose', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.33939, 'lon': -121.89496}, 'state': 'California'}\n {'city': 'Santa Clara', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.35411, 'lon': -121.95524}, 'state': 'California'}\n {'city': 'South San Francisco', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.65466, 'lon': -122.40775}, 'state': 'California'}\n {'city': 'Vallejo', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 38.10409, 'lon': -122.25664}, 'state': 'California'}\n {'city': 'Walnut Creek', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.90631, 'lon': -122.06496}, 'state': 'California'}\n {'city': 'Washington', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}, 'state': 'District of Columbia'}\n {'city': 'Boca Raton', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 26.3669, 'lon': -80.13033}, 'state': 'Florida'}\n {'city': 'Fort Myers', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}, 'state': 'Florida'}\n {'city': 'Jacksonville', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}, 'state': 'Florida'}\n {'city': 'Saint Petersburg', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}, 'state': 'Florida'}\n {'city': 'Marietta', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 33.9526, 'lon': -84.54993}, 'state': 'Georgia'}\n {'city': 'Joliet', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 41.52519, 'lon': -88.0834}, 'state': 'Illinois'}\n {'city': 'Peoria', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}, 'state': 'Illinois'}\n {'city': 'Wichita', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.69224, 'lon': -97.33754}, 'state': 'Kansas'}\n {'city': 'Boston', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}, 'state': 'Massachusetts'}\n {'city': 'Boston', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}, 'state': 'Massachusetts'}\n {'city': 'St. Louis', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}, 'state': 'Missouri'}\n {'city': 'Basking Ridge', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}, 'state': 'New Jersey'}\n {'city': 'Hackensack', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}, 'state': 'New Jersey'}\n {'city': 'Commack', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 40.84288, 'lon': -73.29289}, 'state': 'New York'}\n {'city': 'New York', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}, 'state': 'New York'}\n {'city': 'Rockville Centre', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 40.65871, 'lon': -73.64124}, 'state': 'New York'}\n {'city': 'Sleepy Hollow', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 41.08565, 'lon': -73.85847}, 'state': 'New York'}\n {'city': 'Philadelphia', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}, 'state': 'Pennsylvania'}\n {'city': 'Charleston', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 32.77657, 'lon': -79.93092}, 'state': 'South Carolina'}\n {'city': 'Chattanooga', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 35.04563, 'lon': -85.30968}, 'state': 'Tennessee'}\n {'city': 'Germantown', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 35.08676, 'lon': -89.81009}, 'state': 'Tennessee'}\n {'city': 'Nashville', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}, 'state': 'Tennessee'}\n {'city': 'Nashville', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}, 'state': 'Tennessee'}\n {'city': 'Dallas', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}, 'state': 'Texas'}\n {'city': 'Fort Worth', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}, 'state': 'Texas'}\n {'city': 'Houston', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}, 'state': 'Texas'}\n {'city': 'Houston', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}, 'state': 'Texas'}\n {'city': 'Tyler', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 32.35126, 'lon': -95.30106}, 'state': 'Texas'}\n {'city': 'Richmond', 'country': 'United States', 'facility': None, 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}, 'state': 'Virginia'}\n {'city': 'Buenos Aires', 'country': 'Argentina', 'facility': None, 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}, 'state': None}\n {'city': 'Santa Fe', 'country': 'Argentina', 'facility': None, 'geoPoint': {'lat': -31.63333, 'lon': -60.7}, 'state': None}\n {'city': 'Kogarah', 'country': 'Australia', 'facility': None, 'geoPoint': {'lat': -33.98333, 'lon': 151.11667}, 'state': 'New South Wales'}\n {'city': 'Wahroonga', 'country': 'Australia', 'facility': None, 'geoPoint': {'lat': -33.71816, 'lon': 151.11561}, 'state': 'New South Wales'}\n {'city': 'South Brisbane', 'country': 'Australia', 'facility': None, 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}, 'state': 'Queensland'}\n {'city': 'Bedford Park', 'country': 'Australia', 'facility': None, 'geoPoint': {'lat': -35.03333, 'lon': 138.56667}, 'state': 'South Australia'}\n {'city': 'Woodville', 'country': 'Australia', 'facility': None, 'geoPoint': {'lat': -34.88333, 'lon': 138.55}, 'state': 'South Australia'}\n {'city': 'Frankston', 'country': 'Australia', 'facility': None, 'geoPoint': {'lat': -38.14458, 'lon': 145.12291}, 'state': 'Victoria'}\n {'city': 'Parkville', 'country': 'Australia', 'facility': None, 'geoPoint': {'lat': -37.78333, 'lon': 144.95}, 'state': 'Victoria'}\n {'city': 'Bruxelles', 'country': 'Belgium', 'facility': None, 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}, 'state': None}\n {'city': 'Bruxelles', 'country': 'Belgium', 'facility': None, 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}, 'state': None}\n {'city': 'Edegem', 'country': 'Belgium', 'facility': None, 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}, 'state': None}\n {'city': 'Leuven', 'country': 'Belgium', 'facility': None, 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}, 'state': None}\n {'city': 'LiÃ¨ge', 'country': 'Belgium', 'facility': None, 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}, 'state': None}\n {'city': 'Montreal', 'country': 'Canada', 'facility': None, 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}, 'state': 'Quebec'}\n {'city': 'Quebec City', 'country': 'Canada', 'facility': None, 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}, 'state': 'Quebec'}\n {'city': 'Saskatoon', 'country': 'Canada', 'facility': None, 'geoPoint': {'lat': 52.13238, 'lon': -106.66892}, 'state': 'Saskatchewan'}\n {'city': 'Santiago', 'country': 'Chile', 'facility': None, 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}, 'state': None}\n {'city': 'Temuco', 'country': 'Chile', 'facility': None, 'geoPoint': {'lat': -38.73965, 'lon': -72.59842}, 'state': None}\n {'city': 'Valparaiso', 'country': 'Chile', 'facility': None, 'geoPoint': {'lat': -33.03932, 'lon': -71.62725}, 'state': None}\n {'city': 'Vina del Mar', 'country': 'Chile', 'facility': None, 'geoPoint': {'lat': -33.02457, 'lon': -71.55183}, 'state': None}\n {'city': 'Brno', 'country': 'Czech Republic', 'facility': None, 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}, 'state': None}\n {'city': 'Olomouc', 'country': 'Czech Republic', 'facility': None, 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}, 'state': None}\n {'city': 'Praha 2', 'country': 'Czech Republic', 'facility': None, 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}, 'state': None}\n {'city': 'Herlev', 'country': 'Denmark', 'facility': None, 'geoPoint': {'lat': 55.72366, 'lon': 12.43998}, 'state': None}\n {'city': 'KÃ¸benhavn Ã', 'country': 'Denmark', 'facility': None, 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}, 'state': None}\n {'city': 'Odense', 'country': 'Denmark', 'facility': None, 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}, 'state': None}\n {'city': 'Roskilde', 'country': 'Denmark', 'facility': None, 'geoPoint': {'lat': 55.64152, 'lon': 12.08035}, 'state': None}\n {'city': 'Vejle', 'country': 'Denmark', 'facility': None, 'geoPoint': {'lat': 55.70927, 'lon': 9.5357}, 'state': None}\n {'city': 'Ãrhus', 'country': 'Denmark', 'facility': None, 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}, 'state': None}\n {'city': 'Paris', 'country': 'France', 'facility': None, 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}, 'state': None}\n {'city': 'Berlin', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}, 'state': None}\n {'city': 'DÃ¼sseldorf', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}, 'state': None}\n {'city': 'Freiburg', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}, 'state': None}\n {'city': 'Freiburg', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}, 'state': None}\n {'city': 'Hamburg', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 53.57532, 'lon': 10.01534}, 'state': None}\n {'city': 'Muenchen', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}, 'state': None}\n {'city': 'Muenchen', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}, 'state': None}\n {'city': 'MÃ¼nchen', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}, 'state': None}\n {'city': 'Trier', 'country': 'Germany', 'facility': None, 'geoPoint': {'lat': 49.75565, 'lon': 6.63935}, 'state': None}\n {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': None, 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}, 'state': None}\n {'city': 'Pokfulam', 'country': 'Hong Kong', 'facility': None, 'geoPoint': None, 'state': None}\n {'city': 'Beer Sheva', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}, 'state': None}\n {'city': 'Holon', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 32.01034, 'lon': 34.77918}, 'state': None}\n {'city': 'Jerusalem', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}, 'state': None}\n {'city': 'Jerusalem', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}, 'state': None}\n {'city': 'Kfar-Saba', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 32.175, 'lon': 34.90694}, 'state': None}\n {'city': 'Rehovot', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 31.89421, 'lon': 34.81199}, 'state': None}\n {'city': 'Tel Aviv', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}, 'state': None}\n {'city': 'Tel-Hashomer', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 32.04195, 'lon': 34.85623}, 'state': None}\n {'city': 'Zerifin', 'country': 'Israel', 'facility': None, 'geoPoint': {'lat': 31.95857, 'lon': 4.83723}, 'state': None}\n {'city': 'Napoli', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 40.85216, 'lon': 14.26811}, 'state': 'Campania'}\n {'city': 'Meldola', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}, 'state': 'Emilia-Romagna'}\n {'city': 'Milano', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}, 'state': 'Lombardia'}\n {'city': 'Milano', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}, 'state': 'Lombardia'}\n {'city': 'Milano', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}, 'state': 'Lombardia'}\n {'city': 'Monza', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}, 'state': 'Lombardia'}\n {'city': 'Pisa', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}, 'state': 'Toscana'}\n {'city': 'Prato', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 43.8805, 'lon': 11.09699}, 'state': 'Toscana'}\n {'city': 'Terni', 'country': 'Italy', 'facility': None, 'geoPoint': {'lat': 42.56335, 'lon': 12.64329}, 'state': 'Umbria'}\n {'city': 'Seoul', 'country': 'Korea, Republic of', 'facility': None, 'geoPoint': {'lat': 37.566, 'lon': 126.9784}, 'state': None}\n {'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': None, 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}, 'state': None}\n {'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': None, 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}, 'state': None}\n {'city': 'Penang', 'country': 'Malaysia', 'facility': None, 'geoPoint': None, 'state': None}\n {'city': 'Penang', 'country': 'Malaysia', 'facility': None, 'geoPoint': None, 'state': None}\n {'city': 'Tanjung Bungah', 'country': 'Malaysia', 'facility': None, 'geoPoint': {'lat': 5.45768, 'lon': 100.29307}, 'state': None}\n {'city': 'LeÃ³n', 'country': 'Mexico', 'facility': None, 'geoPoint': {'lat': 21.12908, 'lon': -101.67374}, 'state': None}\n {'city': 'Christchurch', 'country': 'New Zealand', 'facility': None, 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}, 'state': None}\n {'city': 'Hamilton', 'country': 'New Zealand', 'facility': None, 'geoPoint': {'lat': -37.78333, 'lon': 175.28333}, 'state': None}\n {'city': 'Wellington', 'country': 'New Zealand', 'facility': None, 'geoPoint': {'lat': -41.28664, 'lon': 174.77557}, 'state': None}\n {'city': 'Lima', 'country': 'Peru', 'facility': None, 'geoPoint': {'lat': -12.04318, 'lon': -77.02824}, 'state': None}\n {'city': 'Lima', 'country': 'Peru', 'facility': None, 'geoPoint': {'lat': -12.04318, 'lon': -77.02824}, 'state': None}\n {'city': 'Lima', 'country': 'Peru', 'facility': None, 'geoPoint': {'lat': -12.04318, 'lon': -77.02824}, 'state': None}\n {'city': 'Chelyabinsk', 'country': 'Russian Federation', 'facility': None, 'geoPoint': {'lat': 55.15402, 'lon': 61.42915}, 'state': None}\n {'city': 'Kazan', 'country': 'Russian Federation', 'facility': None, 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}, 'state': None}\n {'city': 'Moscow', 'country': 'Russian Federation', 'facility': None, 'geoPoint': {'lat': 55.75222, 'lon': 37.61556}, 'state': None}\n {'city': 'Voronezh', 'country': 'Russian Federation', 'facility': None, 'geoPoint': {'lat': 51.67204, 'lon': 39.1843}, 'state': None}\n {'city': 'Singapore', 'country': 'Singapore', 'facility': None, 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}, 'state': None}\n {'city': 'Barcelona', 'country': 'Spain', 'facility': None, 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}, 'state': None}\n {'city': 'Lerida', 'country': 'Spain', 'facility': None, 'geoPoint': {'lat': 41.61674, 'lon': 0.62218}, 'state': None}\n {'city': 'Valencia', 'country': 'Spain', 'facility': None, 'geoPoint': {'lat': 39.46975, 'lon': -0.37739}, 'state': None}\n {'city': 'Zaragoza', 'country': 'Spain', 'facility': None, 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}, 'state': None}\n {'city': 'Patumwan', 'country': 'Thailand', 'facility': None, 'geoPoint': None, 'state': None}\n {'city': 'Songkhla', 'country': 'Thailand', 'facility': None, 'geoPoint': {'lat': 7.19882, 'lon': 100.5951}, 'state': None}\n {'city': 'Brighton', 'country': 'United Kingdom', 'facility': None, 'geoPoint': {'lat': 50.82838, 'lon': -0.13947}, 'state': None}\n {'city': 'Cardiff', 'country': 'United Kingdom', 'facility': None, 'geoPoint': {'lat': 51.48, 'lon': -3.18}, 'state': None}\n {'city': 'London', 'country': 'United Kingdom', 'facility': None, 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}, 'state': None}\n {'city': 'London', 'country': 'United Kingdom', 'facility': None, 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}, 'state': None}\n {'city': 'Stoke on Trent', 'country': 'United Kingdom', 'facility': None, 'geoPoint': {'lat': 53.00415, 'lon': -2.18538}, 'state': None}]",
         "Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy",
         "A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy",
         "This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial. Participants with advanced breast cancer (ABC) or Metastatic Breast Cancer (MBC) who have experienced recurrence or progression of their disease while receiving aromatase inhibitor (AI) therapy or who have relapsed within 6 months after completing adjuvant AI therapy will be enrolled in Part I of this study. Participants with ABC or MBC who have received prior AI therapy and who have PIK3CA-mutant tumors will be enrolled in Part II of this study. Part I of the study will assess the effect of the addition of GDC-0941 to fulvestrant (Arm A) and of GDC-0980 to fulvestrant (Arm B) on progression free survival (PFS) compared with fulvestrant + placebo (Arm C). Part II of the study will examine the safety and tolerability and to estimate the effect of GDC-0941 in combination with fulvestrant (Arm D) on PFS versus fulvestrant + placebo (Arm E) in participants who received prior treatment with an AI and whose tumors contain a PIK3CA mutation."
        ],
        [
         "45",
         "NCT05264766",
         "Inclusion Criteria:\n\n* Patient undergoing their first open heart surgery using cardiopulmonary bypass\n* Age â¥18 year-old\n* Patient with American Society of Anesthesiologists (ASA) III\n* Patient with Glasgow Coma Scale (GCS) 15, fully aware and oriented\n* Patient fluent in Indonesia\n\nExclusion Criteria:\n\n* Patients did not give consent to participate in the study\n* Patients with central nervous system disease (stroke, intracranial tumor)\n* Patients with psychiatric problem (schizophrenia, depression)\n* Patients with cognitive problem\n* Blind and deaf patient\n* Patient on psychotrophic or narcotics medication\n\nDrop out criteria\n\n* Surgery without cardiopulmonary bypass\n* Patient demise after surgery\n* Patients decided to refrain from the study",
         "COMPLETED",
         "['NA']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Heart; Surgery, Heart, Functional Disturbance as Result']",
         "[\"cooling helmet\", \"neuron specific enolase\", \"delirium\", \"open heart surgery\"]",
         null,
         "{'conditions': array([], dtype=object), 'interventions': None}",
         "[{'city': 'Jakarta Pusat', 'country': 'Indonesia', 'facility': 'Cipto Mangunkusumo Central National Hospital', 'geoPoint': {'lat': -6.1818, 'lon': 106.8223}, 'state': 'DKI Jakarta'}]",
         "The Use of Cooling Helmet for Neuroprotection Management in Open Heart Surgery",
         "The Use of Cooling Helmet for Neuroprotection Management in Patient Undergoing Open Heart Surgery: an Evaluation of Postoperative Neuron-specific Enolase (NSE) and Delirium",
         "To know the relationship between the use of cooling helmet with the changes of NSE level and postoperative delirium event in open heart surgery"
        ],
        [
         "46",
         "NCT00003766",
         "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed surgically resectable solid tumor\n\nPATIENT CHARACTERISTICS: Age: Not specified Performance status: CALGB 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Medically cleared for surgery No active medical or psychiatric disease that would prevent compliance\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Not specified",
         "COMPLETED",
         "['PHASE1']",
         "INTERVENTIONAL",
         null,
         null,
         "ALL",
         "False",
         "['Unspecified Adult Solid Tumor, Protocol Specific']",
         "[\"unspecified adult solid tumor, protocol specific\"]",
         null,
         "{'conditions': array([{'id': 'D009369', 'term': 'Neoplasms'}], dtype=object), 'interventions': array([{'id': 'C064976', 'term': 'O(6)-benzylguanine'}], dtype=object)}",
         "[{'city': 'Chicago', 'country': 'United States', 'facility': 'University of Chicago Cancer Research Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}, 'state': 'Illinois'}]",
         "O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery",
         "Determination of Optimal O6-Benzylguanine Dose to Achieve O6-Alkylguanine-DNA Alkyltransferase Depletion in Patients With Surgically Resectable Solid Tumors",
         "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.\n\nPURPOSE: Phase II trial to study the effectiveness of O6-benzylguanine followed by surgery in treating patients who have solid tumors that can be removed during surgery."
        ],
        [
         "47",
         "NCT03828266",
         "Inclusion Criteria:\n\n* Planned gastrointestinal surgery.\n* Inform consent received.\n\nExclusion Criteria:\n\n* Endoscopic surgery.\n* Inform consent denied.",
         "UNKNOWN",
         null,
         "OBSERVATIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Complication' 'Anastomotic Leak' 'Gastrointestinal Cancer']",
         null,
         null,
         "{'conditions': array([{'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'},\n       {'id': 'D057868', 'term': 'Anastomotic Leak'}], dtype=object), 'interventions': None}",
         "[{'city': 'Beijing', 'country': 'China', 'facility': 'Peking University Cancer Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}, 'state': 'Beijing'}\n {'city': 'Fuzhou', 'country': 'China', 'facility': 'Fujian Medical University Union Hospital', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}, 'state': 'Fujian'}\n {'city': 'Xiamen', 'country': 'China', 'facility': 'Xiamen University First Hospital', 'geoPoint': {'lat': 24.47979, 'lon': 118.08187}, 'state': 'Fujian'}\n {'city': 'Guangzhou', 'country': 'China', 'facility': \"Guangdong People's Hospital\", 'geoPoint': {'lat': 23.11667, 'lon': 113.25}, 'state': 'Guangdong'}\n {'city': 'Guangzhou', 'country': 'China', 'facility': 'The First Affilliated Hospital, Sun Yat-sen University', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}, 'state': 'Guangdong'}\n {'city': 'Guanzhou', 'country': 'China', 'facility': 'South Hospital', 'geoPoint': None, 'state': 'Guangdong'}\n {'city': 'Nanchang', 'country': 'China', 'facility': 'Nanchang University First Hospital', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}, 'state': 'Jiangxi'}\n {'city': 'Changchun', 'country': 'China', 'facility': 'Jilin University Second Hospital', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}, 'state': 'Jilin'}\n {'city': 'Dalian', 'country': 'China', 'facility': 'Dalian Medical University First Hospital', 'geoPoint': {'lat': 38.91222, 'lon': 121.60222}, 'state': 'Liaoning'}\n {'city': 'Xining', 'country': 'China', 'facility': 'Qinghai University Affiliated Hospital', 'geoPoint': {'lat': 36.62554, 'lon': 101.75739}, 'state': 'Qinghai'}\n {'city': 'Jinan', 'country': 'China', 'facility': 'Shandong Provincial Hospital', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}, 'state': 'Shandong'}\n {'city': 'Qingdao', 'country': 'China', 'facility': 'Qingdao University Affiliated Hospital', 'geoPoint': {'lat': 36.06488, 'lon': 120.38042}, 'state': 'Shandong'}\n {'city': 'Shanghai', 'country': 'China', 'facility': 'Fudan University Cancer Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}\n {'city': 'Shanghai', 'country': 'China', 'facility': 'Huashan Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}\n {'city': 'Shanghai', 'country': 'China', 'facility': 'Ruijin Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}\n {'city': 'Shanghai', 'country': 'China', 'facility': 'Zhongshan Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}, 'state': 'Shanghai'}\n {'city': \"Xi'an\", 'country': 'China', 'facility': \"Xi'an Jiao Tong University First Hospital\", 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}, 'state': 'Shanxi'}\n {'city': 'Hangzhou', 'country': 'China', 'facility': 'Hangzhou First Hospital', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}, 'state': 'Zhejiang'}\n {'city': 'Hangzhou', 'country': 'China', 'facility': 'Run Run Shaw Hospital', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}, 'state': 'Zhejiang'}]",
         "Prediction of Abdominal Complications After GastroEnterological Surgery",
         "Abdominal Infectious Complications After Gastrointestinal Surgery in China: a Multi-centered Prospective Registry",
         "The aim of this multi-centered study is to understand the epidemiology of infectious complications after gastrointestinal surgery in China. In total, 17 centers from China will prospectively register their patients undergo gastric or colorectal surgeries. Patient demographic data, operation information, and postoperative data including the infectious complications and the outcomes will be registered. We expect to include 2000 gastric and 2000 colorectal patients within one year and the study is expected to be finished in 2020."
        ],
        [
         "48",
         "NCT02777866",
         "Inclusion Criteria:\n\n* Patients who are planned to a elective gastrointestinal surgery.\n* Biliary-pancreatic open procedures: biliodigestive Derivation, Pancreatoduodenectomy, Pancreato-jejunostomy (Puestow procedure, Frey).\n* Open upper gastrointestinal procedures: total gastrectomy, subtotal gastrectomy (distal gastrectomy with Billroth I reconstruction or Billroth II or Roux-Y), Gastro-jejunum anastomosis, Open gastro-jejunal Roux Y bypass, intestinal resection, intestinal reconnection, intestinal Fistulectomy.\n* Open colorectal procedures: Right or Left Hemicolectomy, total colectomy, low anterior resection, abdominal-perineal resection.\n* Patients who decide signing the informed consent after explained the study.\n* Patients with postoperative follow-up of at least 30 days, in whom the wound and / or local complications will be evaluated.\n\nExclusion Criteria:\n\n* Patients operated laparoscopically.\n* Patients operated at another hospital.\n* Patients with clean surgical wounds.\n* Patients in whom an epidural or subarachnoid block is used.\n* Patients who are unable to sign the informed consent.\n* Patients with less than 50 kg.\n* Patients wiht history of: Malignant hyperthermia, cardiac disease (Heart failure, history of myocardial infarction, arrhythmias), Epilepsy, Allergic to amides.\n* Patients with incomplete follow-up (less than 30 days).\n* Pregnant patients.",
         "UNKNOWN",
         "['NA']",
         "INTERVENTIONAL",
         "18.0",
         null,
         "ALL",
         "False",
         "['Surgical Site Infection' 'Wound Infection' 'Postoperative Pain'\n 'Local Anesthetics']",
         null,
         null,
         "{'conditions': array([{'id': 'D007239', 'term': 'Infections'},\n       {'id': 'D003141', 'term': 'Communicable Diseases'},\n       {'id': 'D013530', 'term': 'Surgical Wound Infection'},\n       {'id': 'D014946', 'term': 'Wound Infection'},\n       {'id': 'D014947', 'term': 'Wounds and Injuries'},\n       {'id': 'D000072836', 'term': 'Surgical Wound'}], dtype=object), 'interventions': array([{'id': 'D002045', 'term': 'Bupivacaine'}], dtype=object)}",
         "[{'city': 'Tlalpan, Mexico City', 'country': 'Mexico', 'facility': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 'geoPoint': None, 'state': 'Mexico City'}]",
         "LAW Trial -The Impact of Local Anesthetics Infiltration in Surgical Wound of Gastrointestinal Procedures",
         "LAW Trial -The Impact of Local Anesthetics Infiltration in Surgical Wound of Gastrointestinal Procedures: A Blind Prospective Randomized Trial",
         "The purpose of this study is to determine if the infiltration of 0.5% Bupivacaine in the surgical wound is effective to diminish the pain and the risk of surgical site infections in patients who go to a open gastrointestinal procedure."
        ],
        [
         "49",
         "NCT05204966",
         "Inclusion Criteria:\n\n* Newborns and infants under 6 months of correctional age\n* Clinically suspected to have dysphagia\n* In case parental consent is obtained\n\nExclusion Criteria:\n\n* In case of cardiopulmonary instability (ECMO, Ventilator, etc. are being applied)\n* When it is not possible to secure sufficient fields for artificial intelligence analysis of images due to factors such as anatomical abnormalities of the head and neck",
         "UNKNOWN",
         "['NA']",
         "INTERVENTIONAL",
         null,
         "6.0",
         "ALL",
         "False",
         "['Dysphagia of Newborn']",
         null,
         null,
         "{'conditions': array([{'id': 'D003680', 'term': 'Deglutition Disorders'}], dtype=object), 'interventions': None}",
         "[{'city': 'Seoul', 'country': 'Korea, Republic of', 'facility': 'Asan medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}, 'state': None}]",
         "Development of Dysphagia Evaluation Via Video Analysis Based on Deep Learning Method in Neonates and Infants and Correlation Between the Evaluation and the Development",
         "Development of Dysphagia Evaluation Via Video Analysis Based on Deep Learning Method in Neonates and Infants and Correlation Between the Evaluation and the Development",
         "The purpose of this study is to develop an evaluation of dysphagia through deep learning-based video analysis in newborns and infants, and to report the correlation with future development."
        ]
       ],
       "shape": {
        "columns": 17,
        "rows": 541897
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phases</th>\n",
       "      <th>study_type</th>\n",
       "      <th>minimum_age</th>\n",
       "      <th>maximum_age</th>\n",
       "      <th>sex</th>\n",
       "      <th>healthy_volunteers</th>\n",
       "      <th>conditions</th>\n",
       "      <th>keywords</th>\n",
       "      <th>interventions</th>\n",
       "      <th>mesh_terms</th>\n",
       "      <th>locations</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_summary</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT01273766</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must have a ...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>False</td>\n",
       "      <td>[Acute Undifferentiated Leukemia, Adult Acute ...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D002051', 'term': 'Bur...</td>\n",
       "      <td>[{'city': 'Winston-Salem', 'country': 'United ...</td>\n",
       "      <td>Deferasirox in Treating Iron Overload Caused B...</td>\n",
       "      <td>Impact of Intervention With Deferasirox on the...</td>\n",
       "      <td>RATIONALE: Deferasirox may remove excess iron ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00787566</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients with histolo...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>False</td>\n",
       "      <td>[Chemotherapy-Induced Nausea and Vomiting]</td>\n",
       "      <td>[\"Highly emetogenic chemotherapy induced nause...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D009325', 'term': 'Nau...</td>\n",
       "      <td>[{'city': 'The study is managed by Kendle Inte...</td>\n",
       "      <td>Phase 2 Study of Efficacy, Tolerability, and S...</td>\n",
       "      <td>A Randomized, Single Administration, Double-bl...</td>\n",
       "      <td>Brief Summary: A randomized, single administra...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00497666</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Diagnosis of Diabete...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>None</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>90.0</td>\n",
       "      <td>ALL</td>\n",
       "      <td>None</td>\n",
       "      <td>[Diabetes, Diabetic Nephropathy, Renal Protect...</td>\n",
       "      <td>[\"Diabetes\", \"Diabetic nephropathy\", \"renal pr...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D007674', 'term': 'Kid...</td>\n",
       "      <td>[{'city': 'Zerifin,', 'country': 'Israel', 'fa...</td>\n",
       "      <td>Association Between Rosiglitazone Use and Clin...</td>\n",
       "      <td>Retrospective Study Evaluating the Association...</td>\n",
       "      <td>Recent data show that Rosiglitazone treatment ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01978366</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Completed both the si...</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>[PHASE2]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>6.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>MALE</td>\n",
       "      <td>False</td>\n",
       "      <td>[Duchenne Muscular Dystrophy]</td>\n",
       "      <td>[\"Duchenne muscular dystrophy\", \"halofuginone ...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D009136', 'term': 'Mus...</td>\n",
       "      <td>[{'city': 'Sacramento', 'country': 'United Sta...</td>\n",
       "      <td>Open Label Extension Study of HT-100 in Patien...</td>\n",
       "      <td>An Open Label Extension Study of HT-100 in Pat...</td>\n",
       "      <td>This study is designed to provide 6-months con...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01971866</td>\n",
       "      <td>Inclusion Criteria:\\n\\nPatients with tumors of...</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>None</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>False</td>\n",
       "      <td>[Set up and Monitoring of Patients Receiving P...</td>\n",
       "      <td>[\"Proton radiation\", \"AlignRT\"]</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>[{'city': 'Jacksonville', 'country': 'United S...</td>\n",
       "      <td>Camera Based System to Monitor Patient Movemen...</td>\n",
       "      <td>Improving Safety and Accuracy of Proton Therap...</td>\n",
       "      <td>This study aims to investigate the advantages ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>541892</th>\n",
       "      <td>NCT04021277</td>\n",
       "      <td>MAIN INCLUSION CRITERIA\\n\\nProviding informed ...</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>[PHASE1]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>False</td>\n",
       "      <td>[Solid Tumor, Colorectal Cancer]</td>\n",
       "      <td>[\"PS101-mediated ACT: the combination of PS101...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D015179', 'term': 'Col...</td>\n",
       "      <td>[{'city': 'Oslo', 'country': 'Norway', 'facili...</td>\n",
       "      <td>PS101-mediated ACT With Chemotherapy in Liver ...</td>\n",
       "      <td>Phase I Trial of the Combination of PS101-Medi...</td>\n",
       "      <td>Part 1: This clinical study will first test th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>541893</th>\n",
       "      <td>NCT03527277</td>\n",
       "      <td>Inclusion Criteria: men and pre-menopausal wom...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>50.0</td>\n",
       "      <td>ALL</td>\n",
       "      <td>True</td>\n",
       "      <td>[Cardiovascular Risk Factor, Type2 Diabetes Me...</td>\n",
       "      <td>[\"orange juice\", \"sugar-sweetened beverage\", \"...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D003924', 'term': 'Dia...</td>\n",
       "      <td>[{'city': 'Davis', 'country': 'United States',...</td>\n",
       "      <td>Orange Juice And Sugar Intervention Study</td>\n",
       "      <td>The Effects of Orange Juice Compared With Suga...</td>\n",
       "      <td>The objectives of this proposal are to address...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>541894</th>\n",
       "      <td>NCT00847977</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Glasgow \\&lt; or equal t...</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>[PHASE3]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>False</td>\n",
       "      <td>[Head Trauma]</td>\n",
       "      <td>[\"Acute head trauma\"]</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D006259', 'term': 'Cra...</td>\n",
       "      <td>[{'city': 'Nantes', 'country': 'France', 'faci...</td>\n",
       "      <td>Interest of Using Balanced Fluid for Infusion ...</td>\n",
       "      <td>IntÃ©rÃªt d'Utiliser Des solutÃ©s de Remplissage ...</td>\n",
       "      <td>isotonic NaCl serum is the first intent soluti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>541895</th>\n",
       "      <td>NCT00715377</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age of 50 and older\\n...</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>[NA]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>50.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>False</td>\n",
       "      <td>[Schizophrenia, Schizoaffective Disorder, Schi...</td>\n",
       "      <td>[\"benztropine\", \"Anticholinergic antiparkinson...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D012559', 'term': 'Sch...</td>\n",
       "      <td>[{'city': 'Toronto', 'country': 'Canada', 'fac...</td>\n",
       "      <td>Anticholinergic Burden in Schizophrenia</td>\n",
       "      <td>Anticholinergic Burden in Schizophrenia</td>\n",
       "      <td>Anticholinergic antiparkinsonian agents often ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>541896</th>\n",
       "      <td>NCT00045877</td>\n",
       "      <td>Diagnosis and disease status:\\n\\n* Subjects wi...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>[PHASE2, PHASE3]</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>18.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>False</td>\n",
       "      <td>[Lymphoma, Non-Hodgkin]</td>\n",
       "      <td>[\"Low-Grade or Follicular Non-Hodgkin's Lympho...</td>\n",
       "      <td>None</td>\n",
       "      <td>{'conditions': [{'id': 'D008223', 'term': 'Lym...</td>\n",
       "      <td>[{'city': 'Little Rock', 'country': 'United St...</td>\n",
       "      <td>Proleukin in Combination With Rituxan in Patie...</td>\n",
       "      <td>None</td>\n",
       "      <td>The purpose of this study is to determine the ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>541897 rows Ã 17 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             nct_id                               eligibility_criteria  \\\n",
       "0       NCT01273766  Inclusion Criteria:\\n\\n* Patients must have a ...   \n",
       "1       NCT00787566  Inclusion Criteria:\\n\\n* Patients with histolo...   \n",
       "2       NCT00497666  Inclusion Criteria:\\n\\n1. Diagnosis of Diabete...   \n",
       "3       NCT01978366  Inclusion Criteria:\\n\\n* Completed both the si...   \n",
       "4       NCT01971866  Inclusion Criteria:\\n\\nPatients with tumors of...   \n",
       "...             ...                                                ...   \n",
       "541892  NCT04021277  MAIN INCLUSION CRITERIA\\n\\nProviding informed ...   \n",
       "541893  NCT03527277  Inclusion Criteria: men and pre-menopausal wom...   \n",
       "541894  NCT00847977  Inclusion Criteria:\\n\\n* Glasgow \\< or equal t...   \n",
       "541895  NCT00715377  Inclusion Criteria:\\n\\n* Age of 50 and older\\n...   \n",
       "541896  NCT00045877  Diagnosis and disease status:\\n\\n* Subjects wi...   \n",
       "\n",
       "       overall_status            phases      study_type  minimum_age  \\\n",
       "0           COMPLETED          [PHASE2]  INTERVENTIONAL         18.0   \n",
       "1           COMPLETED          [PHASE2]  INTERVENTIONAL         18.0   \n",
       "2             UNKNOWN              None   OBSERVATIONAL         18.0   \n",
       "3          TERMINATED          [PHASE2]  INTERVENTIONAL          6.0   \n",
       "4          TERMINATED              None   OBSERVATIONAL         18.0   \n",
       "...               ...               ...             ...          ...   \n",
       "541892     TERMINATED          [PHASE1]  INTERVENTIONAL         18.0   \n",
       "541893      COMPLETED              [NA]  INTERVENTIONAL         18.0   \n",
       "541894     TERMINATED          [PHASE3]  INTERVENTIONAL         18.0   \n",
       "541895     TERMINATED              [NA]  INTERVENTIONAL         50.0   \n",
       "541896      COMPLETED  [PHASE2, PHASE3]  INTERVENTIONAL         18.0   \n",
       "\n",
       "        maximum_age   sex healthy_volunteers  \\\n",
       "0               NaN   ALL              False   \n",
       "1               NaN   ALL              False   \n",
       "2              90.0   ALL               None   \n",
       "3              20.0  MALE              False   \n",
       "4               NaN   ALL              False   \n",
       "...             ...   ...                ...   \n",
       "541892          NaN   ALL              False   \n",
       "541893         50.0   ALL               True   \n",
       "541894          NaN   ALL              False   \n",
       "541895          NaN   ALL              False   \n",
       "541896          NaN   ALL              False   \n",
       "\n",
       "                                               conditions  \\\n",
       "0       [Acute Undifferentiated Leukemia, Adult Acute ...   \n",
       "1              [Chemotherapy-Induced Nausea and Vomiting]   \n",
       "2       [Diabetes, Diabetic Nephropathy, Renal Protect...   \n",
       "3                           [Duchenne Muscular Dystrophy]   \n",
       "4       [Set up and Monitoring of Patients Receiving P...   \n",
       "...                                                   ...   \n",
       "541892                   [Solid Tumor, Colorectal Cancer]   \n",
       "541893  [Cardiovascular Risk Factor, Type2 Diabetes Me...   \n",
       "541894                                      [Head Trauma]   \n",
       "541895  [Schizophrenia, Schizoaffective Disorder, Schi...   \n",
       "541896                            [Lymphoma, Non-Hodgkin]   \n",
       "\n",
       "                                                 keywords interventions  \\\n",
       "0                                                    None          None   \n",
       "1       [\"Highly emetogenic chemotherapy induced nause...          None   \n",
       "2       [\"Diabetes\", \"Diabetic nephropathy\", \"renal pr...          None   \n",
       "3       [\"Duchenne muscular dystrophy\", \"halofuginone ...          None   \n",
       "4                         [\"Proton radiation\", \"AlignRT\"]          None   \n",
       "...                                                   ...           ...   \n",
       "541892  [\"PS101-mediated ACT: the combination of PS101...          None   \n",
       "541893  [\"orange juice\", \"sugar-sweetened beverage\", \"...          None   \n",
       "541894                              [\"Acute head trauma\"]          None   \n",
       "541895  [\"benztropine\", \"Anticholinergic antiparkinson...          None   \n",
       "541896  [\"Low-Grade or Follicular Non-Hodgkin's Lympho...          None   \n",
       "\n",
       "                                               mesh_terms  \\\n",
       "0       {'conditions': [{'id': 'D002051', 'term': 'Bur...   \n",
       "1       {'conditions': [{'id': 'D009325', 'term': 'Nau...   \n",
       "2       {'conditions': [{'id': 'D007674', 'term': 'Kid...   \n",
       "3       {'conditions': [{'id': 'D009136', 'term': 'Mus...   \n",
       "4                                                    None   \n",
       "...                                                   ...   \n",
       "541892  {'conditions': [{'id': 'D015179', 'term': 'Col...   \n",
       "541893  {'conditions': [{'id': 'D003924', 'term': 'Dia...   \n",
       "541894  {'conditions': [{'id': 'D006259', 'term': 'Cra...   \n",
       "541895  {'conditions': [{'id': 'D012559', 'term': 'Sch...   \n",
       "541896  {'conditions': [{'id': 'D008223', 'term': 'Lym...   \n",
       "\n",
       "                                                locations  \\\n",
       "0       [{'city': 'Winston-Salem', 'country': 'United ...   \n",
       "1       [{'city': 'The study is managed by Kendle Inte...   \n",
       "2       [{'city': 'Zerifin,', 'country': 'Israel', 'fa...   \n",
       "3       [{'city': 'Sacramento', 'country': 'United Sta...   \n",
       "4       [{'city': 'Jacksonville', 'country': 'United S...   \n",
       "...                                                   ...   \n",
       "541892  [{'city': 'Oslo', 'country': 'Norway', 'facili...   \n",
       "541893  [{'city': 'Davis', 'country': 'United States',...   \n",
       "541894  [{'city': 'Nantes', 'country': 'France', 'faci...   \n",
       "541895  [{'city': 'Toronto', 'country': 'Canada', 'fac...   \n",
       "541896  [{'city': 'Little Rock', 'country': 'United St...   \n",
       "\n",
       "                                              brief_title  \\\n",
       "0       Deferasirox in Treating Iron Overload Caused B...   \n",
       "1       Phase 2 Study of Efficacy, Tolerability, and S...   \n",
       "2       Association Between Rosiglitazone Use and Clin...   \n",
       "3       Open Label Extension Study of HT-100 in Patien...   \n",
       "4       Camera Based System to Monitor Patient Movemen...   \n",
       "...                                                   ...   \n",
       "541892  PS101-mediated ACT With Chemotherapy in Liver ...   \n",
       "541893          Orange Juice And Sugar Intervention Study   \n",
       "541894  Interest of Using Balanced Fluid for Infusion ...   \n",
       "541895            Anticholinergic Burden in Schizophrenia   \n",
       "541896  Proleukin in Combination With Rituxan in Patie...   \n",
       "\n",
       "                                           official_title  \\\n",
       "0       Impact of Intervention With Deferasirox on the...   \n",
       "1       A Randomized, Single Administration, Double-bl...   \n",
       "2       Retrospective Study Evaluating the Association...   \n",
       "3       An Open Label Extension Study of HT-100 in Pat...   \n",
       "4       Improving Safety and Accuracy of Proton Therap...   \n",
       "...                                                   ...   \n",
       "541892  Phase I Trial of the Combination of PS101-Medi...   \n",
       "541893  The Effects of Orange Juice Compared With Suga...   \n",
       "541894  IntÃ©rÃªt d'Utiliser Des solutÃ©s de Remplissage ...   \n",
       "541895            Anticholinergic Burden in Schizophrenia   \n",
       "541896                                               None   \n",
       "\n",
       "                                            brief_summary  \n",
       "0       RATIONALE: Deferasirox may remove excess iron ...  \n",
       "1       Brief Summary: A randomized, single administra...  \n",
       "2       Recent data show that Rosiglitazone treatment ...  \n",
       "3       This study is designed to provide 6-months con...  \n",
       "4       This study aims to investigate the advantages ...  \n",
       "...                                                   ...  \n",
       "541892  Part 1: This clinical study will first test th...  \n",
       "541893  The objectives of this proposal are to address...  \n",
       "541894  isotonic NaCl serum is the first intent soluti...  \n",
       "541895  Anticholinergic antiparkinsonian agents often ...  \n",
       "541896  The purpose of this study is to determine the ...  \n",
       "\n",
       "[541897 rows x 17 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
